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Abstract 
Parkinson’s disease is a chronic neurodegenerative disorder that affects 1-2% of the world’s 
population over the age of 65. Current treatments that reduce the severity of symptoms 
cause numerous side-effects and lose efficacy over the course of disease progression. 
Leucine-rich repeat kinase 2 (LRRK2) is a novel drug target for the development of disease 
modifying therapeutics for Parkinson’s disease. LRRK2 mutants have elevated kinase 
activity and, as such, chemical inhibitors have therapeutic potential. The physiological 
benefits that arise from chemically inhibiting LRRK2 have been proven through the use of 
generic kinase inhibitors and more recently the selective benzodiazepinone compound 
LRRK2IN1. LRRK2IN1 is a highly potent inhibitor, exhibiting a half-maximal inhibitory 
concentration (IC50) of 9 nM in cellular assays. However, LRRK2IN1 is not biologically 
available in the brain because it has poor physicochemical and pharmacokinetic properties. 
In previous research we rationally designed a LRRK2IN1 analogue (IN1_G) that was 
predicted to have improved metabolic stability and blood-brain barrier permeability. 
Preliminary biological analysis indicated that both LRRK2IN1 and IN1_G potently inhibited 
LRRK2-associated neuro-inflammation in vitro. However, the high molecular weight, 
topological polar surface area and lipophilicity of LRRK2IN1 and IN1_G were predicted to be 
incompatible with functional activity in vivo. Structural modifications were thus required to 
optimise compounds as neuro-protective treatments for Parkinson’s disease. 
Biological evaluation of the structural components of LRRK2IN1 and IN1_G indicated that 
the aniline-bipiperidine 1 motif was a moderately potent inhibitor of neuro-inflammation, 
whilst the tricyclic diazepinone motif IN1_H had no anti-inflammatory efficacy. In the current 
research a series of truncated LRRK2IN1/IN1_G analogues were rationally designed to 
determine if the diazepinone motif could be replaced with low molecular weight bioisosteres 
without affecting functional potency.  
In silico property predictions and scoring functions were used to guide the design of 
truncated analogues. The Schrödinger suite programs LigPrep, QikProp and Marvin were 
used to predict the physicochemical and pharmacokinetic properties of analogues. The 
recently described central nervous system multi-parameter optimisation score was used to 
select analogues that were likely to possess favourable pharmacokinetic and safety profiles. 
Analogues were docked in a homology model of the LRRK2 kinase domain that was 
developed in our previous research. Analogues that conformed to the binding mode of 
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known kinase inhibitors and were predicted by GLIDE to bind to the LRRK2 homology model 
with high affinity were prioritised for synthesis.  
Twenty analogues were synthesised using methods known in the literature. The substrate 
scope of Buchwald-Hartwig chemistry was explored. Novel “all-water” chemistry was 
employed to synthesise N-benzyl aniline analogues. Methodology recently developed in our 
group was used to synthesise diazepine and oxazepine analogues of IN1_H. 
Analogues were assessed for anti-inflammatory efficacy in two cell-based assays. Four 
truncated analogues — 25, 30, 31 and 39 — had equivalent functional efficacy to 
LRRK2IN1/IN1_G, inhibiting the secretion of pro-inflammatory cytokines from stimulated 
primary human microglia by more than 43% at concentrations of 1 µM. These analogues 
were all predicted to have improved pharmacokinetic properties compared to 
LRRK2IN1/IN1_G and are excellent candidates for further development. The synthetic 
intermediate 63 was found to be highly potent (57% inhibition of cytokine secretion at 1 µM), 
which has suggested options for the development of future analogues. The potency of 
analogues 25, 30, 31 and 39 indicated that the tricyclic diazepinone motif was not essential 
for anti-inflammatory efficacy. 
Analogues from this research have been used to identify a role for LRRK2 in the pathology 
of severe brain cancer glioblastoma. Although their mechanisms of action have not yet been 
determined, it is clear that analogues developed in this research have potential applications 
in the treatment of numerous disorders driven by an inflammatory microenvironment. Further 
optimisation of the analogues developed in this research will provide the first disease-
modifying therapeutics for Parkinson’s disease. 
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Chapter 1 - Introduction 
1.1 LRRK2 and Parkinson’s Disease 
1.1.1 Parkinson’s disease 
Over six million people are currently living with Parkinson’s disease. It is the second most 
common chronic, neurodegenerative disease, affecting 1-2% of the global population over 
the age of 65.1 The rate of disease diagnosis is forecast to double by the year 2040, along 
with the high economic burden ($14.4 billion/p.a., U.S.) Parkinson’s disease places on 
society.2 
Parkinson’s disease is clinically characterised by four cardinal symptoms: resting tremor, 
bradykinesia, postural instability, and rigidity. Patients may also exhibit a range of non-motor 
secondary systems including olfactory, autonomic and psychological disturbances.3, 4 
The dominant neuropathological feature of Parkinson’s disease is the progressive loss of 
presynaptic dopamine-secreting neurons in the substantia nigra pars compacta and striatal 
regions of the brain. Decreased concentration of dopamine causes multiple other 
neurotransmitter systems to become deregulated. Intracellular aggregates of phosphorylated 
α-synuclein, tau and ubiquitin proteins are also common but not essential for a diagnosis of 
Parkinson’s disease.4, 5  
1.1.2 Pharmacological Intervention 
The motor symptoms of Parkinson’s disease are treated pharmacologically using a 
combination of synthetic dopamine precursors, dopamine agonists, cholinergic modulating 
agents and catabolic enzyme inhibitors. Levodopa and carbidopa are the most commonly 
prescribed therapeutics for Parkinson’s disease. They are synthetic dopamine precursors 
that were initially introduced in the early 1960s.6, 7 The continued use of levodopa and 
carbidopa, despite significant side-effects and decreasing efficacy over disease progression, 
underscores a lack of progress in the development of Parkinson’s disease 
pharmacotherapies over the past fifty years.8 Non-pharmacological treatments include deep-
brain stimulation, surgery, intensive physiotherapy and language coaching.7, 8 None of these 
options address the underlying progression of neurodegeneration. Seventy to eighty per cent 
of neural loss occurs prior to the onset of physiological symptoms.9 Consequently, it is 
imperative to develop disease-modifying therapeutics that are neuro-protective or stimulate a 
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neuro-regenerative environment. Emerging genetic, stem-cell and whole-cell replacement 
therapies offer promise in this field but are not expected to enter clinical trials for at least 20 
years.7, 8  
1.1.3 Leucine‐rich Repeat Kinase 2 
The aetiology of Parkinson’s disease is a complex interaction between genetics, age-related 
physiological changes and/or exposure to environmental toxins.9 Mutations occurring in 
seven autosomal genes (PARK1, 2, 5, 6, 7, 8, 9, and 14) have been identified as 
Parkinson’s disease risk factors. The clinical phenotype caused by mutation of these genes 
varies in terms of severity, genetic penetrance, pattern of inheritance and age of disease 
onset. PARK1-14 encode a heterogeneous group of proteins ranging from chaperone 
molecules to various catabolic and regulatory enzymes.9, 10 
First cloned in 2004, leucine-rich repeat kinase 2 (LRRK2), is the gene product responsible 
for PARK8 (12p11.2-q13.1)-induced neurodegeneration.11, 12 LRRK2 is widely distributed 
throughout the body and is found in elevated concentrations in brain, kidney, and heart 
tissues, as well as various immune-cell subtypes.11, 13 LRRK2 is a multi-domain serine-
threonine kinase, containing an adenosine triphosphate (ATP)-utilising kinase domain, a 
guanosine triphosphate hydrolase (GTPase) domain (Ras of complex proteins, ROC), and 
several putative protein-protein scaffolding domains, such as the C-terminal of Roc (COR), 
leucine-rich repeat (LRR), ankyrin (Ank) and WD40 domains (Figure 1). Together, these 
structural features implicate LRRK2 in a complex array of intracellular processes, and 
potentially, a diverse number of disease states including neurodegenerative and immune 
disorders,14 peripheral cancers,15 and leprosy.16, 17 Although the endogenous role of LRRK2 
remains unconfirmed, ongoing biological studies have identified a number of interactions that 
might be responsible for the pathological effects of LRRK2 mutants. In the central nervous 
system (CNS), LRRK2 appears to induce neuronal apoptosis by enabling mitochondrial pore 
formation,18 increasing the rate of DLP1-dependent mitochondrial fission,19 and increasing 
the production of pro-apoptotic factors, such as caspase 3 and reactive oxygen species 
(ROS), by inhibiting the antioxidant peroxiredoxin-3.20 LRRK2 was shown to increase the 
secretion of pro-inflammatory cytokines from immune cells,21 up-regulate the expression of 
apoptotic signalling receptors and impede stress response mechanisms at the level of 
transcriptional regulation through phosphorylation of FOXO1 and 4E-BP.22-24 LRRK2 
contributes to the formation of Lewy body pathology by directly phosphorylating aggregating 
proteins and inhibiting the ubiquitin-proteosomal route of protein clearance.25 Finally, LRRK2 
disrupts neuronal morphology,26, 27 vesicular homeostasis,28 and the synaptic concentration, 
release and recycling of dopamine.29 
Chapter 1 - Introduction 
[3] 
 
 
Figure 1. Schematic of LRRK2 protein domain structure. The six pathogenic missense mutations found in 
individuals with Parkinson’s disease are highlighted, including the most common G2019S mutation. 
1.1.4 LRRK2 as a therapeutic target 
More than forty genetic variants of LRRK2 are known. Six mutations have been confirmed to 
contribute to Parkinson’s disease pathology: G2019S, R1441C/G/H, Y1699C and I2020T. 
These mutations are clustered about the DF(Y)G-activation loop of the kinase domain, the 
ROC domain, and the protein dimerisation interface of the COR domain (Figure 1).1, 30 The 
most common variant, G2019S-LRRK2, causes 6% of all hereditary cases and 1-2% of all 
idiopathic cases of Parkinson’s disease. However, the prevalence of LRRK2 mutations 
varies with ethnicity, and G2019S-LRRK2 is causal in up to 39% of Parkinson’s disease 
cases in North African Arab populations.1 Because of the prevalence of LRRK2 mutations 
and their occurrence in both hereditary and idiopathic disease subsets, the kinase is a 
important target for elucidating the underlying pathogenic mechanisms of Parkinson’s 
disease.10  
Early biochemical characterisation of G2019S-LRRK2 indicated that the mutant protein has 
three-fold greater catalytic activity than the wild-type (wt)-LRRK2 enzyme.31, 32 Consequently, 
inhibition of LRRK2 activity represents a novel therapeutic option for Parkinson’s disease.33 
The five less common LRRK2 mutants have been proposed to induce Parkinson’s disease 
through alternative mechanisms, such as disrupting protein stability, dimerisation, GTP-
hydrolysis, or protein-scaffolding functions.32-37 
Comprehensive biochemical analyses and transgenic animal models provided the initial 
precedence for the therapeutic benefits of inhibiting LRRK2 activity. Protein mutation studies 
confirmed that kinase activity is essential for LRRK2-induced neurotoxicity.31 Transgenic 
mice carrying mutant G2019S-LRRK2 have disturbed neuronal morphology, including 
decreased outgrowth and branching of dendrites (Figure 2). Kinase-dead LRRK2 mutants 
(D1994A) ameliorated the phenotypic cellular changes induced by G2019S-LRRK2, resulting 
in reduced protein aggregation and neurodegeneration, and longer duration of cell survival.34 
Early pharmacological studies using generic chemical inhibitors demonstrated that LRRK2 
was susceptible to inhibition, and that decreased kinase activity reduced cellular injury in 
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1.2.1 Drug selectivity 
The majority of kinase inhibitors are competitive reversibly-acting small molecules that bind 
to the ATP-binding site of kinases when the protein is in an active conformation (Type I 
inhibitors). Inhibitors must have low nanomolar binding affinity, as defined by the dissociation 
constant (Ki < 100 nM), in order to compete efficiently with the high physiological 
concentration of ATP. There are over 500 protein kinases encoded in the human genome, in 
addition to numerous ATPases, adenosine receptors and nucleotide binding or exchange 
factors. The ATP-binding site of most kinases is highly conserved, as are the catalytic amino 
acid residues involved in the phosphoryl-transfer reaction. Consequently, there is little 
structural variability to exploit when designing selective inhibitors and off-target toxicity 
frequently limits drug success. Many kinases change between a catalytically active, ATP-
binding conformation and an inactive conformation in response to phosphorylation events. 
This conformational change involves movement of an “activation loop” comprised of three 
amino acid residues: aspartate (D), phenylalanine (F) (or tyrosine (Y) in the case of LRRK2) 
and glycine (G). Currently marketed kinase inhibitors with relatively high selectivity exploit 
additional binding interactions to a hydrophobic pocket that is exposed in the inactive 
(DF(Y)G-out) kinase conformation (Type II inhibitors).42 A series of non-ATP competitive, 
Type-II kinase inhibitors that are active against wt-LRRK2 have been reported.43, 44 
Unfortunately, these compounds lose potency and/or demonstrate an ATP-competitive mode 
of inhibition against mutant G2019S-LRRK2.43 Gly-2019 forms part of the DF(Y)G activation 
loop. Mutation of Gly-2019 to Ser-2019 thermodynamically stabilises the active conformation 
of LRRK2 by enabling additional hydrogen bonding interactions. As such, Type II inhibitors 
might not be useful for treating Parkinson’s disease caused by G2019S-LRRK2.43, 45, 46 A 
third class of inhibitors (Type III inhibitors) achieve selectivity by binding to an allosteric 
pocket away from the active site.47 LRRK2 is not known to possess an allosteric pocket, but 
within the past month studies using bi-dentate ligands have pointed towards previously 
unidentified binding sites on the external edge of the kinase hinge which may lead to 
improved inhibitor selectivity in the future.48 
1.2.2 Traditional Drug Discovery  
The medical chemistry pipeline shown in Figure 3 identifies key stages of traditional drug 
discovery and development. Initial discovery of a hit(s) compound often relies on high-
throughput screening (HTS). Derivatisation of gross structural features to generate structure-
activity relationships (SARs) results in the identification of a lead(s) candidate. Minor 
structural modifications to fine-tune molecular properties then yield a preclinical candidate 
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1.2.3 Structure‐based drug design 
The “rational” modification of molecular structure based on X-ray images of proteins co-
crystallised with ligands is known as structure-based drug design (SBDD). SBDD has rapidly 
become a firmly established tool for medicinal chemists, since it was originally described in 
1980s.52-54 While SBDD has been highly successful it suffers a number of limitations, the 
most obvious being the requirement of a crystal structure of the target protein. The LRRK2 
kinase domain has not yet been crystallised. Crystal structures of the ROC domain and the 
ROC-COR tandem domains are available and have provided insight into the pathogenic 
mechanism of other Parkinson’s disease-associated mutations such as R1441C/G/H-
LRRK2.36, 55, 56  
The catalytic domains of many other kinases have been successfully co-crystallised with 
relevant ligands. The afore-mentioned amino acid sequence and structural conservation of 
the catalytically active site, make kinases highly amenable to homology modelling.57 
Homology models are computer simulations of molecular structures constructed by 
overlaying the amino acid sequence of related proteins, and artificially mutating variant 
residues. Complex free-energy minimisation algorithms then adjust protein conformation in 
response to applied parameters. A number of studies, including our own previous work (see 
Chapter 1.4.1),58 have developed protein homology models for LRRK2.13, 50, 59-63 The 
identification of structural features shared between LRRK2 inhibitors and their biochemical 
potencies have been used in conjunction with homology models to yield information about 
important binding interactions and the structure of the LRRK2 active site.50, 64 Structural 
features that may impart drug resistance (A2016T), or alternatively, engender inhibitor 
selectivity (Phe-1883, Leu-1947, Arg-1949, Ser-1954) were identified by comparing the 
sensitivity of various LRRK2 mutants to inhibition.45, 50, 60, 65 
While there are many examples of successful SBDD in the literature, the technique 
continues to be limited by the quality and number of crystal structures available, variation 
between protein conformation when crystalline or soluble, and dynamic changes that occur 
over the course of ligand binding and catalysis. As such, modelling can only provide a guide 
to drug design. 
1.2.4 Structure‐property relationships 
Drugs require a complex profile of physicochemical properties to ensure efficient absorption, 
distribution to target tissues, resistance to metabolic clearance and low toxicity. Drugs 
targeting molecules in the CNS, like LRRK2, must possess a narrower property profile to 
Chapter 1 - Introduction 
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cross the lipophilic blood-brain barrier (BBB). The BBB is comprised of tight cell-junctions, 
efflux proteins, transporters and catabolic enzymes that act together to prevent the CNS 
from being exposed to exogenous substances.66 
A poor pharmacokinetic profile is one of the major sources of attrition during clinical-phase 
drug development.67, 68 Traditionally, emphasis has been placed on the optimisation of drug 
potency using SAR studies, but the need to optimise physicochemical and pharmacokinetic 
properties during early-phase drug development is gaining increasing recognition. Numerous 
in vitro, in vivo and in silico methods have been developed to aid the assessment and 
prediction of these properties. A balance must be struck between the speed, resource 
efficiency, and quality of data generated using each of these techniques.68, 69 
In silico pharmacokinetic prediction and scoring functions have held an importance place in 
drug design since Lipinski proposed the Rule of Five in 1995.70 Computational prediction of 
pharmacokinetic parameters has significantly advanced over the last decade and is a 
valuable tool during lead optimisation to direct structural modifications in favour of an 
improved biological profile71 and to rank analogues in terms of synthetic priority.72 
The applications and limitations of these predictive methods are further discussed in Chapter 
2. 
1.3 Progress in the field of LRRK2 Inhibitors 
1.3.1 Generic Kinase Inhibitors 
Over 1700 publications and 94 inhibitor-related patents pertinent to LRRK2 have been 
produced since PARK8 was cloned in 2002. Preliminary HTS of libraries of known kinase 
inhibitors led to the identification of several potent non-selective tool compounds that were 
calculated to inhibit LRRK2 enzyme activity by more than 50% at low nanomolar 
concentrations (IC50). Staurosporine (IC50 = 1-2 nM), sunitinib (IC50 = 15-79 nM), ROCK 
inhibitor H-1152 (IC50 = 244 nM), JAK3 inhibitor VI (IC50 = 22-25 nM) and Ro-31-8220 (1.6-
4.5 µM), among others, provided preliminary support for LRRK2 inhibition as a potential 
therapeutic option for Parkinson’s disease (Figure 4). 32, 50, 64, 65, 73 
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Figure 4. Non-selective LRRK2 kinase inhibitors. Functional groups predicted to bind the adenine binding 
pocket (A-pocket) in the LRRK2 active site are shown in red. Other functional groups predicted to be important 
for binding to the active site are shown in blue. 
 
These known generic kinase inhibitors also inhibited many other enzymes. Subsequent 
studies focused on developing inhibitors selective for LRRK2. HTS of diverse chemical 
libraries identified numerous chemotypes that offered promise as LRRK2 inhibitors. In 
particular, the amino-pyrimidine 2, pyrazolo-pyridine 3, and thiopheno-pyridin-one 4 motifs 
were derivatised in extensive structure-activity relationship studies (Figure 5). Hundreds of 
small molecule LRRK2 inhibitors based on these scaffolds have been reported in patent 
literature to have low nanomolar binding affinity or half-inhibitory constants (Ki or IC50 < 100 
nM). Selectivity properties for the majority of these compounds have not been reported.50, 74-
84, 85, 86 
 
Figure 5. LRRK2 inhibitor scaffolds prevalent in patent literature. Motifs pertinent to binding to the adenine 
pocket (A-pocket) of the LRRK2 active site are drawn in full. Pendant groups that interact with other areas of the 
active site are represented as R. 
 
1.3.2 Selective LRRK2 Inhibitors 
The first selective LRRK2 inhibitor, LRRK2IN1, was reported by Deng et al in 2011 (Figure 
6). LRRK2IN1 was developed through using HTS kinase-profiling to identify molecules 
which exhibited low binding promiscuity against a diverse panel of relevant human kinases, 
followed by structure-based optimisation.61 LRRK2IN1 is exceptionally potent against both 
the wildtype (wt)-LRRK2 (IC50 = 13 nM) and mutant G2019S-LRRK2 (IC50 = 6 nM) proteins. 
It is considered highly selective for a kinase inhibitor, interacting with only 12 of 470 other 
kinases tested, and only 5 at sub-micromolar concentrations (IC50 < 1 µM). For comparison, 
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the currently marketed selective Her2 kinase inhibitor imatinib (Gleevec®) inhibits 12 of 317 
other kinases when evaluated in similar assays. LRRK2IN1 has neuroprotective benefits in 
vitro and inhibits the activity of LRRK2 in peripheral tissues (kidney and spleen) when 
administered in vivo to mice. LRRK2IN1 has been used extensively over the past two years 
as the compound of choice for studying the biological role and pathophysiology of LRRK2.27, 
39, 87-89 Unfortunately, LRRK2IN1 is not biologically available in the CNS, which halted further 
clinical development of this compound. The physicochemical basis for this poor in vivo 
efficacy was the subject of previous research in our group, and is detailed in Chapter 1.4.58 
Shortly after LRRK2IN1 was reported, Cellzome released the details of sunitinib analogue 
CZC25146, which was developed through a similar kinase-profiling approach based on 
chemical proteomics analysis. Like LRRK2IN1, CZC25146 was potent (wt-LRRK2 IC50 = 4 
nM, G2019S-LRRK2 IC50 = 7 nM), selective (5 of 185 kinases inhibited) and had functional 
neuro-modulatory activity in vitro, but unable to cross the BBB.13 The focus of research 
subsequently shifted towards identifying LRRK2 inhibitors that were active in the CNS. 
Anaplastic lymphoma kinase (ALK) inhibitor TAE684, and novel compound GSK2578215A, 
were identified as potent inhibitors of LRRK2 through HTS of a library of BBB penetrant 
compounds.90, 91 As with LRRK2IN1 and CZC25146, TAE684 and GSK2578215A inhibited 
LRRK2 activity in peripheral tissues. Unexpectedly, although adequately penetrating the 
BBB, neither TAE684 nor GSK2578215A were effective at inhibiting LRRK2 activity in the 
CNS. In the case of TAE684, reports suggested this might have resulted from non-specific 
protein binding interactions.90  
1.3.3 CNS Active LRRK2 Inhibitors 
GNE-7915 was the lead candidate in a series of amino-pyrimidine inhibitors that were 
reported by Genetech in late 2012 (Figure 6).60, 76, 92 GNE-7915 was the first potent (Ki = 1 
nM, IC50 = 9 nM) and selective (1/187 and 10/392 kinases inhibited with IC50 < 100 nM) 
inhibitor that was capable of inhibiting LRRK2 activity in the CNS. GNE-7915 progressed to 
preclinical studies in cynomolgus monkeys,92 at which point potential toxicity or poor 
pharmacokinetic parameters made it necessary to optimise this series of compounds further. 
In early 2013, Chan et al. described a pyrazole analogue (18) of GNE-7915 with improved 
metabolic stability and reduced toxicity. But these attributes came at the cost of a modest 
decrease in potency (Ki = 9 nM, IC50 = 28 nM) and selectivity (8/183 kinases inhibited with 
IC50 < 1 µM).93  
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Figure 6. Chronology of LRRK2 inhibitors reported since the identification of the first selective potent 
and selective inhibitor LRRK2IN1 in 2011. 
 
1.3.4 Recently Reported LRRK2 Inhibitors  
In the past four weeks alone, researchers from Genentech had five separate patent 
applications published under the applicant Hoffman-LA-Roche. The patents detailed phenyl- 
or pyridyl-amino-pyrimidine analogues of GNE-7915 with low nanomolar binding affinities for 
LRRK2.93-97 
Numerous novel chemotypes have also been published over the last six months. Some 
important examples are summarised here, although a more exhaustive list can be found in 
the literature. Macrocylic LRRK2 inhibitors, comprised of 14-16 membered rings, were 
recently reported by a group from Ipsen Pharma in France.98 These compounds 
incorporated pyrazolo-pyrimidine heterocycles, presumably as a hinge binding motif, 
cyclised using peptidomimetic structures. Inhibitory concentrations less than 100 nM were 
reported for a small number of analogues (Figure 7a). Bidentate-binding dual-specificity 
inhibitors targeting both the c-Jun N-terminal kinase (JNK3) and LRRK2 in concert have 
been reported (Figure 7b). JNK kinases have been linked to multiple neurological disorders, 
including Parkinson’s disease, Huntington’s disease, Alzheimer’s disease, multiple sclerosis 
and amyotrophic lateral sclerosis (ALS).48 Many successfully marketed drugs are moderately 
non-selective. Promiscuous binding might allow modulation of multiple pathogenic targets at 
once and prevent drug effects from being made redundant through compensatory 
biochemical pathways. Additionally, non-selective binding between different mutant isoforms 
of a given drug target increases the proportion of the disease affected population that may 
benefit from treatment.67, 99, 100 Currently bi-dentate dual-specificity inhibitors are only 
moderately potent against LRRK2, have poor selectivity and poor pharmacokinetic 
properties.48 In contrast, analysis of the binding mode of bi-dentate LRRK2 inhibitors has 
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provided insight into the structure of novel binding pockets in the active site that may be 
exploited in the design of new inhibitors (see Chapter 2.1).  
A number of analogues from a series of substituted cyanoquinolines have excellent in vitro 
potency and inhibit LRRK2 activity in the CNS when administered in vivo to mice (Figure 7c). 
At present the selectivity if these analogues has only been assessed across a small number 
of kinases.63 A series of triazolopyridazine analogues have also been reported recently by 
the same research groups at Elan Pharamceuticals (Figure 7d). The triazolopyridazines 
were low nanomolar inhibitors which were more potent against G2019S-LRRK2 than 
wildtype-LRRK2, especially when compared with previously described inhibitors. 
Unfortunately, this series of inhibitors was limited by the susceptibility of the aryl thoiether to 
oxidative metabolism and by poor solubility properties.101  
Currently, the development of LRRK2 therapeutics is limited by the need to achieve a 
balance between high selectivity and potency, and favourable physicochemical or 
pharmacokinetic properties. The continued elucidation of the complex role of LRRK2 in 
human disease, the exponential rise in the number of publications reporting novel LRRK2 
inhibitors and the increased focus on optimising drug properties on holistic scale, imply that 
we can expect LRRK2 inhibitors to be in the clinic within the next 10 years. 
 
Figure 7. Recently reported LRRK2 inhibitors containing novel chemophores. (a) Macrocyclic LRRK2 
inhibitors,98 (b) Dual-specificity bidentate LRRK2 inhibitors,48 (c) Cyanoquinoline-type LRRK2 inhibitors, 63 (d) 
Triazolopyradizine LRRK2 inhibitors101 
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1.4 Previous Research 
1.4.1 In silico Modelling for Structural Modification 
In recent work we employed a resource efficient approach to rationally modify the structure 
of LRRK2IN1 for improved bioavailability in the CNS. As outlined above in Chapter 1.3.2 
Selective LRRK2 Inhibitors, LRRK2IN1 was selective, potent in vitro and in peripheral 
tissues, but unable to cross the BBB. We used molecular modelling software to predict 
physicochemical properties that might be responsible for poor CNS permeability. Analysis of 
the results generated when LRRK2IN1 was analysed using the Schrödinger suite programs 
LigPrep and QikProp led us to propose that biotransformation of LRRK2IN1 into hydrophilic 
metabolites may prevent CNS penetration. Oxidative metabolism by cytochrome p450 
enzymes is an important mechanism by which the body increases the water solubility of 
exogenous compounds to aid excretion by kidney filtration or conjugation in the biliary 
system.102 Dealkylation or aromatic hydroxylation reactions were predicted to occur at six 
sites on the structure of LRRK2IN1 (Figure 8). Analysis of metabolite IN1_M resulting from 
these reactions using the Schrödinger suite software indicated that metabolite(s) would be 
unlikely to cross the BBB. This was clearly conveyed through the dramatically reduced 
lipophility (cLogP), increased topological polar surface area (tPSA), poor predicted oral 
absorption and low penetration of MDCK cells, which represent the BBB, that were predicted 
for metabolite IN1_M (Table 1).  
 
Figure 8. Selective and potent LRRK2 inhibitor LRRK2IN1, predicted metabolite IN1_M and proposed 
analogue scaffold. Functional groups predicted to be important for binding to the LRRK2 active site are shown 
in blue, functional groups introduced by oxidative biotransformation are shown in red and proposed bioisosteric 
substituents are shown in green.  
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We proposed that inhibiting the metabolism of LRRK2IN1 by incorporating bioisosteric 
substituents would allow LRRK2 inhibitors to retain their favourable physicochemical 
properties and penetrate the CNS (Figure 8). 
To aid our design of LRRK2IN1 analogues, we constructed a homology model of the LRRK2 
kinase domain. We selected Lymphocyte specific kinase (Lck) as a structural template (PDB 
1qpc) because of the high homology between the amino acid sequences of the Lck and 
LRRK2 active sites, the Lck crystal structure was high resolution (1.6 Å) and the kinase had 
been co-crystallised with a relevant substrate (phosphoaminophosphonic acid-adenylate 
ester). We validated the integrity of the homology model and its binding predictions by 
screening extensive libraries of kinase inhibitors in silico. 
LRRK2IN1 was docked into this model using the molecular mechanics free energy 
minimisation docking program GLIDE (Grid-based Ligand Docking with Energetics). Key 
functional groups necessary for binding to the active site were identified and these were 
retained when LRRK2IN1 analogues were designed. GLIDE was also used to predict the 
relative binding affinity of LRRK2IN1 and proposed analogues, which enabled us to assign 
synthetic priority.  
A series of synthetic targets were identified by the iterative incorporation of 
pharmacologically proven bioisosteres, in combination with metabolic stability and binding 
affinity predictions. 
 
Table 1. Predicted physicochemical and pharmacokinetic properties of LRRK2IN1, proposed metabolite 
IN1_M and novel analogue IN1_G. Predictions calculated using LigPrep and QikProp Schrödinger suite 
software.103, 104  
 MW cLogP tPSA (Å2) F % MDCK (nm s-1) G-score 
LRRK2IN1 570.69 2.82 106 50 (49.3)61 27 -5.53 
IN1_M 576.60 -0.42 215 0 0.05  
IN1_G 560.10 4.36 93 84 293 -8.08 
MW – Molecular weight; cLogP – calculated octanol-water partition coefficient; tPSA – topological polar surface 
area; F (%) – per cent oral absorption 
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1.4.2 Synthesis of IN1_G 
LRRK2IN1, a number of analogues and some key synthetic intermediates have been 
successfully synthesised. The synthetic route to one of these analogues IN1_G is shown in 
Scheme 1.  
 
 
 
Scheme 1. Synthesis of IN1_G, a LRRK2IN1 analogue predicted to have an improved metabolic stability 
and binding affinity. Reagents and conditions: (a) H2SO4 (6 equiv., 98 %w/v)), HNO3 (2 equiv. 70% w/v), 50 °C, 
3 h, 6 92%; (b) POCl3 (5 equiv.), N,N-dimethylaniline (2.5 equiv.), reflux, 3 h, 7 43%; (c) ethyl 2-
(methylamino)benzoate 8 (1 equiv.), 2,4-dicloro-5-nitropyrimidine 7 (1.5 equiv.), DIPEA (2 equiv.), dry 1,4-
dioxane (0.2 M), 55 oC, 3 h, 9 57%; (d) 9 (1 equiv.), Fe powder (10 equiv.), AcOH (0.07 M), 50 oC, 9 h, 10 58%; 
(e) 10 (1 equiv.), NaH (3.5 equiv.), MeI (1.2 equiv.), DMA (0.08 M), -10-0 oC, 1.5 h, IN1_H quant.; (f) 11 (1 
equiv.), 12 (1.2 equiv.), AcOH (2 equiv.), Na(OAc)3BH (2 equiv.), DCE (0.36 M), 0 oC- r.t., o.n., 13 25%; (g) 4 M 
HCl in 1,4-dioxane (10 equiv.), r.t. 1 h, 14, quant.; (h) 14 (1 equiv.), 15 (1 equiv.), EDCI (1.25 equiv.), HOBt (1.25 
equiv), DIPEA (3.9 equiv.), 1 93%, (i) 1 (1 equiv.), IN1_H (1.05 equiv.), Pd2(dba)3 (0.04 equiv.), X-Phos (0.15 
equiv.), tBuOK (1.05 equiv.), 1,4-dioxane (2.8 M), 60 oC, 21 h, IN1_G 39%  
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1.4.3 Preliminary biological results 
Preliminary biological analysis of the functional activity of these analogues and synthetic 
intermediates was carried out in late 2012. Compounds were tested for their ability to inhibit 
the secretion of pro-inflammatory cytokines from activated microglial cells. This pathway was 
shown to be dependent on LRRK2 kinase activity by Kim et al in 2012.21 
Results confirmed that LRRK2IN1 had potent anti-inflammatory efficacy. Administration of 
LRRK2IN1 to human microglia that had been stimulated with lipopolysaccharide (LPS) 
decreased the secretion of tumour necrosis factor alpha (TNFα) by 76% when administered 
at 10 µM, and 68% at 1 µM concentrations, compared to cells that were treated with a 
DMSO vehicle (Figure 9a). Analogue IN1_G had a similar, if not greater, inhibitory efficacy, 
reducing the secretion of TNFα by 84% at 10 µM, and 70% at 1 µM. A 98% reduction in the 
secretion of a second pro-inflammatory cytokines interleukin 1-beta (IL-1β) was observed at 
IN1_G concentrations as low as 1 µM (Figure 9b).  
We screened a number of synthetic intermediates to investigate which aspects of the 
LRRK2IN1/IN1_G chemophore might be contributing to the anti-inflammatory efficacy 
observed. Only ortho-chloroaniline fragment 1 ([1,4'-bipiperidin]-1'-yl(4-amino-3-
chlorophenyl)methanone) showed significant efficacy, reducing the secretion of IL-1β by 
33% when administered at 10 µM. In comparison, the diazepinone fragment IN1_H (Scheme 
1), which was common to the structures of both LRRK2IN1 and IN1_G had no functional 
efficacy. The apparent elevation in IL-1β secretion seen with IN1_H in Figure 9b indicated 
that microglia might not have been stimulated maximally with LPS in the control.  
From these observations we hypothesised that the diazepinone motif IN1_H might not be 
essential for the anti-inflammatory efficacy of LRRK2IN1 and IN1_G. We proposed that 
truncated analogues, substituted with simplified aromatic groups in place of the diazepinone 
IN1_H moiety, might retain functional potency, whilst concomitantly improving other 
physicochemical and pharmacokinetic properties. 
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Figure 9. Anti-inflammatory efficacy of LRRK2 inhibitor LRRK2IN1, analogue IN1_G and key synthetic 
fragments. (a) Percentage reduction in the LPS-induced secretion of pro-inflammatory cytokine THFα when 
compounds were administered at a concentration of 10 µM; (b) Percentage reduction in the LPS-induced 
secretion of pro-inflammatory cytokine IL-1β. Microglial cells obtained from different donor brains are shown 
separately as bold or shaded columns. 
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1.5 Project Aims  
Physicochemical properties such as molecular weight, lipophilicity, polar surface area and 
ionisation affect the pharmacokinetic properties of drugs. Optimal value ranges for these 
parameters have been established to guide the design of pharmaceutics for CNS 
applications. LRRK2IN1 and recently developed analogue IN1_G (see Chapter 1.4), both 
had a large MW and tPSA (Table 1). LRRK2IN1 was also poorly absorbed from the 
gastrointestinal tract (F = 50%, in mice),61 unable to cross the BBB and was predicted to be 
highly susceptible to metabolism.105 We proposed to address these defects through 
synthesising a series of truncated LRRK2IN1/IN1_G analogues. Ortho-chloroaniline 1 was 
recently identified as a moderately potent inhibitor of pro-inflammatory immune responses 
linked to LRRK2 activity. Generating truncated analogues based on fragment 1 was 
proposed to improve the poor physicochemical and pharmacokinetic profile of LRRK2IN1 
and IN1_G, and improve synthetic access to this class of compounds.  
We proposed to use in silico modelling programs to predict physicochemical and 
pharmacokinetic properties of truncated analogues. Ligand scoring functions and docking 
analysis would be used to direct our design process and prioritise analogues for time and 
resource efficient synthesis. 
We proposed to investigate and optimise challenging steps in the synthesis of LRRK2IN1-
type compounds as a secondary component to this work. Improved synthetic access would 
allow a greater variety of pharmacologically interesting bioisosteres to be incorporated into 
LRRK2IN1/IN1_G analogues 
1.5.1 Summary of Project Aims 
1. Design a series of truncated LRRK2IN1/IN_G analogues, using molecular modelling 
and predictive parameters, to investigate the importance of the diazepinone motif in 
functional efficacy. 
2. Synthesise a library of truncated analogues using standard organic synthetic 
techniques. 
3. Apply recently developed methodology to improve the synthesis of diazepinone 
IN1_H analogues. 
4. Assess truncated analogues for anti-inflammatory efficacy in cell-based assays. 
5. Full biological characterisation of efficacious analogues in kinase binding, metabolic 
and pharmacokinetic assays. 
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Chapter 2 – Molecular Modelling 
2.1 Predictive Tools for Drug Design and Development 
2.1.1 Introductory remarks 
In silico modelling and property predictions are important components of modern 
pharmaceutical programs. The employment of these tools can improve resource, time and 
economic efficiency at all stages of the drug discovery and development pipeline.68 They are 
most beneficial during early phases of hit identification and lead prioritisation, when the pool 
of candidates is large and individual experimental characterisation is not feasible. At this 
point in silico modelling tools provide a rational method of selecting the best candidates to 
pursue.68, 106 
Predictive parameters have commonly been used to identify toxic or metabolically 
susceptible pharmacophores, calculate physicochemical properties known to be correlated 
with in vivo pharmacokinetics, identifying functional groups that may contribute to binding 
affinity or functional efficacy, and characterise the binding site of the molecular target.106 
2.1.2 In Silico Pharmacokinetic Property Prediction 
Physicochemical properties that have been shown to correlate with important 
pharmacokinetic parameters include: molecular weight (MW), lipophilicity (as calculated by 
the logarithm of the octanol-water partition coefficient [cLogP] or distribution coefficient at pH 
7.4 [clogD]), ionisability (pKa), topological polar surface area (tPSA), number of rotatable 
bonds and the number of hydrogen bond donor-acceptor (HBD-HBA) groups that are 
present in a molecule.70, 107-109 Software such as the Schrödinger suite programs QikProp 
and Epik and ChemAxon’s Java applet Marvin enable the calculation of these properties 
without using resource intensive biological studies.104, 110, 111 
QikProp uses Monte Carlo-like simulations calculate a huge number of physical properties. 
Input structures must be three-dimensional and are usually generated in an energy 
minimised conformation through molecular mechanics simulations such as LigPrep prior to 
analysis in QikProp to improve the accuracy of predictions.103 Computed properties are 
reported, in addition to relevant pharmacokinetic predictors like cLogP, human oral 
absorption, central nervous system activity, plasma protein binding, and permeability across 
various experimental cell-lines that are used to model the gastrointestinal tract (Caco-2 
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cells)112 and the blood-brain barrier (MDCK cells).113, 114 QikProp identifies reactive functional 
groups and predicts metabolic stability with moderate to high fidelity (85% success),115  but 
predictions are currently limited to oxidation, dealkylation, and nitro-group reduction 
reactions.114 Finally, QikProp identifies molecules which are likely to fail clinical trials owing 
to cardiac toxicity, as measured by inhibition of hERG ion channels. Desirable ranges for 
these parameters are reported, as determined from the acceptable population of 95% of 
marketed drugs.114 
Drug ionisation plays a key role in absorption across lipophilic biological membranes, 
solubility and excretion.116 Epik, calculates the acid dissociation constants (pKa) of ionisable 
functional groups as a molecule is sequentially deprotonated. Analysis of pKa values allows 
the ionisation state of a molecule to be determined over the variable pH environments of the 
body, and is essential for generating the correct molecular structure for analysis in enzyme-
ligand docking scenarios.110, 117 
Marvin can be used to determine the lipophilicity of a molecule at physiological pH (7.4) by 
calculating how ionisation effects the relative partitioning of species between an organic and 
aqueous phase [cLogD 7.4].111 
2.1.3 Scoring Functions 
Optimal value ranges for the aforementioned properties have been proposed based on 
empirical observations and surveying hit, lead and marketed drug libraries. A number of 
scoring parameters derived from these observations have been developed to aid selection of 
appropriate candidates over the course of drug discovery. MW and lipophilicity have been 
found to strongly correlate with improved binding affinity; however these properties are also 
closely aligned with poor CNS permeability, reduced safety thresholds and increased binding 
promiscuity.118, 119, 120 The ligand efficiency scoring functions: ligand efficiency (LE), lipophilic 
ligand efficiency (LLE) and ligand-efficiency-dependent lipophilicity (LELP) normalise for 
these effects by penalising MW and lipophilic contributions to drug potency.120-123 Empirically 
determined acceptable ranges for these values are shown in Table 2. LE (Equation 1) 
provides a measure of drug binding or potency per heavy atom (non-hydrogen atom).121 A 
minimum LE of 0.3 has been suggested to guide hit selection, so as to allow scope for MW to 
increase during optimisation, whilst remaining within Lipinski’s guidelines (MW < 500 Da).122 
LLE prioritises compounds whose lipophilic contribution to potency is low (Equation 2).120 
LELP combines both MW and lipophilicity into a single scoring term to improve the versatility 
and predictive power of the scoring function (Equation 3).123 Lower absolute values (-10 < 
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LELP < 10) reflect properties more closely aligned with marketed drugs or lead 
compounds.119  
 
Equation 1.    ࡸࡱ ൌ ࢖ࡷ࢏	࢕࢘	࢖ࡵ࡯૞૙#ࢎࢋࢇ࢜࢟	ࢇ࢚࢕࢓࢙ 
Equation 2.    ࡸࡸࡱ ൌ ࢖ࡷ࢏	ሺ࢕࢘	࢖ࡵ࡯૞૙ሻ െ ࢉࡸ࢕ࢍࡼ	ሺ࢕࢘	ࢉࡸ࢕ࢍࡰሻ 
Equation 3.    ࡸࡱࡸࡼ ൌ ࢉࡸ࢕ࢍࡼ	ሺ࢕࢘	ࢉࡸ࢕ࢍࡰሻࡸࡱ  
 
Scoring functions which optimise potency with respect to a single physicochemical 
parameter, such as LE and LLE, often show little reproducibility between different drug 
targets or chemotypes.123 In contrast, the CNS multi-parameter optimisation (MPO) algorithm 
developed by Wager et al. (2010) has been shown to give robust correlations in more than 
thirty studies to date.124 The CNS MPO algorithm includes weighted components (score 0-1) 
for six physicochemical parameters: MW, cLogP, cLogD, tPSA, HBD and pKa of the most 
basic functional group. The values are combined in an additive manner, which maximises 
design flexibility, removes hard cut-off values for individual parameters and recognises that 
different combinations of properties may result in a similar biological profile. A high CNS 
MPO score (0-6) is correlated with important pharmacokinetic properties, such as increased 
passive permeability across the BBB, reduced P-glycoprotein (P-gp) transporter-mediated 
efflux, reduced intrinsic clearance of the unbound drug and improved cell viability in toxicity 
studies.124  
Table 2. Predictive scoring functions and relative scores for prospective and marketed drugs. 
Scoring Function 
Optimal Value Ranges 
Candidates Drugs 
LE 0.3 (hits)122  
LLE 3.8 5-6.2109, 119 
LELP 11 6.4119 
CNS MPO  ≥ 4 (74% of drugs)124 
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2.1.4 Homology modelling 
As mentioned, kinases are highly amenable to homology modelling because the active site 
is closely conserved between different enzymes, the kinase domain may be crystallised 
independently of the rest of the protein, and large databases of kinase crystal structures in 
complex with relevant ligands have been compiled. In silico docking can help direct drug 
design by identifying important binding interactions and predict ligand binding affinity.67, 125 
We have previously described our development of a LRRK2 homology model (see Chapter 
1.4.1).58 
A thorough understanding of the structure and attributes of the LRRK2 active site is essential 
for SBDD. The amino acid residues, binding pockets and global conformation that have been 
proposed in the literature are the outcome of rigorous sequence analysis and alignment, 
comparison of enzyme inhibitor profiles, inhibition studies using mutant LRRK2 isoforms and 
docking analysis in LRRK2 homology models.43, 50, 60, 64, 126, 127 
The LRRK2 kinase domain is comprised of a small N-terminal lobe and larger C-terminal 
lobe, which form the ceiling and floor of the active site respectively (Figure 10). The N and C-
terminal lobes are bridged by a convex hinge region. The frontal portion of the hinge 
contains the key amino acid residues Glu-1948 and Ala-1950 which interact with the adenine 
ring of ATP through hydrogen bonds from amide groups in the polypeptide backbone. The 
remainder of the adenine binding pocket (A-pocket) is dominated by aliphatic amino acid 
residues (Leu-1885, Val-1893, Ala-1904, Ile-1933, Leu-1949 and Leu-2001).67 The catalytic 
ion-pair (Lys-1906 and Glu-1920) are located at the back of the hinge, separated from the 
ATP-binding site by a bulky gatekeeper residue (Met-1947). The flexible DF(Y)G kinase 
activation loop, comprised of Asp-2017, Tyr-2018 and Gly-2019 (or Ser-2019 in G2019S-
LRRK2) lies on the far side of the catalytic residues. The side-chain of Asp-2017 chelates 
the Mg2+ ion that bridges between ATP phosphate residues.67, 128 Recently, two novel binding 
pockets P1 (between Lys-1952 and Tyr-2006) and P2 have been postulated. These pockets 
lie on the external edge of the frontal hinge region, where they may play a role in substrate 
binding.48 
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Figure 10. Homology model of the active site of LRRK2 indicating key amino acid residues and 
postulated binding pockets. Homology model based on the structure of Lck (PDB 1qpc). The LRRK2 
adenine binding site (A pocket) (A); key adenine binding residues Glu-1948 and Ala-1950 in red; DF(Y)G 
activation loop in blue; catalytic residues Lys-1906 and Glu-1920 in purple; hydrophobic residues Leu-1885, Val-
1893, Ala-1904, Ile-1933, Leu-1949 and Leu-2001 in brown; gatekeeper residue Met-1947 in yellow; and 
postulated substrate binding P1-pocket in cyan. Image constructed using Discovery Studio 3.5 Visualiser.129 
 
Competitive LRRK2 inhibitors are thought to reversibly bind to the A-pocket of the kinase 
hinge. It is therefore unsurprising that the pharmacophore of potent LRRK2 inhibitors often 
mimics adenine, containing a hydrophobic, often aromatic moiety, substituted with a HBD-
HBA groups correctly orientated for complementarity to Glu1948 and Ala-1950.67  
The Schrödinger program GLIDE can be used to predict the most probable pose(s) a ligand 
will assume when docked to a protein, the potential binding interactions and the free energy 
or binding affinity of the pose. The pose of a ligand refers to its conformation, and its position 
and orientation with respect to the active site. Poses are filtered by assessing both spatial fit 
and complementarity of possible protein-ligand interactions.130 Constraints may be set to 
restrict the selection of acceptable poses to those fulfilling defined criteria. The application of 
constraints can ensure that only ligands demonstrating similar binding poses to known 
inhibitors are selected. This increases the accuracy of calculated binding affinities for a 
series of ligands, but may also mean that potent ligands are discarded if they dock in a novel 
pose(s). Therefore, docking ligands under variable levels of constraint is useful for identifying 
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novel binding, selectivity or resistance patterns in poorly characterised molecular targets 
such as LRRK2.131 
Free energy minimisation matches allowed pose(s) to a pre-defined grid interface, and 
optimal poses are selected using an E-model scoring function which assesses the 
energetics of the free ligand, docked ligand, and the internal energy changes associated with 
assuming the optimal pose. The free energy of the pose(s) is calculated as a GLIDE score 
(G-score), which takes into account weighted components of all docking interactions 
(Equation 4). Negative magnitude predicts stronger binding affinity.130, 132  
 
Equation 4. ۵	ܛ܋ܗܚ܍	 ൌ 	૙. ૙૟૞ ∗ ܞ܌܅൅ ૙. ૚૜૙ ∗ ۱ܗܝܔ ൅ ۺܑܘܗ ൅ ۶܊ܗܖ܌ ൅ 	ۻ܍ܜ܉ܔ ൅ ۰ܝܚܡ۾ ൅ ܀ܗܜ۰ ൅ ܁ܑܜ܍	  
(vdW = van der Waals; Coul = coulomb; Lipo = hydrophobic/lipophilic; Hbond = hydrogen bonding; Metal = metal 
ligation; Site = non-hydrogen binding polar interactions; BuryP = penalty for buried polar groups; RotB = penalty 
for freezing rotatable bonds 
 
2.2 Rationale for Lead Selection 
2.2.1 Functional Potency  
Initial biological analysis of key synthetic intermediates from previous research identified 
aniline 1 as a moderately potent inhibitor of pro-inflammatory cytokine secretion.  
These results suggested that the diazepinone IN1_H motif of LRRK2IN1 and IN1_G may 
contribute minimally to inhibitor binding and/or functional activity. Owing to the poor 
physicochemical properties of LRRK2IN1 and IN1_G, and the functional activity of 1, it was 
attractive to investigate whether truncated analogues expressing a simplified diazepinone 
bioisostere could improve pharmacokinetic parameters whilst retaining functional activity.  
2.2.2 Pharmacokinetic Properties 
Using the in silico modelling programs, Marvin and LipPrep, QikProp, and Epik from the 
Schrödinger software suite, the relevant physicochemical and pharmacokinetic parameters 
for LRRK2IN1 and IN1_G were calculated (Table 1, Chapter 1.4.1).103, 104, 110 IN1_G was 
predicted to be more stable to oxidative metabolism than LRRK2IN1, which supported our 
previous work on the use of bioisosteres to block oxidative biotransformation. Unfortunately, 
the structural modifications introduced in IN1_G to improve stability did not improve some 
other physicochemical properties. In particular both LRRK2IN1 and IN1_G exceeded 
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Lipinski’s guidelines for maximum MW, had a large tPSA, and in the case of IN1_G, a high 
cLogP (Table 1, Chapter 1.4.1).70  
In contrast, aniline 1 was calculated to have optimal physicochemical properties The MW 
(322 g mol-1), cLogP (2.4) and tPSA (58 Å2) calculated for 1 were all close to the median 
values of CNS active drugs (MW = 305 g mol-1, cLogP = 2.8, tPSA = 44.5 Å2). Aniline 1 was 
predicted to be orally bioavailable (F = 86%), able to penetrate the BBB (MDCK = 351 nm 
s-1), and have only one metabolically labile functional group.  
2.2.3 Lead Validation Using Scoring Functions 
To validate our selection of aniline 1 as a lead compound for this work we consulted various 
scoring parameters (Table 3). 
The similarity between the LE scores calculated for LRRK2IN1, IN1-G and 1 indicated 
strong correlation between MW and potency. The low LE of diazepinone IN1_H conveyed 
that only a small proportion of molecular bulk contributed to potency, consequently low MW 
bioisosteres might retain similar potency whilst improving pharmacokinetic properties. Aniline 
1 was selected as a lead compound because its low MW provided scope to optimise 
pharmacokinetic properties, potency and selectivity. The incorporation of rationally selected 
bioisosteres of IN1_H into the scaffold of 1 was predicted to increase potency 
disproportionately to MW if binding contacts in the active site were optimised.  
The tabulated LLE values are in accordance with what would be expected from literature for 
drug-like (LRRK2IN1 and IN1_G) and lead-like (1) compounds (Table 2). The LLE of 
diazepinone IN1_H fell well below acceptable values. The lower LLE of IN1_G compared to 
LRRK2IN1 suggested that non-specific hydrophobic interactions primarily contributed to the 
improved potency of IN1_G.123  
Of the ligand efficiency parameters, LELP has been reported to predict drug safety and 
pharmacokinetic profiles most accurately.109, 119 The low LELP score calculated for aniline 1 
reflected properties more closely aligned with lead candidates (LELP = 11, Table 2) and 
successfully marketed drugs.119 In contrast, the high LELP scores of LRRK2IN1 and IN1_G 
supported our initial predictions that these compounds may have a poor biological profile. 
While the ligand efficiency scores presented in Table 3 correlate well with literature values, 
they should only be used for direct comparison within the given compound series. LE 
calculations normally use potency as measured by the negative log of IC50 or Ki values when 
determining LE scores. We calculated scoring parameters from potency as measured as the 
per cent inhibition of cytokine secretion at a single inhibitor concentration, because of limited 
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preliminary biological data. Scores were validated by comparison with values calculated from 
LRRK2IN1 IC50 values reported in the literature.61 Good agreement between the two sets of 
scores suggested a relatively small margin of error was introduced using our method. 
The CNS MPO scores calculated for LRRK2IN1, IN1_G, aniline 1 and diazepinone IN1_H 
supported our choice of 1 as a lead candidate. The moderate CNS MPO scores of 4.2 and 
3.4 that were calculated for LRRK2IN1 and IN1_G respectively supported our prediction that 
these compounds may exhibit a poor in vivo pharmacokinetic profile (Table 3, Chapter 
2.2.3).124 As expected, high MW and lipophilicity primarily contributed to the low CNS MPO 
scores. In contrast, aniline 1 was calculated to have a near optimal CNS MPO score of 5.124 
Compounds of the same chemotype and equivalent CNS MPO scores reported in the 
literature were orally bioavailable, CNS penetrant, and relatively stable to metabolic 
clearance.92 We proposed that aniline 1 and related analogues might exhibit similarly 
favourable in vivo pharmacokinetics.  
Predicted binding affinity (G-score) for each compound was calculated using the 
Schrödinger suite docking software GLIDE. The G-scores calculated for LRRK2IN1, IN1_G 
and aniline 1 correlate with the functional efficacy determined for the respective compounds 
in preliminary biological analysis, with more negative G-scores indicating stronger binding 
affinity. The consistency between predicted binding affinity for LRRK2 and the functional 
efficacy of these compounds provides support that anti-inflammatory efficacy may have been 
achieved through inhibition of LRRK2. However, inferences were made with caution as 
experimental binding constants have not been determined and further data was required to 
establish consistent correlation between in silico and experimental results. 
 
Table 3. Calculated scoring functions of preliminary/lead LRRK2 inhibitors. 
Compound LE LLE LELP CNS MPO G-score 
LRRK2IN1 0.22 6.6 12.6 4.2 -5.5 
IN1_G 0.24 5.3 18.1 3.4 -8.1 
1 0.22 2.3 11.4 5.0 -3.8 
IN1_H 0.07 -0.7 28.1 N/Aa N/Ab 
a – Not calculated; b – No acceptable poses; LE – ligand efficiency; LLE lipophilic ligand efficiency; CNS MPO – 
central nervous system multiparameter optimisation; G-score – grid-based ligand docking with energetics 
(GLIDE) score 
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2.2.4 Assessment of Conformation 
Two distinct poses were identified when potent LRRK2 inhibitor LRRK2IN1 and functionally 
active analogue IN1_G were docked in our previously described LRRK2 homology model 
(see Chapter 1.4.1). Both poses involved hydrogen-bonding interactions with A-pocket 
residues Glu-1948 or Ala-1950 through the diaryl-amine motif highlighted in Figure 11a and 
11b. Secondary hydrogen-bonding interactions from quaternary piperidinium or piperazinium 
ions also contributed to predicted binding affinity. LRRK2IN1 was show to hydrogen bond 
with Asp-2017, or nearby residues His-1998 and Asn-1999 in close proximity to the DF(Y)G 
activation loop. IN1_G was predicted to bind to Asp-1956 in the postulated P1 pocket. These 
additional binding interactions may be responsible for the high selectivity of LRRK2IN1. As 
previously mentioned, the majority of competitive kinase inhibitors bind through hydrogen 
bonding interactions in A-pocket, and exploiting binding interactions with additional amino 
acid residues is essential for target selectivity. Additionally, hydrogen bonding to activation 
loop residue Asp-2017 may explain the improved potency of LRRK2IN1 against mutant 
G2019S-LRRK2 (biochemical IC50 = 6 nM) compared to wt-LRRK2 (biochemical IC50 = 13 
nM),61 although these binding interactions have not been previously reported in literature.  
In the docking poses of both LRRK2IN1 and IN1_G the aniline fragment primarily 
contributed to binding interactions, while the diazepinone fragment was orientated in 
opposite directions making few bonding contacts. In LRRK2IN1, the diazepinone motif 
pointed towards the solvent exposed edge of the active site (Figure 11a), while in IN1_G it 
was predicted to be positioned in close proximity to the DF(Y)G loop. Consequently, 
predicted binding interactions, like functional potency, appeared to be independent of the 
diazepinone motif.  
Aniline 1 docked in a similar pose to LRRK2IN1, with the bipiperdine motif directed towards 
the DF(Y)G activation loop with the piperidinium ion in close proximity to Asp-2017. The 
primary aniline group docked in the A-pocket where it was predicted to hydrogen bond with 
Glu-1948. 1 was also predicted to form hydrogen bonding interactions with catalytic residue 
Lys-1906 through the aniline carbonyl group. We sort to exploit this novel binding interaction 
when designing truncated analogues because essential amino acid residues like Lys-1906 
are less likely to mutate and promote drug resistance.  
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Figure 11a and 11b. Docking poses of LRRK2IN1 (11a) and IN1_G (11b) in the active site of LRRK2 
homology model. Key hydrogen bonding interactions and functional groups involved in predicted binding 
interactions are shown. Hydrogen bonding interactions between the pyrimidinyl-aniline groups and the A-pocket 
residue Ala-1950 are indicated with green arrows. Hydrogen bonding of the piperzine/piperidine amines with 
amino acids in the DF(Y)G loop (11a) and P1-pocket (11b) are indicated for LRRK2IN1 and IN1_G respectively. 
2.3 Analogue Design 
A library of analogues were designed in a stepwise process, using information we garnered 
from analysing the docking poses of LRRK2IN1, IN1_G and 1 to guide our selection of 
appropriate diazepinone bioisosteres. LRRK2 inhibitors reported in the literature were 
docked in our LRRK2 homology model. Functional groups predicted to be important for 
binding to the A-pocket were selected as appropriate diazepinone bioisosteres, as they have 
proven potency, and would increase the diversity of our analogue library. The 
physicochemical and pharmacokinetic properties of proposed compounds were predicted 
using the previously described Schrödinger suite of software. Analogues predicted to have 
an improved pharmacokinetic profile, in particular a lower MW, lower cLogP and reduced 
susceptibility to metabolism than LRRK2IN1/IN1_G, were prioritised. Analogues were 
docked in our LRRK2 homology model to predict whether incorporated bioisosteres made 
productive contacts with the active site. 
Analogues were docked in our LRRK2 homology model and binding affinities were predicted 
using the Schrödinger program GLIDE. Constraints were applied through the software to 
favour docking poses that conformed with the established binding modes known inhibitor 
LRRK2IN1 and close analogue IN1_G. Poses were favoured if they correctly orientated 
hydrogen bond donor-acceptor functional groups (> 90o for donor atoms and > 60o for 
acceptor atoms) within close proximity (1.2-2.5 Å) to A-pocket residue Glu-1948 (amide 
C=O) or Ala-1950 (amide NH). 
(a) (b) 
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A number of analogues did not dock productively under the specified constraints. We 
subsequently analysed the analogue series in the absence of constraints to determine if they 
might bind to the active site in novel pose(s), which might be indicative of previously 
unidentified binding interactions. 
GLIDE was used to predict the relative binding affinity of analogues. G-scores were used as 
a final step to prioritise analogue for synthesis 
Classes of truncated LRRK2IN1/IN_G analogues that were selected for synthesis are briefly 
described below, along with design rationale and predicted binding conformation. The 
physicochemical and pharmacokinetic parameters and scoring functions of the selected 
analogue library are then overviewed in Chapter 2.4. 
2.3.1 Survey of the Literature  
To guide our design strategy we initially surveyed the literature to identified functional groups 
common to LRRK2 inhibitors, or shown to bind in the A-pocket of other relevant kinases. We 
analysed the binding pose(s) adopted by previously-identified, generic LRRK2 kinase 
inhibitors (Fig. 3, Chapter 1.3.1) using GLIDE and our LRRK2 homology model. These 
studies led us to propose a number of analogues that are summarised in Figure 12.75, 77, 78, 80, 
86, 92, 133 We sort to pursue analogues that contained functional groups which were supported 
by literature precedent as a means of improving the success rate and diversifying the 
chemistry of our analogue library. Analogues containing a common kinase inhibitor motif 
were predicted to improve the potency of 1, whilst selectivity might be retained through 
binding interactions of the bipiperidine motif.  
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Figure 12. Selected analogues incorporating functional groups identified from the literature.  
2.3.2 Five‐membered Heteroaromatic Analogues 
A number of potent LRRK2 inhibitors identified in the literature contain five-membered 
heteroaromatic rings as A-pocket binding motifs. Five-membered heterocycles are common 
in biologically active natural products and are regularly used as substitutes for phenyl rings, 
because of their high metabolic stability and favourable physicochemical properties.134 We 
proposed to synthesise a series of five-membered heterocyclic analogues, either directly 
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bonded to aniline 1, or separated by a carbon linker. Analogues were predicted to mimic the 
hydrogen bonding interactions of the diazepinone-pyrimidine ring whilst only increasing the 
MW of 1 minimally. Docking studies supported our design proposal predicting that analogue 
21 and 22 would hydrogen bond to the A-pocket through the heteroaromatic group and 
aniline NH group. Analogue 21 was predicted to have the best binding affinity of all analogue 
selected for synthesis (G-score = -7.8). Strong hydrogen bonding interactions between the 
pyrrole carboxamide motif and the A-pocket were unsurprising considering the ubiquity of 
the amide group in the structure of the peptide backbone. In contrast, analogues 20 and 22 
were predicted to adopt alternative binding poses, presumably because the tertiary 
heteroatoms were unable to hydrogen bond productively with the A-pocket. Pyrrole 
carboxamide 21 was also predicted to dock in close proximity to poorly conserved amino 
acid residue Phe-1883.60 We proposed that 21 might therefore exhibit high selectivity 
between kinases. 
All five membered heterocyclic analogues were predicted to have excellent physicochemical 
properties and high metabolic stability.   
 
Figure 13. Five-membered heteroaromatic aniline analogues predicted to have favourable 
pharmacokinetic properties. 
2.3.3 Pyrimidinyl‐Analogues 
A series of pyrimidinyl and pyridinyl substituted analogues were designed as direct mimics of 
the pyrimidinyl-diazepinone ring of LRRK2IN1/IN1_G. Hydrogen bonding interactions 
between pyrimidinyl heteroatoms and the A-pocket had been predicted to contribute to the 
binding interactions of LRRK2IN1/IN1_G in docking studies. We proposed that analogues 
substituted with heteroaromatic groups, such as 23, 24, 25, and 26 would allow the 
importance of these binding interactions to be investigated (Figure 14). The 2-pyrimidinyl 
aniline analogue 23 was designed to directly mimic the heteroaromatic group of the 
diazepinone motif. We sort to probe whether either the position of the heteroatoms and/or 
the number of heteroatoms was of importance to potency. Unsubstituted phenyl aniline 27 
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was designed as a negative control. However, it was also thought to improve the potency of 
1 through non-specific van der Waals contacts with the hydrophobic A-pocket.127 
Analysis of the docking poses of the heteroaromatic series of analogues supported our 
proposal that 2-pyrimidinyl aniline 23 analogue could form similar hydrogen bonding 
interactions to the A-pocket as LRRK2IN1, and was predicted to bind with equivalent affinity 
(G-score x = -5.1). Changing the orientation of the heteroatoms (25 and 26) was predicted to 
dramatically alter the binding orientation and decrease binding affinity from a G-score of -5.5 
for 25 to -1.1 for 26. (2/3-pyridinyl). Binding affinity was predicted to increase marginally with 
fewer heteroatoms, which may reflect the hydrophobicity of the active site.  
 
Figure 14. Six-membered heteroaromatic mimics of the pyrimidinyl-diazepineone functional group IN1_H.  
2.3.4 Substituted Aryl Analogues 
Substituted phenyl aniline analogues were designed to investigate whether polar functional 
groups at the ortho position of the aromatic ring (analogue 28 and 29) could mimic the 
predicted hydrogen bonding interactions of diazepinone heteroatoms. Analogues substituted 
at the meta and para positions were designed to gain insight in to the C4-amine and C5-
amide structures of the diazepinone (analogues 30, 31, 32, and 33). The C4-amine and C5-
amide were not predicted to be important in binding interactions, but they were predicted to 
be in close proximity to the DF(Y)G activation loop and catalytic residues in the docking pose 
of IN1_G, or the P1 pocket in the docking pose of LRRK2IN1. We thought to introduce 
favourable binding interactions with these residues by varying the nature of the C4/para and 
C5/meta substituents. 
Both electronic and steric factors contribute to binding interactions. Consequently, we 
selected analogues of varying inductive and resonance electron affinity and of different sizes 
and substitution patterns in an attempt to gain a broad overview of the SARs of this series. 
Docking analysis predicted that both the position and nature of substituents strongly effected 
both binding pose and binding affinity. Numerous novel hydrogen bonding interactions were 
identified in both the P1 pocket and DF(Y)G activation loop.  
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The binding pose of acetamide substituted aniline 33 indicated hydrogen bonding 
interactions between the secondary amide NH and A-pocket residue Ala-1950. This 
observation suggested that the potency of diazepinone IN1_H might also improve if the 
tertiary amide was dealkylated. We further investigated this possibility in our design of seven 
membered heterocyclic analogues (Chapter 2.3.7).  
 
Figure 15. Substituted phenyl aniline analogues. 
2.3.5 Benzyl Analogues 
Benzyl aniline analogues 34, 35, 36, and 37, substituted with equivalent functional groups as 
the afore-mentioned phenyl aniline series were designed to provide insight into a number of 
aspects of inhibitor binding. 
We proposed that increasing the distance between the aniline and polar aryl substituents 
might allow new bonding interactions to the A-pocket without disrupting interactions between 
the bipiperidine motif and DF(Y)G activation loop (Asp-2017, Lys-1906) or P1 pocket (Asp-
1956). The methylene bridge between the aniline and aryl groups would disrupt planarity and 
increase molecular flexibility, further favouring novel binding interactions. We also proposed 
that extending the aryl group further from the aniline could favour previously identified sigma-
pi interactions between Leu-2001 and IN1_G without the necessity of the diazepinone motif. 
Finally, the increased basicity of the aniline NH in benzyl analogues compared to phenyl 
aniline analogues would allow the strength of hydrogen bonding interactions to be evaluated.  
Docking analysis supported our design decisions, indicating that benzyl substituents mapped 
more closely to the position of the diazepinone motif of LRRK2IN1/IN1_G than their phenyl 
aniline counterparts. Benzyl aniline 34 was predicted to form similar sigma-pi interactions to 
Asp-2017 as identified between IN1_G and Leu-2001. Asp-2017 and Leu-1906 are in close 
proximity and the difference in interaction is believed to be because of increased flexibility of 
the benzyl group compared to diazepinone. Benzyl aniline 334 was also predicted to 
hydrogen bond with gatekeeper residue Met-1947. Met-1947 is poorly conserved across the 
kinome and could be used to engender inhibitor selectivity.67 Similarly, we predict that 4-
nitrobenzyl aniline 36 might be highly selective for LRRK2, as it was predicted to hydrogen 
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bond with Ser-1954 through the bipiperidine amide group (C=O) in a manner reminiscent of 
potent LRRK2 inhibitors reported in the literature.59 Ser-1954 has previously been identified 
as one of four non-conserved residues in the LRRK2 active site.60 In contrast to the other 
benzyl analogue that retained a similar binding pose to previously identified compounds 
LRRK2IN1 and IN1_G, 4-methyl benzyl aniline 37 was predicted to form additional hydrogen 
bonding interactions to Glu-1906 in the recently identified P2 pocket.48 The good G-score 
calculated for analogue 37 (G-score = 5.4) indicated the bonding interactions in the P2 
pocket compensated for interactions lost with the DF(Y)G activation loop.  
The novel binding interactions and relatively low MW of the benzyl aniline analogue made 
them a high priority for synthesis. 
 
Figure 16. Substituted benzyl aniline analogues. 
2.3.6 Aliphatic Analogues 
We proposed to synthesise a number of aliphatic derivatives to investigate whether 
aromaticity was necessary for functional activity. Sigma-pi interactions had previously been 
identified between the diazepinone motif of IN1_G and hydrophobic amino acid residue Leu-
2001. Substitution of the aromatic group for a linear or cyclic alkane such as in analogues 38 
and 39 would enable us to probe the importance of these binding interactions. Additionally, 
analogues 38 and 39 would provide insight into the relative efficacy of secondary versus 
primary 1 anilines, and would contribute to binding affinity through increasing non-specific 
hydrophobic interactions. The additive contribution of hydrophobic interactions to binding 
affinity is often overlooked during drug development because the interactions are non-
selective between protein targets.120, 135 However, we proposed that non-specific steric 
interactions could also be used to shift the position of the aniline fragment and optimise 
hydrogen bonding interactions with the A-pocket. By varying the size of alkyl substituent we 
hoped to investigate the importance of steric factors in orientating binding groups for potent 
interactions.  
The predicted pose and binding affinity of the cyclohexyl aniline 39 was very similar to 
aniline 1, indicating that the cyclohexane ring did not directly participate in any bonding 
Chapter 2 – Molecular Modelling 
[34] 
 
interactions. The bulk of the cyclohexane substituent shifted the aniline fragment slightly, to 
favour hydrogen and halogen bonding interactions with the A-pocket through the o-
chloroaniline motif. Halogen bonding interactions between an aryl chloride and aspartate 
residue were recently reported to cause a 20-fold increase in binding affinity of CDK kinase 
inhibitor purvalanol A.67  
 
Figure 17. Aliphatic aniline analogues. 
2.3.7 Diazepinone Analogues and Previously Identified Analogues  
Direct analogues of the diazepinone fragment IN1_H were designed to probe the importance 
of specific functional groups in the anti-inflammatory efficacy of LRRK2IN1 and IN1_G. 
Diazepine aniline analogue 40 was designed to probe the importance of the lactam carbonyl 
group. The lactam had not been previously identified to be important in binding and we 
hypothesised that its removal would not affect potency. Dealkylation to produce diazepine 41 
was thought to possibly improve the potency of IN1_H by introducing additional hydrogen 
bond donor groups. We also designed oxazepine analogues 42 and 43, as previous work 
indicated that the diaryl ether of oxazepin-one analogue improved metabolic stability by 
deactivating adjacent aromatic rings towards oxidative metabolism. We had experienced 
difficulty in previous research alkylating oxazepinone analogues of IN1_H, and presumed 
that alkylated oxazepines might be more accessible because of the increase basicity of the 
nitrogen atom and decreased steric hindrance. 
Analogue 40 was predicted to dock in an almost identical pose to LRRK2IN1. The bulky 
diazepine substituent was orientated towards the P1 pocket at the exterior of the active site, 
and not predicted to partake in any binding interactions. The similarity of the structure and 
predicted binding pose of these analogues suggested that they might be potent inhibitors of 
LRRK2 with good anti-inflammatory efficacy. 
Analogues 40, 41, 42 and 43 were not predicted to improve pharmacokinetic parameters, 
but were selected for synthesis because of their potential to make a valuable contribution to 
understanding the LRRK2 active site and inhibitor pharmacophore. 
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Figure 18. Diazepine and oxazepine aniline analogues designed to investigate the importance of lactam 
and amine functional groups in LRRK2 inhibitor potency.  
2.4 Predicted Physicochemical Parameters and Scoring Functions 
The physicochemical properties of the proposed analogues were calculated and relevant 
pharmacokinetic parameters were predicted using the previously described suite of 
Schrödinger software programs. Cursory analysis of the predicted properties indicated the 
MW and tPSA of all truncated analogues was less than LRRK2IN1 and IN1_G, which should 
correlate with improved solubility, absorption and cellular permeability. The MWs of all 
compounds except diazepine analogue 40 were higher than the median expected for CNS 
active compounds (MW = 305 Da), but lower than the upper threshold set by Lipinski (MW = 
500 Da).70, 109 The cLogP values calculated for the majority of analogues also exceed the 
median value reported in literature for CNS drugs (cLogP	 = 2.8). However, it is generally 
accepted that kinase inhibitors have larger MWs (mean = 392-437) and cLogP (mean = 3.0-
4.1) values than other classes of drugs in clinical development because they need to make a 
higher number of ligand-protein interactions to confer selectivity.118, 136  
Half of the proposed analogues were predicted to have equivalent metabolic stability to 
rationally designed inhibitor IN1_G, and only one of the selected analogues was predicted to 
be as susceptible to metabolism as LRRK2IN1. As expected, the analogues containing five-
membered heteroaromatic groups, particularly the pyrazole 20 and substituted pyrrole 21 
and 22 analogues were predicted to have high resistance to oxidative metabolism. In 
comparison, the six-membered heteroaromatic analogues 24 and 26 were predicted to be 
highly susceptible to metabolism. As described in previous research, incorporating electron 
withdrawing substituents onto the aromatic ring of these analogues may decrease oxidative 
biotransformation.58 
All proposed analogues were predicted by QikProp to readily penetrate the BBB and be 
active in the CNS. All analogues were predicted to be highly absorbed from the 
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gastrointestinal tract (oral absorption [F] > 80%). In comparison, the predicted and 
experimentally determine oral absorption of LRRK2IN1 were only 47% and 50% 
respectively.61  
Lead-to-drug optimisation with respect to a single physicochemical property, such as MW or 
cLogP, has a low success-rate because it does not align multiple drug-like properties at 
once. We calculated the CNS MPO score of each of the proposed analogues, and used 
these values to select analogues that were likely to have a favourable pharmacokinetic 
profile in future biological studies. After assessing the scores, we selected a series of 
truncated analogues from the proposed compounds that had CNS MPO scores comparable 
with more than 53% of marketed CNS active drugs (3< CNS MPO < 5).124 Ninety five per 
cent of the selected compounds had CNS MPO score greater than IN1_G and 32% had a 
score greater than LRRK2IN1. This data strongly suggested that the proposed analogues 
were more likely to be aligned with desirable properties such as increased CNS penetration, 
reduced promiscuity, lower levels of metabolic clearance and an improved safety profile.124 
Only N-methylpyrazole aniline 20 was predicted to have an equivalent or higher CNS MPO 
score than aniline 1. The high CNS MPO score of 1 was a primary factor in our initial 
selection of 1 as a good lead candidate. 
 All analogues based on aniline 1 were predicted to have a higher pKa than median for 
marketed drugs (pKa = 8.4) because of the basicity of the tertiary piperidinyl amine. Highly 
basic amines are known to be a risk factor for hERG-channel inhibition.137 We suggest that 
the basicity of this series of analogues may need to be tuned in later optimisation steps to 
adjust for this potential toxicity. We did not address this aspect in the current analogue series 
owing to the predicted importance of the protonated piperidinium ion for binding in the active 
site. 
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Chapter 3 – Chemical Synthesis 
The following discussion of chemical synthesis and outcomes has been subdivided 
according to the chemical structures of truncated LRRK2IN1/IN1_G analogues and the 
synthetic reactions used to access a certain class of analogues. A general discussion of the 
utility of synthetic procedures and suggested optimisation in future work is overviewed.  
3.1 Retrosynthetic Analysis 
The synthesis of 1 has been described in our previous research and is summarised in 
Scheme 1, Chapter 1.4.2. The desired library of truncated LRRK2IN1/IN1_G analogues 
could be accessed following a convergent synthetic route with 1 as a key intermediate 
(Scheme 2). We perceived that appropriately activated aromatic/aliphatic motifs could be 
coupled to 1 using one of a number of known nucleophilic substitution procedures. The 
functionalised electrophilic fragments 45 would be accessed from their respective precursors 
44 by electrophilic aromatic substitution with halogens, or directly from commercial sources. 
Decorating amide functional groups for analogues 47 and 49 could be synthesised from the 
respective amine 46 and carboxylic acid 48 components under standard amide bond forming 
conditions. Aniline 1 would be accessed as described in Scheme 2, Chapter 1.4.1, from the 
commercially available 4-amino-3-chlorobenzoic acid and synthesised 1,4’-biperidinyl amine 
14. 1,4’-bipiperidine 14 could be synthesised from an appropriately N-protected analogue, 
which itself could be arrived at through reductive amination of the respective N-protected 
piperidone 11 and piperidine 12 precursors which are commercially available. 
The convergent nature of the proposed route was thought to be cost, time and resource 
efficient. By following standard reaction procedures, and procedure shown in the literature to 
have diverse substrate scope, we thought to maximise the variety of analogues that could be 
accessed through this route. 
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Scheme 2. Retrosynthesis of truncated LRRK2 inhibitors. 
3.2 Synthesis of Electrophilic Fragments  
The majority of aromatic, heteroaromatic, or aliphatic electrophiles used in the synthesis of 
truncated LRRK2 inhibitor analogues were available on-hand, or obtained at low cost from 
commercial sources. Uncommon electrophiles such as the halogenated five-membered 
heteroaromatic compounds and 4-iodoacetamide were obtained through short synthetic 
procedures that are briefly described in the follow subsections. The seven-membered 
diazepine and oxazepine analogues of diazepinone motif IN1_H were synthesised according 
to an optimised route recently devised in our group for the synthesis of similar 
benzopyrazolo-diazepine fragments.138 
3.2.1 Pyrazoles  
To access analogue 20, which was predicted to be a 
metabolically stable and CNS penetrant analogue of 
LRRK2IN1/IN1_G, we synthesised a halogenated 
pyrazole electrophile 45. We selected to synthesise 
the iodo-pyrazole because aryl iodides are the most 
reactive coupling partners for Buchwald-Hartwig 
aromatic substitution reactions, which would be used 
in the subsequent synthetic step.139, 140 5-Iodopyrazole 45 was synthesised from N-methyl 
Scheme 3. Synthesis of 5-iodo-1-methyl-1H-
pyrazole. Reagents and conditions: 44 (1
equiv.), n-BuLi (1.1 equiv.), TMEDA (1.1
equiv.), iodine (1.2 equiv.), THF, (0.24 M), -78
oC to -10 oC, 3.5 h, 45 69% 
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pyrazole 44 (Scheme 3), via the corresponding organolithium intermediate. Resonance 
electron donation from the heteroatom lone pair of electrons directed lithiation selectively to 
the electron-rich 5C-position.141 Nucleophilic attack of the pi-electrons on the iodine 
electrophile proceeded rapidly to generate 45 in acceptable yield (69 mol%).  
3.2.2 Maleimides  
Halogenated maleimides have been shown to 
react with amine nucleophiles in thermal or base 
promoted aromatic substitution reactions.142, 143 3-
bromomaleimide was synthesised by heating 
bromine and the unsubstituted maleimide 
precursor 50 to reflux in chloroform (Scheme 4). 
Base-promoted elimination of hydrogen bromide 
from the 2,3-dibromosuccinimide 51 intermediate 
yielded the desired mono-halogenated electrophile 
52 (70 mol% over 2 steps).144 
We also attempted to synthesise the respective N-nitrophenyl protected maleiminde 
derivative 55 because alkyl- or aryl-protection would improve the stability of the electrophile 
in subsequent substitution reactions. We experienced considerable difficulty with this 
reaction, obtaining a complex and insoluble mixture of uncyclised products. The electron 
withdrawing effects of the 4-nitroaniline substituent most likely deactivated the anilide 
nucleophile, preventing intramolecular condensation and formation of the cyclised maleimide 
55. Substitution of the 4-nitroaniline 54 with a more electron rich nucleophile might prove 
more successful. N-Protected maleimides have also been synthesised in the literature from 
maleimide and an appropriate alcohol nucleophile using Mitsunobu chemistry.145 The 
synthesis of these fragments will be investigated in future research.  
 
Scheme 5. N-protected maleimides. Reagents and conditions: (a) maleic anhydride 53 (1 equiv.), 4-nitroaniline 
54 (1 equiv.), Et2O (5 M), 0 oC, 10 min, then acetic anhydride (5 equiv.), NaOAc (0.6 equiv.), 60 oC, 2 h; (b) 
maleic anhydride 53 (1 equiv.), 4-nitroaniline 54 (1 equiv.), acetone (1 M), 55 oC, 1 h, then Et3N (0.88 equiv.), 
acetic anhydride (0.52 equiv.), NiSO4 (15% w/v solution, 0.001 equiv.), r.t. – 80 oC, 48 h.  
Scheme 4. Synthesis of 3-bromomaleimide.
Reagents and conditions: 50 (1 equiv.), bromine
(1equiv.), CHCl3 (0.13 M), reflux, 2 h, r.t., 1 h.
(ii) 51 (1 equiv.), Et3N (1.05 equiv.), THF (0.30
M), 0 oC, 1 h, 52 70% 
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3.2.3 Aryl Amides  
To probe the importance of the diazepinone IN1_H lactam motif in binding to the LRRK2 
active site we were interested in synthesising analogues of 1 bearing aryl amide 
substituents. 
The N-phenylacetamide group of analogue 33 closely mimicked the structure of the lactam 
amide and was predicted to allow additional hydrogen bonding interactions through the 
secondary anilide –NH group. The necessary electrophilic coupling partner N-(4-
iodophenyl)acetamide 47 was synthesised from 4-iodoaniline 46 and acetyl chloride 56 in 
the presence of N,N-diisopropylethylamine (Scheme 6). The reaction was rapid and high 
yielding (94 mol%). 
Thiophenes are very stable five-membered heterocyclic compounds. They are under-
represented in medicinal chemistry literature despite possessing excellent physicochemical 
and pharmacokinetic properties. Based on recent examples in patent literature we 
suggested that thiophenyl analogues of aniline 1 might be potent LRRK2 inhibitors.85, 86 A 
simple thiophene carboxamide electrophile 49 was synthesised for incorporation into our 
truncated analogue series. Comparison of analogue 18 with the corresponding pyrrole 
carboxamide 21, acetamide 33 and diazepine 40 analogues would provide insight into the 
importance of the IN1_H lactam motif for functional activity. Electrophile 49 was synthesised 
in good yield (84 mol%) from 5-bromo-2-thiophene-carboxylic acid 48, and pyrrolidine 57, 
using 1-ethyl-3-(3-dimethylaminopropyl)carbodimide hydrochloride, and 1-
hydroxybenzotriazole to activate the carboxylic acid, and N,N-diisopropylethylamine as a 
hindered base, in dichloromethane (Scheme 6).  
 
Scheme 6. Synthesis of aryl amide electrophiles. Reagents and conditions: (a) 4-iodoaniline 46 (1 equiv.), 
acetyl chloride 56 (1.1 equiv.), DIPEA (1.5 equiv.), dry THF (0.36 M), r.t., 2.5 h, 47 93%;(b) 5-bromothiophene-2-
carboxylic acid 48 (1 equiv.), pyrrolidine 57 (1 equiv.), EDCI (1.25 equiv.), HOBt (1.25 equiv.), DIPEA (3.9 equiv.), 
dry DCM (0.04 M), 0 oC - r.t., 3 h, 49 84%. 
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3.2.4 Seven‐membered Heteroaromatic Compounds 
We desired to synthesise diazepine 40 and 41 and oxazepine 42 and 43 analogues of 
IN1_H to investigate electronic, conformational and hydrogen bonding characteristics that 
might contribute to binding affinity and functional activity. Initial attempts to access these 
fragments from the corresponding diazepinone or oxazepinone by lactam reduction with 
hydride or borane reducing reagents were unsuccessful. The di/ox-azepinone precursors 
were either unreactive, degraded or rapidly eliminated the pyrimidinyl-chloride atom that was 
necessary for subsequent coupling reactions to aniline 1.  
Recently our group developed a novel route to access benzopyrazolo-diazepine analogues 
of medicinal important oxytocin agonists.138 Using this methodology we were able to access 
di/ox-azepine electrophilic fragments 63, 64, 65 and 66, and concomitantly explore the 
scope of the synthetic route for heterocycles other than pyrazole (Scheme 7).  
The functionalised synthetic fragment 7 has been reported in our previous work (Scheme 1, 
Chapter 1.4.2)58 and is repeated here for clarity. Nitration of uracil 5 under standard 
electrophilic aromatic substitution conditions using concentrated nitric acid and concentrated 
sulfuric acid, yielded 5-nitrouracil x in 93 mol%.146 Chlorination of 6 using freshly distilled 
phosphorus oxychloride and the hindered base N,N-dimethylaniline gave 7 in low, but 
acceptable yield (43 mol%).147  
2-Aminobenzaldehyde 59 was obtained from 2-nitrobenzaldehyde 58 under mild reducing 
conditions using iron powder and dilute hydrochloric acid.148 This reaction was very efficient, 
yielding 98 mol% of the desired 2-aminobenzaldehyde 59. The phenolic analogue 60 was 
obtained directly from commercial sources and used without further purification.  
Nucleophilic aromatic substitution of pyrimidine 7 with either 2-amino 59 or 2-
hydroxybenzaldhydes 60 was rapid and highly regioselective because of the directing effects 
of the 5-nitro substituent and pyrimidinyl nitrogen atoms. Formation of 2,4-disubstituted by-
products was a primary contributor to the moderate reaction yields of 61 (78 mol%) and 62 
(68 mol%). By-product formation was greater when using the phenolic nucleophile 60 
compared to aniline 59. A probable explanation was the increased electrophilicity of product 
62 imparted by the more electron withdrawing aryl ether substituent. In contrast, the aniline 
in product 61 would be more likely to increase the electron density of the pyrimidine by 
delocalisation of the nitrogen lone-pair and deactivate the C2-chlorine towards further 
substitution.  
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With 61 and 62 in hand, we proceeded with the synthesis of diazepine 63 and oxazepine 64 
electrophiles. Previous success synthesising a precursor to diazepinone IN1_H using a 
tandem nitro-reduction-aminolysis reaction (Scheme 1, Chapter 1.4.2) prompted us to 
optimise conditions with the hope of yielding 63 and 64 by the analogous one-step nitro-
reduction-reduction amination reaction. Previous research had shown this was achievable 
for unsubstituted benzopyrazolo-diazepines using palladium on carbon as a catalyst under a 
reducing atmosphere of hydrogen gas.138 We believed that these conditions would be 
unsuitable for substrates 61 and 62 because of the labile pyrimidinyl chloride substituent.149 
As such, we first investigated the reaction of 61 under activated metal catalysis, using either 
zinc or iron powder and glacial acetic acid. Similar conditions had previously been shown to 
tolerate a wide range of functional groups including heteroaromatic halides.150 The 5-nitro 
group was rapidly reduced to the corresponding aniline at low temperatures using either iron 
or zinc catalytic systems. Intramolecular condensation of the resulting aniline to the 
benzaldehyde was only observed with zinc powder and acetic acid. A complex mixture of the 
imidic acid, imine and amine products was obtained at room temperature. Product ratios 
were not improved by heating the reaction, or using a sealed reaction tube. We also 
attempted to form 63 using a two-step procedure first reducing the nitro group using iron 
powder and acetic acid, and then subjecting the crude aniline intermediate to reductive 
amination conditions using acetic acid and sodium triacetoxyborohydride in 1,2-
dichloroethane. A small amount of diazepine 63 was detected by mass spectrometry but 
yields were exceptionally low.  
Adam’s catalyst (platinum(IV) dioxide) is a mild alternative to palladium on carbon which 
allows chemoselective hydrogenation of nitro groups without dehalogenation of aryl 
halides.149 Under a hydrogen atmosphere we found that Adam’s catalyst rapidly reduced the 
nitro group of 61 at room temperature, without formation of the diazepine 63. But when the 
reaction was heated to reflux in methanol, almost quantitative yields of the crude diazepine 
63 were obtained after 48 hours. Mass spectrometry confirmed that the important pyrimidinyl 
chloride group remained intact. Reaction progress could be easily monitored using 1H-NMR 
to observe the change in proton frequencies as the aldehyde and imine hydrogen signals 
shifted from far downfield to the more electron-rich methylene environment upfield.  
Gratifyingly, these conditions were also successful at catalysing the tandem nitro reduction-
reductive amination reaction of 62 to form oxazepine 64. The reaction with substrate 62 was 
not optimised because of time constraints, and consequently, product yield was markedly 
reduced (40 mol%). The low yield of 64 might have resulted from hydrogenolysis of the aryl 
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ether bond and degradation of the starting material.151 Similar observations had been made 
during the synthesis of an oxazepinone analogue during previous research.58  
In the final synthetic step the diazepine 63 and oxazepine 64 amines were methylated at low 
temperatures using iodomethane, sodium hydride as a non-nucleophilic base and the polar 
aprotic solvent N,N-dimethylacetamide. Quantitative yields were obtained of diazepine 65 
but low yields (33 mol%) were obtained of oxazepine 66. Given time constraints we only had 
the opportunity to trial the reaction with oxazepine 66 once. Optimisation of conditions might 
result in improved yields, however previous attempts to methylate a similar oxazepinone 
compound were unsuccessful under numerous reaction conditions. Our success methylating 
64 indicated that steric interactions from the carbonyl group or the reduced nucleophilicity of 
the amide nitrogen atom compared to the amine of 64, might have contributed to the poor 
reactivity of the oxazepinone.  
 
Scheme 7.Synthesis of diazepine and oxazepine analogue of diazepinone IN1_H for use in nucleophilic 
substitution reactions with aniline 1. Reagents and conditions: (a) H2SO4 (6 equiv., 98 %w/v)), HNO3 (2 equiv. 
70% w/v), 50 °C, 3 h, 6 92%; (b) POCl3 (5 equiv.), N,N-dimethylaniline (2.5 equiv.), reflux, 3 h, 7 43%;(c) 2-
nitrobenzaldehyde 58 (1 equiv.), Fe powder (3 equiv.), aqueous HCl (0.16 equiv. 0.15 M), EtOH (0.35 M), reflux 1 
h, then r.t. 0.5 h, 59 98%; (d) 2-aminobenzaldehyde 59 or 2-hydroxybenzaldehyde 60 (1 equiv.), 2,4-dicloro-5-
nitropyrimidine 7 (1.5 equiv.), DIPEA (2 equiv.), dry 1,4-dioxane (0.2 M), 65 oC, 1.75 h, 61 78%, or 50 oC, 1.5 h  
62 68%; (e) 61 or 62 (1 equiv.), PtO2 (0.03-0.06 equiv.), H2 gas, MeOH (0.1 M), reflux, 24-48 h, 63 quant., 64 
40%; (f) 63 (0.5 equiv.) or 64 (1 equiv.), NaH (3.5 eq.), MeI (1.2 eq.), DMA (0.08 M), -10-0 oC, 1.5 h, 65 quant., 
66 33%. 
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3.3 Synthesis of Six‐membered Aromatics Analogues 
3.3.1 Buchwald‐Hartwig Chemistry 
Aromatic compounds are unable to undergo substitution reactions by standard SN1 or SN2 
mechanisms because the required sp2-hybridised carbocation intermediate is highly 
unstable and access to the appropriate anti-bonding orbital is hindered by the aromatic ring. 
Aromatic compounds substituted with strong electron withdrawing groups (EWGs) may react 
by a nucleophilic aromatic substitution (SNAr) mechanism. SNAr involves sequential 
nucleophilic addition, formation of a negatively charged Meisenheimer intermediate and 
elimination of an appropriate leaving group. Aromatic compounds may also react through a 
benzyne intermediate in an elimination-addition-type mechanism, but these reactions are 
less common. The necessity of strong EWGs to promote SNAr reactions significantly limits 
the scope of this chemistry. The development of transition metal catalysed SNAr reactions 
had an enormous impact on organic synthesis, and particularly the field of medicinal 
chemistry. In 1994, Stephen L. Buchwald and John F. Hartwig independently described the 
development of a novel palladium(0)(Pd(0))-catalysed nucleophilic aromatic substitution 
reaction between aryl halides or triflates, and either oxygen or nitrogen nucleophiles.152, 153 
The reaction initially involved in situ formation of organnostannane intermediates, but was 
revised in 1995 to avoid the use of toxic tin species.154, 155 Modern Buchwald-Hartwig 
reactions employ electron donating, bulky phosphine ligands to promote oxidative addition to 
the organo-halide electrophile and a stoichiometric quantity of base to deprotonate the 
nucleophile after it adds to the palladium complex. The mechanism of the Buchwald-Hartwig 
reaction has not been unequivocally elucidated, however, it is thought to follow similar steps 
to other transition metal-catalysed and cross-coupling reactions: ligand dissociation (i); 
oxidative addition of the electrophile to the catalytic Pd(0) complex (ii); coordination of the 
nucleophile to the Pd(II) complex (iii); deprotonation with base (iv); and, finally, reductive 
elimination to form the substituted arene and regenerate the catalytic Pd(0) species (v).156 
Alternatively, study of the reaction kinetics has suggested coordination of the nucleophile or 
alkoxide base to the Pd(0) complex might occur prior to oxidative addition. The exact 
mechanism is thought to depend on the relative concentration of the reactive species, and 
the type of base, solvent and phosphine ligand included in the catalytic system.157, 158 
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Figure 19. Proposed mechanism of Pd(0) catalysed nucleophilic aromatic substitution: ligand 
dissociation (i); oxidative addition; (ii); coordination of the nucleophile (iii); deprotonation (iv); reductive 
elimination (v)159 
 
The scope of Buchwald-Hartwig chemistry has been expanded over the past two decades by 
optimising reaction temperature and duration, and selecting an appropriate solvent, base, 
phosphine ligand and palladium pre-catalyst. A diverse range of electrophilic and 
nucleophilic species can now be coupled in high yields.159, 160 The versatility of the 
Buchwald-Hartwig reaction made it an obvious selection for the synthesis of truncated 
LRRK2IN1/IN1_G analogues from aniline 1 and aromatic electrophiles.  
Previous research established that lead aniline 1 was a poor nucleophile under a range of 
acid or base catalysed, thermal or microwave-promoted reaction conditions. In contrast, 
aniline 1 reacted under Buchwald-Hartwig reaction conditions, but product yields were low 
and unpredictable for the catalytic system initially employed.58 After surveying the literature 
and trialling numerous reagent combinations and conditions, we developed the generalised 
reaction conditions shown in Scheme 8. Caesium carbonate was selected because mild 
bases improve functional group tolerance compared to commonly employed alkoxide 
bases.161 In addition, caesium carbonate is non-nucleophilic and does not compete with 
nucleophiles for addition to the palladium catalyst. Common palladium(0) pre-catalyst tris-
dibenzylidene acetone dipalladium (Pd2(dba)3) was selected as it is commercially available 
as an easy-to-handle, air and moisture-stable chloroform complex.162 Palladium(II) pre-
catalysts may also be used in Buchwald-Hartwig reactions, as they are reduced in situ by 
reaction with phosphine ligands. An exhaustive number of phosphine ligands have been 
developed for transition metal catalysed reactions, each of which has been demonstrated to 
improve catalyst reactivity towards specific classes of coupling partners. It was not 
economically viable to employ a different phosphine ligand for the synthesis of each 
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LRRK2IN1/IN1_G analogue. The electron-rich and bulky ligand 2-dicyclohexylphosphino-
2’,4’,6’-triisopropylbiphenyl (X-Phos) was selected because of its applicability to a diverse 
range of substrates. Activated and deactivated aryl halides and anilines, heteroaromatic 
compounds and those bearing sensitive functional groups have all been successfully reacted 
together using X-Phos as a ligand.163 Numerous different solvents have been successfully 
used in Buchwald-Hartwig chemistry, but non-polar, aprotic solvents like toluene and 1,4-
dioxane are most common. These solvents increase the ratio of desired products, do not 
chelate the palladium catalyst and are non-nucleophilic.164 We selected 1,4-dioxane because 
it enhanced the solubility of aniline 1, allowed reactions to be performed with consistency at 
a moderately high temperature (bp = 101 oC), and allowed microwave-assisted coupling 
conditions to be employed when required. 
Table 4 summarises experiments performed to synthesise 13 truncated LRRK2IN1/IN1_G 
analogues. The structure of the respective electrophile, number of equivalents relative to 
aniline 1 and product yield are described. The following Chapter 3.3 subsections detail 
important observations, draw relevant comparisons and discuss unexpected results from this 
series or experiments. 
 
Scheme 8.General reaction conditions for the Buchwald-Hartwig amination of substituted aryl halides. 
Reagents and conditions: 1 (1-2 equiv.), Electrophile (1-2 equiv.), Pd2(dba)3 (0.05 equiv.), X-Phos (0.10 equiv.), 
Cs2CO3 (3 equiv.), dry 1,4-dioxane (0.1-0.2 M), reflux, 2-6 hours. 
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Table 4. Truncated aryl aniline analogues synthesised using Buchwald-Hartwig chemistry. Electrophiles 
were reacted with aniline 1 in anhydrous, degassed 1,4-dioxane, in the presence of Pd2(dba)3 (0.05 equiv.), X-
Phos (0.1 equiv.), Cs2CO3 (3 equiv.). The number equivalents of electrophile relative to aniline 1 is reported, 
along with mol % of the desired product that was obtained.  
Exp. Code Aryl Halide Eq.a Yield 
1. 67 
 
0.5 29, 0% 
2. 68 
 
0.5 25, 0% 
3. 69 
 
0.8 25, 31%b 
4. 70 
 
0.5 23, 27% 
5. 65 1.05 40, 3%c 
6. 71 
 
0.75 105, 33%b 
7. 72 
 
2 25, 66% 
8. 73 
 
2 26, 47% 
9. 74 
 
0.7 24, 12% 
10. 75 
 
1 27, 71% 
11. 76 
 
0.5 29, 91% 
12. 77 
 
0.5 31, 98% 
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13. 47 
 
1.1 33, 45% 
14. 78 
 
1.1 32, Quant. 
15. 79 
 
2.7 28, Quant. 
16. 80 
 
2 30, 94% 
a - Number of equivalents of electrophile relative to aniline 1; b – not purified, yield calculated from 1H-NMR 
integration; c – 10% b.r.s.m.
 
3.3.2 Aryl Halide Leaving Group 
Metal-catalysed SNAr reactions exhibit an inverse preference for the halogen leaving group 
compared to non-metal catalysed SNAr reactions. The rate determining step of traditional 
SNAr reactions is addition of the nucleophile to the aromatic ring to form an anionic 
Meisenheimer intermediate. Polarisation of the electrophilic carbon centre is a key driving 
force for the reaction. Consequently, aryl fluorides are more reactive than arenes substituted 
with less electronegative halogens (rate (k) = C-F > C-Cl > C-Br > C-I). In contrast, the rate 
determining step of Buchwald-Hartwig reactions is thought to be oxidative addition of the aryl 
halide to the palladium catalyst. Therefore, carbon-halogen bond strength primarily 
determines electrophile reactivity, mirroring the reactivity order of standard SN2 reactions 
(rate (k) = C-I > C-Br > C-Cl > C-F).139, 140  
The results of experiments 2, 3, and 7 exemplify the expected order of reactivity. Reaction of 
the 2-pyridinyl fluoride 68, chloride 69 or bromide 73 electrophiles yielded 0 mol%, 31 mol% 
and 66 mol% of desired analogue 25 respectively. Where possible, we subsequently used 
aryl iodide or bromide electrophiles to synthesise our library of aniline analogues. Aryl 
chloride or fluoride electrophiles were trialled where economic considerations or availability 
restricted access to the more reactive coupling partners. 
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3.3.3 Carbocyclic Substituent Effects 
The broad substrate scope of Buchwald-Hartwig chemistry has been integral to its success 
and utilisation in medicinal chemistry. Transition metal catalysed reactions are less 
susceptible to electronic and steric substituent effects than standard SNAr reactions for a 
number of reasons: the reactivity of the catalyst can be readily tuned by altering the 
properties of the phosphine ligands, mild bases and low temperatures can be employed to 
increase functional group tolerance, and ligation of the catalyst by the reactive species 
prevents formation of a crowded tetrahedral Meisenheimer intermediate. When substituent 
effects are observed they mirror trends seen in normal SNAr reactions. EWGs activate 
electrophiles towards oxidative addition by lowering the energy of the lowest unoccupied 
molecular orbital and decreasing electron density at the reaction centre.139 In contrast, EDGs 
deactivate electrophiles. The opposite trends are observed for the nucleophilic coupling 
partner. Aniline 1 was a particularly poor nucleophile because of the electron withdrawing 
chloride (σo = 1.28)165 and amide (σp = 0.36)166 groups that were positioned ortho and para 
to the reactive amine. Electron density is altered through both inductive and resonance 
contributions and therefore the relative position of substituents also effects reactivity.  
We had the opportunity to observe these trends in our synthesis of a library of truncated 
LRRK2IN1/IN1_G analogues. Excellent yields of the 2 and 4-nitroaniline analogues 29 (92 
mol%) and 31 (98 mol%) were obtained when they were synthesised from their respective 
aryl iodide precursors 76 and 77. Nitro groups are strong inductive EWGs (σo = 1.99, σp = 
0.78)165, 166 and also participate in resonance stabilisation when substituted ortho or para to 
the reactive centre. Steric hindrance to nucleophilic attack by the ortho-nitro substituents 
could be implied by the slightly reduced yield of 29 compared to unhindered analogue 31, 
however, within the scope of the current synthesis the magnitude of these differences is 
considered negligible.  
The relative reactivity of the 2/4-nitrosubstituted electrophiles 76 and 77 compared with 
unsubstituted electrophile 75 (Exp. 10, vs. 11 and 12) provided support for the beneficial 
effects of EWGs in promoting nucleophilic substitution. Comparison of experiments 12 and 
13 provided further support for this conclusion. N-phenyl acetamide analogue 33 was 
obtained in only low to moderate yields of 41 mol%, suggesting that replacing the para-nitro 
substituent with the electron neutral anilide group (σp = 0.00)166 removes activation of the 
corresponding aryl iodide 47 towards nucleophilic substitution. The high yield of 3-
methyoxyphenyl analogue 30 (94 mol%) was also in accordance with our expectations. Aryl 
ethers positioned meta to the reaction centre inductively withdraw electron density because 
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of the electronegative oxygen atom and do not participate in resonance stabilisation of the 
reaction centre (σm = 0.12)166. 
In contrast, we were surprised to find that reaction with 4-methyl and 2-methoxy substituted 
aryl iodides 78 and 79 also yielded near quantitative conversion to the desired analogues 32 
and 28 (Exp. 14 and 15). para-Methyl substituents are moderately electron donating (σ = -
0.17)166 because of hyperconjugation of the sigma C-H bonding orbitals and the aromatic pi 
system. As such, we expected product yield to be reduced in comparison to unsubstituted or 
activated aryl halides. Methoxy substituents are both electron-donating through resonance 
and electron-withdrawing through inductive effects. Our results suggest that inductive effects 
dominate when the ether is substituted ortho to an electrophilic reaction centre. Ortho-
substituents have also been reported to improve the rate and yield of some Buchwald-
Hartwig reactions by sterically enhancing reductive elimination from the catalyst, which might 
also explain our high yields.167 
Over this series of analogues we confirmed that the Buchwald-Hartwig reaction was 
relatively insensitive to substituent effects, achieving product yields of 41-100 mol%. The 
absence of a formal negative charge on the reaction intermediate and dependence on 
oxidative addition, not nucleophilic attack, are likely to have contributed to this effect.  
3.3.4 Heterocyclic Versus Carbocyclic Electrophiles 
Heteroaromatic rings are activated for nucleophilic attack at carbon atoms at ortho and para 
to ring nitrogen atoms because the electron rich intermediate is stabilised by the 
electronegative heteroatom.168 Each nitrogen atom in a heterocycle lowers electron density 
of the aromatic system to an equivalent degree as nitro-substituents. We desired to 
synthesise heteroaromatic-aniline 1 analogues to mimics the pyrimidine ring of the 
LRRK2IN1/IN1_G diazepinone moiety. In previous research we had experienced difficulty 
coupling aniline 1 to various 2-pyrimidinyl electrophiles.58 The synthesis of our library of 
truncated analogues provided the opportunity to investigate and optimise this chemistry 
further.  
As per theoretical prediction, product yield was improved when synthesising 2-pyridinyl 
aniline 25 (66 mol%) compared to 3-pyridinyl aniline 26 (47 mol%) from their respective aryl 
bromide precursors 72 and 73 respectively (Exp. 7 and 8). Furthermore improved product 
yields were obtained when synthesising the 2-pyrimidinyl aniline 23 analogue (27 mol%) 
compared to the 5-pyrimidinyl aniline 24 (12 mol%) analogue (Exp. 4 and 9). These results 
confirmed that the position of the nitrogen heteroatoms was of paramount importance to 
electrophile reactivity. While the difference in yield between experiments 4 and 9 was small, 
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the preference for aryl bromide electrophiles over aryl chloride electrophiles described above 
must be taken into account.  
In contrast to our expectations and reports in the literature, increasing the number of 
aromatic nitrogen atoms had minimal effect on electrophile reactivity. Comparing the 
syntheses of 2-pyridinyl aniline 25 and 2-pyrimidinyl aniline 23 from their respective aryl 
chloride electrophiles (Exp. 3 and 4) we observed similar yields (31 mol% and 27 mol% 
respectively), although 23 was not purified from excess aniline 1 starting material. Oxidative 
addition at C2 (σ = 0.53)166 of pyrimidine is slower than addition to C4 (σ = 0.53)166 because 
of the higher electron density at C2 and greater potential for the adjacent nitrogen 
heteroatoms to chelate the palladium catalyst.169 These effects might have been sufficient to 
negate the decreased electron density of the aromatic compared to 2-chloropyridine 70 (σ = 
0.17)166. The syntheses of 3-pyridinyl-aniline 26 and 5-pyrimidinyl aniline 24 from their 
respective aryl bromides 73 and 74 (Exp. 8 and 9) similarly indicated that increasing the 
number of heteroatoms did not improve reactivity. Despite pyrimidines being more electron 
deficient than pyridine rings in general, we proposed that as both heteroatoms were situated 
meta to the reaction centre for Exp. 9, they would have had little inductive and no resonance 
contribution to the electron density of the reaction centre.168  
We attempted to increase the reactivity of the 2-chloropyridine electrophile 69 (Exp. 3) by 
incorporating an electron withdrawing aldehyde substituent (σo = 0.17)165 ortho to the 
reaction centre 71 (Exp. 6). Formation of product 105 was detected by 1H-NMR and mass 
spectrometry but yield was insufficient for isolation. It is possible that the combined effect of 
the heteroatom and carbonyl group either side of the reaction centre hindered oxidative 
addition to the palladium catalyst through sterics or chelation. Alternatively, nucleophilic 
addition of aniline 1 to the activated pyridinyl aldehyde might have resulted in by-product 
formation and thus reduced product yield.  
One of the final analogues that was synthesised as part of this project was diazepine-
coupled aniline 40 (Exp.5). The poor reactivity of heteroaryl-chloride electrophiles (Exp. 3 
and 4) was accentuated in diazepine 65, which probably was the result of the electron 
donating tertiary amine substituents oriented meta and para to the reaction centre (σm = -
0.16, σp = -0.83).166 Little reactivity was detected over the progress of the reaction by thin 
layer chromatography and the desired product was nearly impossible to separate from 
starting material even after extensive chromatography. Under the same reaction conditions 
IN1_G had been previously synthesised from the corresponding diazepinone IN1_H in 39 
mol%, further indicating the effect of the para amine versus anilide substituent on 
heterocycle reactivity.58 Owing to time constraints, synthesis of the diazepine and oxazepine-
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coupled aniline analogues 41, 42, and 43 has not been attempted. We speculate that the 
oxazepine 66 may be relatively more reactive than the diazepine 65 because of the electron 
withdrawing aryl ether substituted meta to the reaction centre.  
Phenyl aniline analogue 27 was synthesised as a negative control to determine if basic 
heteroatoms or other hydrogen-bonding functional groups were necessary to inhibit the 
functional activity of LRRK2. Reaction of iodobenzene 75 with aniline 1 proceeded in good 
yield (71 mol%) over a moderate reaction duration of 7 hours. These results conflicted with 
our expectation that oxidative addition would be slower to carbocycles compared to the 
electron deficient heteroaromatic compounds employed in Experiments 1-9.168, 169 The iodide 
leaving group used when synthesising the substituted phenyl aniline analogues (Exp. 10-16) 
compared to the bromide and chloride leaving groups employed in the synthesis of the 
heteroaromatic series might provide some explanation for this observation.  
An alternate explanation is that our catalytic system was not optimal for reaction with 
heteroaromatic electrophiles. Basic heterocycles can co-ordinate to palladium through 
donation of the heteroatom lone pair of electrons. To avoid this occurring and quenching of 
the palladium catalysts, an appropriate phosphine ligand must be selected that is capable of 
co-ordinating to palladium more strongly than the heteroatom.162  
3.3.6 Effect of the Nucleophile 
Kinetic studies have provided insight into the role of the various reaction species and 
mechanism of palladium(0) catalysed substitution reactions. Oxidative addition has 
traditionally been considered to be the rate determining step of Buchwald-Hartwig reactions, 
implying that rate should be independent of both the concentration and nature of the 
nucleophile. More recent studies have shown that identical aryl halides-catalyst systems 
display different kinetics when other factors like base, solvent, or temperature are varied.158, 
170 Anionic palladium complexes formed from addition of the nucleophile or alkoxide base to 
the catalyst prior to oxidative addition with the aryl halide have also been reported. The rate 
of oxidative addition with anionic complexes is rapid, and consequently the basicity of the 
nucleophile may significantly affect reaction rate.158 Our experience trying to couple aniline 1 
to various electrophiles supports involvement of the nucleophile in the rate determining step 
of the Buchwald-Hartwig reaction reported in this thesis. The low nucleophilicity and highly 
acidic character of aniline 1 were thought to be responsible for the limited substrate scope 
and moderate yields achieved over experiments 1-16.  
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3.3.7 Anhydrous and Inert Atmospheric Conditions 
The reaction conditions employed here were highly sensitive to both oxygen and water. This 
was exemplified by the dramatic difference in reaction duration, reagent equivalents and 
product yield when analogue 33 was synthesised in the presence of reagent grade, 
unpurified 1,4-dioxane (60 hours, 2-fold increase in reagent equivalents, 31% yield) or 
anhydrous solvent (6 hours, standard equivalents, 41% yield). Conversion of the phosphine 
ligand to phosphine oxide, nucleophilic substitution of the aryl halide with hydroxide and 
hydrolytic cleavage of the amine-palladium complex may all account for the observed 
results.171 Water or aqueous hydroxide bases have been reported to induce rate 
enhancements in some literature examples of Buchwald-Hartwig reactions but the effect is 
highly sensitive to the catalytic system employed. In particular, significant reduction in yield 
has been reported for reactions involving a dibenzylidene acetone-palladium(0) pre-
catalyst.171 Consequently, solvents were rigorously dried prior to use in all other Buchwald-
Hartwig reactions described in this section.  
3.3.8 Palladium Catalysis 
Aryl halides substituted with EWGs, or made to be electron deficient by ring heteroatoms, 
can react by SNAr in the absence of transition metal catalysts. The majority of electrophiles 
listed in Table 4 met this criterion and literature examples indicated that the series of six-
membered aromatic aniline analogues that had been selected for synthesis could be arrived 
at using Brönsted acid/base promoted conditions. Whilst this was a desirable prospect 
because it avoided using expensive palladium catalysts or phosphine ligands, evidence from 
numerous experiments indicated that aniline 1 was not a suitable substrate for SNAr. 
Attempting to react aniline 1 precursor 4-amino-3-chlorobenzoic acid 15 with electron-
deficient 2-bromo-5-fluoropyridine 81 under microwave irradiation in the presence of a 
catalytic quantity of hydrochloric acid proved unsuccessful (Scheme 9).76 Acid catalysis was 
expected to activate the electrophile for nucleophilic substitution by protonating the basic 
pyridine nitrogen atom. However, concomitant protonation of amino benzoic acid 15 to the 
corresponding anilinium ion most likely further deactivated the aniline precursor, preventing 
SNAr.168  
In contrast to transition-metal catalysed reactions, standard SNAr reactions favour aryl 
fluorides as electrophilic coupling partners.139 1-fluoro-2-nitrobenzene 67 was an optimal 
electrophile for SNAr because the reaction centre was strongly polarised by both the fluoride 
leaving group and the adjacent nitro-substituent. The lack of reactivity of 67 with aniline 1 
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under Buchwald-Hartwig conditions (Exp. 1) also indicated that aniline 1 was unlikely to be 
sufficiently nucleophilic for standard SNAr reactions. Despite the aryl fluoride 67 being 
unreactive towards oxidative addition with the palladium catalyst, the presence of excess 
base, an appropriate solvent and thermal heating was expected to promote substitution by 
SNAr. No formation of the desired analogue 29 was detected, providing support for our use 
of the Buchwald-Hartwig reaction.  
Copper(II) oxide nanoparticles have been reported to catalyse the reaction of deactivated 
aniline nucleophiles with iodobenzene in the presence of potassium hydroxide and dimethyl 
sulfoxide. The catalytic cycle is thought to be similar to that of Buchwald-Hartwig reactions, 
but occurs in the absence of phosphine ligands. Copper readily undergoes oxidative addition 
to carbon iodine bonds to form a highly reactive organocuprate intermediate.172 Experiment 
12, which had previously yielded 31 in 98 mol% under Buchwald-Hartwig conditions was 
repeated using copper(II) catalysis. No reaction was observed and aniline 1 was recovered 
in good yield and purity. This result further justified our continued use of Buchwald-Hartwig 
chemistry but it was not possible to determine whether the base, solvent, or metal catalyst 
was responsible for the difference in reactivity that was observed.  
 
Scheme 9 Brönsted acid-promoted microwave-assisted nucleophilic aromatic substitution conditions 
were not sufficient to couple aniline 1 precursor 15 with electrophile 81. 
3.3.9 Reagent equivalents 
Owing to the optimisation of reaction conditions, the equivalents of aniline 1 and the 
respective aryl or heteroaryl halides presented in Table 1 was not held constant. We felt that 
comparisons could still be made between the experiments because there was sufficient 
evidence to suggest that the ratio of these species had negligible, if any, effect on reaction 
yield. For example, product yield was considerably different in experiments 1 and 11, despite 
the ratio of nucleophile to electrophile being consistent. Because the nature of the aryl 
substituent was also the same, we ascribed these result to the effect of the halide leaving 
group.  
As a second example, by comparison of Experiments 7 and 8, in which both the halide 
leaving group and number of reagent equivalents were held constant, we were able to 
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conclude that the substitution pattern of the heterocycle was responsible for the different 
product yield obtained.  
3.3.10 Homocoupling 
One particularly interesting outcome from our work with Buchwald-Hartwig chemistry was 
the self-condensation of lead aniline 1 when reacted under the standard conditions 
described in Scheme 10, in the presence of aryl fluoride electrophiles 67 or 68 (Exp. 1 and 
2). This homocoupling was not observed to occur in any other experiment except in minute 
quantities when synthesising 2-nitrophenyl aniline analogue 29 from the respective 
electrophile 1-iodo-2-nitrobenzene electrophile 76 (Exp. 11). From the reaction of 2-
fluoropyridine 68 and aniline 1 (Exp. 1), 65 mol% of the aniline starting material was 
recovered pure and unaltered and 3 mol% of the aniline 1 starting material was isolated as 
homocoupled aniline 84. In experiment 2, 53 mol% of aniline 1 was recovered for use in 
subsequent reactions, 3 mol% of the aniline was converted to homocoupled by-product 84 
and a further 3 mol% was converted to the symmetrical tricyclic compound 83.  
We have been unable to explain these results. Unreacted aniline 1 was recovered from 
numerous experiments over the course of our research, including from reactions that 
included identical solvent, temperature, duration, base and reagent equivalents as 
experiments 1 and 2. In addition, aniline 1 has been recovered from reactions that were 
performed at a range of temperatures, in the presence of Lewis acids, Brönsted acids or 
bases and under microwave assisted conditions. We have shown that oxidative addition to 
aryl chlorides (Exp. 3-6) was slow and disfavoured using our Buchwald-Hartwig catalytic 
system. Consequently, the observed effect appeared to be highly specific to the fluoride 
leaving group. We presumed that by-product formation was much lower in experiment 11 
because oxidative addition to the aryl iodide was kinetically favoured. The formation of by-
product 106 supports this conclusion.  
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Scheme 10. Homocoupling of aniline 1 
3.4 Synthesis of N‐Benzyl Analogues 
Four N-benzyl aniline analogues were designed and synthesised to provide insight into the 
pharmacophore of LRRK2 inhibitors. The aromatic substituents for this series were selected 
to mirror the substituted phenyl aniline analogues described in Chapter 3.3. We proposed to 
synthesise the N-benzyl aniline analogues from aniline 1 and the respective benzyl halides 
electrophiles 85, 86, 87, and 88 because they were commercially available at low cost and 
enabled us to follow the convergent synthetic route devised during our retrosynthetic 
analysis (Chapter 3.1).  
Unlike primary alkyl halides, the nucleophilic substitution of primary benzylic halides may 
proceed by either an SN1 or SN2 mechanism. Delocalisation of the positive charge over the 
aromatic system stabilises the primary carbocation intermediate generated during the SN1 
mechanism. SN2 reactions are also possible because nucleophiles are not sterically 
hindered from accessing the anti-bonding C-X orbital, and the transition state [Nu-C-X] is 
stabilised by conjugation with the pi-system of the adjacent aromatic ring. The nature of the 
halogen leaving group, aromatic substituents, nucleophile, solvent, reagents and 
temperature all combine to determine whether a given reaction follows an SN1 or SN2 
mechanism.139 
3.4.1 Base ‐promoted Nucleophilic Substitution 
Mono-N-alkylation of deactivated aniline nucleophiles is frequently cited as problematic in 
the literature, requiring strong bases, high temperatures and long reaction times. We trialled 
numerous alkylation procedures in our attempt to synthesise analogues 85-88 from their 
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respective benzyl bromide electrophiles. A range of different organic and inorganic bases, 
polar and non-polar aprotic solvents, and thermal or microwave-assisted conditions were 
investigated. Little or no product formation was detected under the majority of reaction 
conditions and aniline 1 was recovered for use in subsequent experiments. These results 
indicated that not only was aniline 1 an exceptionally poor nucleophile, but that it was also 
very stable, and resistant to dimerisation in the absence of appropriate conditions (see 
Chapter 3.3.10). Product yields were greatest when aniline 1 was heated with substituted 
benzyl bromides and 1.5-2.5 equivalents of powdered potassium hydroxide in 1,4-dioxane 
(Scheme 11).173 When benzyl bromide 85 was made to react under these conditions, a yield 
of 43 mol % of mono or di-N-benzylated aniline 34 was obtained in 1:0.15 ratio (37 mol % of 
desired analogue 34). We proposed that reaction of 4-nitrobenzyl bromide 87 would result in 
improved yields of the corresponding N-benzyl analogue 36, because the electron 
withdrawing para-nitro substituent would polarise the benzylic reaction centre for SN2-type 
nucleophilic attack (σp = 0.78,166 σp+ = +0.79174). However, no formation of desired product 
36 was detected, suggesting that an SN1-mechanism was favoured. EWGs decrease the 
rate of SN1-reactions by destabilising the carbocation intermediate. It was therefore 
surprising that 3-methoxybenzyl bromide 86 reacted rapidly (0.5 hours), at room temperature 
to yield a mixture of the mono- and di-N-benzylated aniline analogue 35 (6 mol%, 2:1 ratio of 
mono/di-benzylated analogue). Aryl ethers have a mild electron withdrawing effect (σm = 
0.12,166 òm+ = 0.05174) when substituted meta to the reaction centre and are unable to 
stabilise benzylic carbocations by resonance delocalisation. As yields of analogue 35 were 
lower than those obtained with the unsubstituted benzyl bromide 85 we still thought an SN1 
mechanism was most likely.  
3.4.2 “Green” Benzylation 
Considering the poor product yield and purity obtained following these base-promoted 
substitution procedures, we scoured to literature and uncovered an “all-water” “green” 
method of N-alkylating anilines.175 We were delighted to find that aniline 1 reacted rapidly 
with the respective benzyl bromide electrophile 85 (1-1.2 equiv.) when heated to reflux in a 
small quantity of tap water. Substitution proceeded so rapidly that it was impossible to 
prevent formation of the tertiary aniline. A mixture of mono-N-benzylated aniline analogue 34 
(60 mol%) and di-N-benzylated by-product (yield not calculated) was obtained regardless of 
attempts to modify the reaction stoichiometry, temperature or the rate-of-addition of the 
electrophile. Dibenzylation occurred because the secondary aniline product 34 was more 
nucleophilic than the corresponding starting material 85 because of sigma electron donation 
from the benzyl substituents.7, 175  
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Analogue 35 (43 mol%) was synthesised from 3-methoxybenzyl bromide 86 using the same 
conditions. 4-Nitrobenzyl bromide 87 was also found to be compatible with all-water 
chemistry, unlike the previously trialled base-promoted alkylation conditions (Chapter 3.4.1). 
The yield of the corresponding 4-nitrobenzyl aniline analogue 36 (15 mol%) was significantly 
lower than that obtained with either the unsubstituted 34 or weakly electron deficient 35 
electrophiles. These results suggested that the all-water substitution reaction also proceeded 
by an SNAr mechanism. To investigate the effect of weakly EDGs (σp = -0.17,166 σ+ = -
0.31174) on this unorthodox benzylation procedure, and for comparison with 4-methylphenyl 
aniline analogue 32 in later biological studies, we synthesised the corresponding 4-
methylbenzyl aniline 37. Yields of 37 (21 mol%) were low considering electronic substituent 
effects we had observed with electrophiles 85, 86 and 87. Poor solvation of the more 
lipophilic benzyl bromide electrophile 37 might have contributed to this result.  
 
Scheme 11.Synthesis of N-benzyl aniline analogues. Reagents and conditions: (a) 1 (1 equiv.), 85-88 (1-1.2 
equiv.), tap water (0.5 M), reflux, 2.5-5 hours, 34 (60 %), 35 (42%), 36 (15%), 37 (21%); (b) 1 (1 equiv.), 85-87 
(1.1-2.6 equiv.), powdered KOH (1.5-2.5 equiv.), 1,4-dioxane (0.15 M), r.t. – 60 oC, o.n., 34 37% unpurified, 35 
6% unpurified, 36 0%.  
 
The proposed mechanism of all-water promoted benzylation is described as “hydrogen-bond 
mediated electrophile-nucleophile dual activation” (Figure 20). Electron density on the aniline 
is increased through hydrogen bonding to water as a proton donor, while the benzylic carbon 
is activated as an electrophile by halogen bonding between water and the bromide leaving 
group, which acts as a hydrogen bond acceptor. Further hydrogen bonding interactions 
between solvent molecules are thought to bring the reactive species into close proximity for 
substitution. Reactivity correlations between the hydrogen-bond donor-acceptor parameters 
of various solvents and their efficiency in promoting N-benzylation of an o-nitroaniline have 
been reported to support this mechanism.175 Further studies have correlated the hydrogen 
bond donor ability of thiol nucleophiles with reaction yield. In contrast to expected trends for 
SN1/2 reactions, nucleophiles substituted with EWGs were shown to be more reactive in all-
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water chemistry. Whist decreasing nucleophilicity, EWGs increase the hydrogen bonding 
ability of nucleophiles by weakening the N-H or S-H bond.176 The electron deficient nature of 
aniline 1 that had proved problematic in the majority of other reactions we tried was actually 
beneficial for all-water water chemistry. This may also explain why we were unable to 
obtained selective mono-N-benzylation of aniline 1, despite precedence in literature 
describing all-water chemistry.175 Whilst we initially thought that reactivity might have only 
been enhanced by mutual repulsion from water molecules forcing the substrates into closer 
proximity, literature indicates that reactions performed neat, or at concentration greater than 
1 M resulted in significant reductions in product yield and longer reaction times.176 
 
Figure 20. All-water electrophile-nucleophile dual-actiavtion of nucleophilic substitution reactions.176 
3.5 Synthesis of Aliphatic Analogues 
3.5.1 Aliphatic Analogues 
As mentioned in Chapter 3.4 we experienced considerable difficultly synthesising benzyl or 
alkyl aniline analogues from benzyl or alkyl halides because of the weak basicity of the 
nitrogen nucleophile. Synthesis of n-propyl aniline 83 from 1-bromopropane using base-
promoted substitution was also unsuccessful. No reaction occurred in the presence of either 
triethylamine or powdered potassium hydroxide, or when a catalytic quantity of potassium 
iodide was added to promote an in situ Finkelstein halogen exchange.159  
In light of our success synthesising benzyl aniline analogues using all-water chemistry we 
attempted to apply the same methodology to the synthesis of a simple N-alkyl aniline 90 
(Scheme 12). Little to no reactivity was observed between 1-iodo-2-methylpropane 89 and 
aniline 1. This disappointing result was in accordance with literature reports for electron 
deficient aniline nucleophiles.175 In contrast, mono-N-alkylation of electronically neutral 
anilines, or those with mildly electron donating substituents, has been reported to occur with 
a range of aliphatic alkyl chlorides or bromides using a microwave-assisted variant of the all-
water method.177 This reaction will be pursued in future research in the hope of synthesising 
a greater variety of alkylated aniline analogues. The lack of reactivity of 1-iodo-2-
methylpropane 89 with aniline 1 provided further support for the SN1 mechanism of N-
benzyl/alkylation that we had proposed earlier. 1-Iodo-2-methylpropane 89 was extremely 
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unlikely to react by an SN1 mechanism because the primary alkyl carbocation intermediate 
formed would be highly unstable, even in the presence of a highly polar solvent like water.139 
 
Scheme 12. All-water chemistry was not a successful method to synthesise N-alkyl aniline analogues.  
 
To determine if aniline 1 would be reactive with a more polarised carbonyl electrophile we 
decided to utilise reductive amination conditions to synthesise alkylated aniline analogues 38 
and 39 (Scheme 14). Under the standard reaction conditions employed for deactivated 
amine nucleophiles, which included an excess of aldehyde 91 (2 equiv.), glacial acetic acid 
(6 equiv.) and the reducing reagent sodium triacetoxyborohydride (2-3 equiv.), we obtained 
analogue 38 in 28 mol%. Under similar reaction conditions the cyclohexyl aniline analogue 
39 was only obtained in 12 mol% from the respective cyclohexanone 92. The reduction in 
yield between analogue 38 and 39 reflects steric and electronic deactivation of ketones 
compared to aldehydes. Improved yields (23 mol%) of analogue 39 were obtainable under 
more forcing reaction conditions. The number of equivalents of the electrophile 92 (6 equiv.) 
and reducing agent (4.5 equiv.) were both increased, and the reaction was carried out in 
neat glacial acetic acid to promote the formation of the iminium ion intermediate (iii) and aid 
the elimination of water (ii). Anhydrous magnesium sulfate was also added to remove water  
and disfavour the reverse reaction (Scheme 13).  
 
Scheme 13. Mechanism of reductive alkylation/amination. 
 
The improved reactivity of aniline 1 with carbonyl compounds compared to alkyl halides 
reflects the relative difference in the HOMO-LUMO gap for these two coupling reactions. 
Nucleophilic attack at a carbonyl carbon is under electrostatic control and involves addition 
to the π* anti-bonding orbital. In comparison, substitution with primary alkyl bromides/iodides 
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involves nucleophilic attack on the higher energy σ* anti-bonding orbital of the weakly 
polarised carbon-bromine or carbon-iodine bond. Owing to multiple EWGs, the energy of the 
HOMO of aniline 1 would be low and, as we observed, reaction with the lower energy 
carbonyl LUMO should be favoured.139 
 
Scheme 14. Synthesis of aliphatic aniline analogues 38 and 39 by reductive amination. Reagents and 
conditions: (a) 1 (1 equiv.), 91 or 92 (2 equiv.), AcOH (6 equiv.), NaBH(OAc)3 (2.8 equiv.), DCE (0.15 M), 0 oC - 
r.t., 20 h, 38 (28%), 39 (12%); (b) 1 (1 equiv.), 92 (6 equiv.), NaBH(OAc)3 (4.5 equiv.), MgSO4 (10 equiv.), AcOH 
(0.18 M), r.t., o.n., 39 (23%). 
3.6 Synthesis of Five‐membered Heteroaromatic Analogues 
Survey of the literature and an analysis of the pharmacophores of known LRRK2 inhibitors 
using docking studies indicated that truncated analogues substituted with five-membered 
heteroaromatic rings could be potent LRRK2 inhibitors. We were particularly interested in 
maleimide, thiophene and pyrazole containing aniline analogues because they were 
predicted to possess favourable physicochemical and pharmacokinetic properties. 
3.6.1 Synthesis by SNAr 
Five-membered heteroaromatic compounds exhibit markedly different reactivity to their six-
membered heteroaromatic counterparts. They are electron-rich and resist nucleophilic 
substitution, except for those substituted with strong EWGs.  
Halogenated maleimides (halo-1H-pyrrole-2,5-diones) are good substrates for SNAr 
reactions because the carbonyl groups at carbon 2 and 4 stabilise the anionic reaction 
intermediate by resonance electron delocalisation of electrons onto the electronegative 
oxygen atoms. Unfortunately, the reaction of freshly synthesised 3-bromomaleimide 52 and 
lead aniline 1 did not yield any of analogue 16, despite precedence in the literature for the 
reaction of weak nitrogen nucleophiles.142, 143 We employed the hindered organic base N,N-
diisopropylethylamine (DIPEA) or triethylamine (Et3N) in this reaction to discourage the 
formation of by-products that might occur when using nucleophilic bases. But in all 
experiments 3-bromomaleimide 52 appeared to degrade leaving aniline 1 able to be 
recovered in good yield and purity.  
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5-Chloro-4-pyrazolo-carbaldehydes are commonly used electrophiles for SNAr reactions 
because they can be readily synthesised in one-step by Vilsmeyer-Haack formylation and 
concomitant chlorination of the 5-hydroxypyrazoles. The aldehyde group activates the 
adjacent carbon-chlorine bond inductively and also stabilises the Meisenheimer-intermediate 
by resonance delocalisation. Previous work in our group has shown success in coupling 
similar pyrazoles with deactivated 2-nitroanilines using either organic or inorganic bases, in 
various solvents and at temperatures as low as 66 oC.138 Consequently, we were surprised 
and disappointed that reaction of 5-chloro or 5-iodo-4-pyrazolocarbaldehyde 93 or 94 with 
lead aniline 1 did not produce any of the substituted aniline product (Figure 21). Various 
conditions were trialled including altering reagent equivalents, using either powdered 
potassium hydroxide or sodium hydride as bases, changing solvents between ethanol and 
N,N-dimethylformamide, and employing conventional or microwave irradiation to achieve 
temperatures from 0 to 200 oC over reaction durations up to 24 hours in length. Aniline 1 
was always reisolated in good yield and pyrazoles 93 and 94 were stable up to temperatures 
of 100 oC when heated conventionally. In contrast, pyrazoles 93 and 94 rapidly degraded 
when subjected to microwave irradiation above 100 oC. Some reactivity was detected at 
elevated temperatures but characterisation of the products using NMR and mass 
spectrometry suggested that aniline 1 was primarily adding to the electrophilic products of 
N,N-dimethylformamide degradation. 
 
Figure 21. Five-membered heteroaromatic electrophiles for use in SNAr and Buchwald-Hartwig reactions 
with aniline 1. 
 
3.6.2 Synthesis Using Buchwald‐Hartwig Chemistry 
Halo-thiophenes, and to a lesser extent halo-furans or benzofurans, are reported to react 
with amines in transition-metal catalysed nucleophilic substitution reactions, such as the 
previously described Buchwald-Hartwig reaction.169 Nitrogen containing heterocycles like 
pyrrole and pyrazole, are less commonly used as electrophiles because they are more 
electron rich and resistant to oxidative addition. More often, nitrogen containing heterocycles 
are used as the nucleophile in metal-catalysed substitution reactions, but some examples in 
which N-alkylated nitrogen heterocycles act as electrophiles are known.134 
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We attempted to couple three different thiophenyl-halide electrophiles 95, 49, and 96 with 
aniline 1 (Figure 21). 2-iodothiophene 95 was trialled first because thiophenes are most 
electron deficient at carbon atoms adjacent to the sulfur heteroatom and the weak carbon-
iodine bond is optimal for oxidative addition to the palladium catalyst. No reaction was 
observed between 95 and 1 using the catalytic system described in Chapter 3.3. Both 
starting materials remained after the reaction mixture was heated to reflux for 24 hours, and 
aniline 1 was recovered in good yield. Sulfur has a high affinity for palladium and it is 
possible that ligation of the catalyst through the heteroatom hindered the reaction 
progress.169 The composition of the catalytic system, particularly the phosphine ligand and 
base that are selected, can dramatically affect the success of Buchwald-Hartwig reactions 
involving poorly electrophilic substrates like five-membered heteroaromatic halides. Alkoxide 
bases have been suggested to be beneficial for Buchwald-Hartwig reactions involving weak 
electrophiles because they can ligate the palladium catalyst to form an anionic complex that 
is more reactive towards oxidative addition.158 To test this possibility, we attempted to couple 
aniline 1 with the more electron deficient 5-bromo-2-thiophenyl carboxamide 49, using 
Pd2(dba)3, XPhos and potassium tert-butoxide in 1,4-dioxane. No product was observed to 
form when the reaction was heated to reflux for 24 hours or subjected to microwave 
irradiation at 100 oC. Both aniline 1 and thiophene 49 were recovered unaltered from the 
reaction mixture. Tri-tert-butylphosphine (PtBu3) is a highly electron-rich phosphine ligand 
that has been widely used to promote Buchwald-Hartwig reactions involving deactivated 
electrophiles.134, 169, 178 Various halo-thiophene, furan, thiazole and oxazole electrophiles 
were reported by Hooper et al. (2003) to react with unsubstituted diaryl amine nucleophiles 
under optimised conditions using Pd2(dba)3, PtBu3 and an alkoxide base in toluene. 
Unfortunately, these conditions also failed to yield the desired analogue 18 when aniline 1 
and thiophene 49 were made to react together. The lower nucleophilicity of primary versus 
secondary anilines, and the presence of multiple EWGs on aniline 1 might account for our 
results using this catalytic system.  
One particular publication reported that 3-bromothiophene 96 was more reactive than 2-
bromothiophene in Buchwald-Hartwig chemistry.134 Having the appropriate electrophile 96 at 
hand, we repeated the procedure that had been reported in the literature using aniline 1 as a 
nucleophile. However, as with previous experiments, no formation of the desired product 
was observed after heating the reaction to reflux for 24 hours and aniline 1 was recovered 
from the reaction mixture.  
The original catalytic system described in Chapter 3.3 (Pd2(dba)3, XPhos, Cs2CO3, and 1,4-
dioxane) and that reported by Hooper et al. (Pd2(dba)3, PtBu3, KtBuO, and toluene) were 
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both used in our attempts to promote the nucleophilic substitution of an N-protected 
iodopyrazole 45 with aniline 1.76, 134 As with thiophene electrophiles 95, 49 and 96, we did 
not detect formation of the desired product 20. Both aniline 1 and pyrazole 45 remained 
unreacted in solution even after heating at high temperatures (100-120 oC) for multiple days. 
These disappointing results reflected the poor nucleophilicity of aniline 1, an ongoing theme 
that permeates the course of our synthetic discussion.  
Interestingly aniline 1 did not form any of the products of dimerisation 83 or 84 that were 
described in Chapter 3.3.10 in any of the afore-mentioned reactions. The catalytic systems 
trialled with the five membered heterocycles altered numerous factors including the 
phosphine ligand, base, solvent, temperature and heating method. Aniline 1 did not dimerise 
with any of these changes which suggested that dimerisation was specific to experiments 
involving electrophiles 67 and 68. 
3.7 Extended Pyrrole Analogues 
We desired to access benzylic-type heteroaromatic analogues of aniline 1 to further probe 
whether we could optimise interactions with both A-pocket and catalytic amino acid residues 
at the same time. In addition, as the direct amination of five–membered heterocycles was 
synthetically challenging, these analogues offered us an alternative opportunity to 
incorporate five membered heteroaromatic groups into our library of truncated 
LRRK2IN1/IN1_G analogues using simple and robust reactions.  
3.7.1 Pyrrole methanamine Analogue 
Analogue 22 was synthesised from the corresponding aldehyde 97 by the standard reductive 
amination procedure described in Chapter 3.6 (Scheme 16). Yields (37 mol%) were higher 
than expected based on our previous experience (39, 12 mol%, 38, 28 mol%) and were 
particularly surprising as electron donation through resonance with the adjacent 
heteroaromatic system was expected to deactivate the carbonyl carbon.179  
Pyrrole carbaldehydes are considered to exhibit similar properties to benzaldehydes 
although they are slightly less reactive.179 Our success synthesising analogue 22 from the 
carbaldehyde precursor 97 suggested that the desired benzyl-analogues 34, 35, 36 and 37, 
might also by accessible through this mechanism. Synthesis from respective benzaldehyde 
precursors might reduce formation of the undesired di-N-benzylated by-products that 
contributed to the low yields described in Chapter 3.4.139 
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Scheme 15. Synthesis of pyrrole aniline analogue 22 by reductive amination. Reagents and conditions: 1 (1 
equiv.), 97 (2 equiv.), AcOH (6 equiv.), Na(OAc)3BH (2.8 equiv.), DCE (0.2 M), 0 oC, 3 h, r.t., 24-48 h, 22 37%. 
 
3.7.2 Pyrrole carboxamide Analogue 
Pyrrole carboxamide analogue 21 was predicted by molecular modelling to bind with high 
affinity to a homology model of LRRK2 and to possess favourable physicochemical and 
pharmacokinetic properties. We envisioned that 21 could be synthesised from 1H-pyrrole-2-
carboxylic acid 98 and aniline 1 using standard amide bond forming reaction conditions 
(Scheme 16). We initially trialled two different procedures, both supported by literature 
precedence for coupling similar heteroaromatic carboxylic acids and halo-aniline 
substrates.180, 181 The first employed carboxylate activating reagents 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (EDCI) and 1-hydroxybenzotriazole (HOBt), 
and hindered base N,N-diisopropylethylamine (DIPEA) to activate the aniline and quench 
acidic by-products. We had previously had success with this procedure coupling a diverse 
range of substrates, including a thiophene carboxylic acid 48, and in a separate reaction, the 
deactivated 4-iodoaniline 46 (Chapter 3.2.3). However, no reaction occurred between aniline 
1 and electrophile 98 after more than 72 hours at room temperature. We subsequently tried 
a two-step coupling procedure, first converting the 2-pyrrole carboxylic acid 98 to the acid 
chloride derivative, and then coupling this activated electrophile with aniline 1 in the 
presence of an appropriate base triethylamine (Et3N). Again, no reaction was observed after 
24 hours at room temperature. These results were surprising considering aniline 1 had 
previously reacted with weaker aldehyde 91 and ketone 92 electrophiles during the 
synthesis of aliphatic analogues 38 and 39 by reductive amination.  
The addition of a catalytic quantity of N,N-dimethylaminopyridine (DMAP) to both of the 
afore-mentioned amide bond forming reaction mixtures resulted in the rapid formation of 
product 21 as detected by thin layer chromatography. DMAP is an acyl transfer reagent that 
facilitates amide bond formation by activating the carboxylate group. To explain the effect of 
DMAP relative to EDCI, HOBt and acyl chloride formation, we suggest that the basic 
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heterocycle might also activated the aniline nucleophile or that the cationic acyl-pyridinium 
intermediate was more electrophilic than the corresponding HOBt-ester intermediate.  
Purification of the crude reaction mixture from the coupling reactions between aniline 1 and 
all electrophiles mentioned throughout Chapter 3 was challenging. Low product conversion 
and the similar polarity of the residual aniline 1 and the desired truncated analogues 
contributed significantly to the low yields that have been reported throughout. Extensive 
chromatographic purification on silica gel media was required, and sometimes purification 
was repeated two or three times in various eluent systems for a given reaction. Pyrrole 
carboxamide analogue 21 was impossible to isolate from unreacted aniline 1 by silica gel 
chromatography. Reverse-phase chromatography using a lipophilic carbon-18 coated silica 
gel was able to resolve the crude mixture and a sufficient quantity of analogue 21 (14 mol%) 
was isolated for biological testing.  
 
Scheme 16. Synthesis of Pyrrole Analogues. Reagents and conditions: 98 (1,2 equiv.), oxalyl chloride (6.8 
equiv.), 50 oC, 1 h, then 1 (1 equiv.), Et3N (1.2 equiv.), DCM, 0 oC – r.t., 24 h, then DMAP (catalytic), r.t, 20 h, 21 
14%.  
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Chapter 4 –Biological Analysis 
4.1 LRRK2: A pro‐inflammatory kinase 
4.1.1 Role in Parkinson’s disease 
Neuroinflammation is increasingly being recognised an important factor in the aetiology of 
Parkinson’s disease.182 Microglia are an immunocompetant, phagocytic subset of glial cells 
that reside in the CNS. They are activated in response to exposure to pathogenic molecules, 
such as Gram-negative bacterial endotoxin lipopolysaccharide (LPS). Activated microglia 
secrete proinflammatory cytokines (IL-6, IL-1β, TNFα) and ROS, activate various caspase 
proteins, and upregulate cell-surface immune receptors. If pathogenic activation is 
sustained, microglia localise and adhere to nearby neurons where they become phagocytic. 
LPS-induced microglial neurotoxicity primarily results in the destruction of dopaminergic 
neurons because microglia are expressed in four-fold higher concentrations in substantia 
nigra than other areas of the brains. Dopaminergic neurons are also innately more 
susceptible to oxidative stress than other neural cells because they have low intracellular 
levels of the endogenous anti-oxidant glutathione. Finally, LPS mediated microglial activation 
has been used to induce a Parkinson’s disease-like phenotype in animal models, which 
strongly supporting this model as an important contributing factor to Parkinson’s disease. For 
more in-depth analysis of the role of inflammation in Parkinson’s disease readers are 
directed towards a recent review by Whitton et al (2007).182  
The biological role of LRRK2 has not yet been confirmed. However, the general consensus 
that it might function as a stress response kinase is supported by extensive experimental 
evidence. Genome-wide analyses have linked PARK8 to autoimmune and inflammatory 
conditions such as Chrohn’s disease and leprosy.14, 17 LRRK2 is highly expressed in various 
immune cell subtypes, including microglia in the CNS.183 Research published by Kim et al. in 
April 2012 identified LRRK2 as a mediator of LPS-induced microglial inflammatory 
responses. Genetic knockdown of LRRK2 significantly reduced the expression of nitric oxide 
synthase (iNOS) and pro-inflammatory cytokines IL-1β, TNFα and IL-6. LPS stimulates 
microglia by binding to Toll-like receptor 4 (TLR4), which induces the production of 
inflammatory mediators by signalling through p38 MAPK and JNK kinases to promote 
translocation of transcription factor NF-κB into the nucleus (Figure 22). Studies have shown 
that LRRK2 phosphorylates a number of kinases involved in this pathway in vitro, including 
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Figure 23. Anti-inflammatory efficacy of LRRK2IN1, close analogue IN1_G and synthetic intermediates 
aniline 1 and diazepinone IN1_H in U87 glioblastoma cells. U87 cells were incubated with compounds or 
DMSO for 1 hour prior to stimulation with IL-1β. The concentration of IL-6 in cell lysate was determined after 24 
hours and normalised against a DMSO treated and LPS stimulated control. Control 1 (Ctr. 1) was not stimulated 
with IL-1β. 
4.2  Anti‐inflammatory  Efficacy  of  Truncated  LRRK2IN1/IN1_G 
Analogues 
4.2.1 Functional Screening Assays 
The anti-inflammatory efficacy of LRRK2IN1, IN1_G, aniline 1 and diazepine IN1_H in 
microglia was previously described in Chapter 1.4.3. Recently we observed that these 
compounds also potently inhibited the secretion of pro-inflammatory and mitogenic cytokine 
IL-6 from cancerous brain cells that had been stimulated with IL-1β (Figure 23). We 
proposed that the anti-inflammatory efficacy of truncated LRRK2IN1/IN1_G analogues could 
be assessed most efficiently by using the microglia and glioblastoma cellular assay in 
tandem.  
Primary analysis was performed in U87 glioblastoma cells because they are a robust, rapidly 
proliferating cell-line. Analogues were assessed for their ability to decrease the secretion of 
IL-6 from U87 cells that had been stimulated with IL-1β. Results were determined by 
measuring the concentration of IL-6 (pg/mL) in cell lysate after 24 hours using an enzyme-
linked immunosorbant assay (ELISA). Results were recorded either as per cent cytokine 
secretion remaining relative to an IL-1β-stimulated DMSO control (Figure 24), or per cent 
inhibition of cytokine secretion (Table 5).  
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Efficacious compounds were subsequently analysed in a secondary screening assay that 
was performed using primary human microglial cells. Microglia cannot be cultured in vitro 
and must be collected directly from a donor individual. The sequential screening assays 
ensured that only potent compounds were tested, thus conserving valuable and limited 
resources. Compound efficacy in the secondary assay was determined by a percentage 
decrease in IL-6 secretion from microglia after they had been incubated with LPS for 24 
hours (Figure 25, Table 5, Chapter 4.3.6).  
 4.2.2 Results Summary 
Twenty analogues and two synthetic intermediates 63 and 65 were analysed in the primary 
screening assay to determine their efficacy at reducing glioblastoma-related immune 
inflammation. Thirteen analogues and the two synthetic intermediates 63 and 65 were then 
analysed for anti-inflammatory efficacy in primary human microglial cells to determine their 
relevance as disease-modifying treatments for Parkinson’s disease.  
Compounds could be divided in cohorts based on efficacy in the primary screening assay. 
The diazepine analogue 40 and synthetic fragment 63 were highly potent, decreasing the 
secretion of IL-6 from stimulated U87 cells by more than 85%. A second cohort of 
analogues: 2-nitrophenyl 29, 4-nitrophenyl 31, 4-nitrobenzyl 36, 3-methoxyphenyl 30 and 4-
acetamide 33 aniline, in addition to the methylated diazepine synthetic fragment 65, each 
inhibited approximately 70% of IL-6 secretion. All other analogues inhibited IL-6 secretion by 
more than 50%, except for phenyl 27, 4-methylphenyl 32, and 4-methylbenzyl 37 aniline 
(Figure 24, Table 5).  
Chapter 4 – Biological Analysis 
[71] 
 
 
Figure 24. Anti-inflammatory efficacy of truncated LRRK2IN1/IN1_G analogues. Primary screening assay 
carried out in U87 glioblastoma cells, a model for the inflammatory immune component of brain cancer. 
Glioblastoma cells were incubated with analogues at 10 µM, or a DMSO control, from 1 hour prior to simulation 
with IL-1β. The concentration (pg/mL) of IL-6 secreted by glioblastoma cells after 24 hours was recorded and 
calculated as a percentage of the IL-1β stimulated control. 
 
Potent compounds were subsequently analysed for anti-inflammatory efficacy in primary 
human microglial cells. Compounds were administered at 1 µM and 10 µM concentrations to 
LPS-stimulated microglial cells. 4-Nitrophenyl 31, 3-methoxyphenyl 30, cyclohexyl 39, and 2-
pyridinyl 25 substituted anilines were equipotent with previously identified compounds IN1_G 
and lead 1. These analogues and synthetic intermediate 63 inhibited IL-6 secretion more 
than 50% at 1 µM (IC50 < 1 µM). Three analogues 3-methoxybenzyl 35, 4-nitrobenzyl 36 and 
diazepine 40 anilines were moderately active, inhibiting IL-6 secretion between 5-50% at 1 
µM concentrations (Figure 25a, Table 5). At a concentrations of 10 µM, all analogues 
inhibited IL-6 secretion with moderate to good potency (25-49% IL-6 inhibition), except for 
the 5-membered heteroaromatic analogues 21 and 22, and the methylated diazepine 
intermediate 65. Analogues 29, 30, 31, 33, 34, 35, 36, 39 and 40 were more active than lead 
1 at 10 µM (Figure 25,Table 5, Chapter 4.3.6).  
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Figure 25a and 25b. Anti-inflammatory efficacy of LRRK2IN1/IN1_G analogues in primary human 
microglia. Microglia were incubated with analogues at 1 µM (Fig. 25a) or 10 µM (Fig. 25b), or a DMSO control, 
from 1 hour prior to simulation with LPS. The concentration (pg/mL) of IL-6 secreted after 24 hours was recorded 
and calculated as a percentage of the LPS-stimulated control.  
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4.2.3 Assessment of Screening Methodology 
Both time and resource efficiency were improved by the use of two different cellular assays 
to assess the functional efficacy of truncated LRRK2IN1/IN1_G analogues. Results reflected 
the therapeutic potential of analogues for treating both glioblastoma and Parkinson’s disease 
which are two important neurological conditions that are promoted by an inflammatory 
microenvironment. Our use of a primary screening assay to assess the potency of truncated 
analogues and select a subset of compounds that were likely to demonstrate efficacy in a 
Parkinson’s disease cell-assay was justified by the consistent relative potencies of 
LRRK2IN1, IN1_G, 1 and IN1_H when previously assessed in these two assays. Consistent 
trend in efficacy between the two assays also improved our confidence that analogues may 
be exerting anti-inflammatory effects by engaging with LRRK2. LRRK2IN1 is a highly 
selective LRRK2 inhibitor and only inhibits a small number of other human kinases. 
Consequently it is likely that the efficacy of LRRKIN1 and structural similar analogues 
observed in the respective assays was being mediated through inhibition of LRRK2. 
Analogues whose activity varied significantly between the primary and secondary assays, 
relative to other compounds, might have been exhibiting off-target activity.  
The magnitude of inhibitory efficacy of the analogues shifted systematically between the 
primary and secondary assays. All compounds inhibited cytokine secretion less in the 
secondary assay than the primary assay, when administered at 10 µM. Variation in the 
magnitude of inhibition between assays was expected, because cell permeability, 
microenvironment, and ATP concentration differ between cell-types. Additionally, the 
magnitude of inhibition might reflect engagement of LRRK2 in the separate signalling 
pathways of glioblastoma cells and microglia. Signalling pathways are complex, often 
involving multiple kinases, various phosphorylation events, and feedback loops. The 
increased sensitivity of glioblastoma cells to inhibition by LRRK2IN1/IN1_G analogues 
suggests that signalling through the IL-1 β-p38 MAPK pathway to secrete IL-6 might be 
more dependent on LRRK2, than the equivalent pathway in microglial cells. All analogues 
were analysed in microglial cells that came from a single donor. Genetic variation between 
donors leads to different levels of microglial activation and consequently a different 
magnitude of inhibitory efficacy. In this case, such as in Figure 9a, Chapter 1.4.3, data from 
both donors have been reported.  
As expected, the magnitude of anti-inflammatory efficacy decreased when lower 
concentrations of the analogues were administered to microglia (Figure 25a, b), but the fold-
change was not consistent between different analogues. Variation in activity was amplified at 
lower concentrations which allowed stronger correlation to be made when assessing SARs.  
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The data generated in these assays is preliminary and was used to help us identify 
compounds which were likely to decrease the inflammation associated with neurological 
diseases. We were also able to assess whether analogues were likely to reach the target 
molecule when administered in vivo. The cellular assays used to assess efficacy 
necessitated that potent analogues also possess suitable physicochemical properties to 
cross biological membranes. Through this approach we were confident that analogues 
identified as potent would progress further in preclinical drug development than if a 
biochemical assay had been employed.  
The cellular assays that we used cannot provide any information regarding the mechanism 
of action of truncated LRRK2IN1/IN1_G analogues. Whilst LRRK2 has been identified as an 
important component in the signalling pathways involved in IL-6 production we do not know if 
analogues are inhibiting LRRK2, or if they are achieving functional efficacy through an 
alternative mechanism. Subsequent biochemical analysis will be performed to validate what 
these potent compounds are interacting with in the cells and how selective they are for the 
target molecule. 
4.3 Structure Activity Relationship Analysis 
By comparing the anti-inflammatory efficacy of truncated LRRK2IN1/IN1_G analogues in 
two separate models of neuro-inflammation, and at different concentrations, simple 
structure-activity relationships were identified. Protein-ligand docking was used to enrich our 
analysis of SARs, but as the mechanism-of-action of truncated analogues is unconfirmed, 
suggestions relating to LRRK2 inhibition are considered speculative. We hope to strengthen 
our understanding of SARs that are important for binding to LRRK2 through biological 
binding affinity studies in the near future.  
4.3.1 Heterocyclic vs. Carbocyclic Aniline Analogues 
Comparison the 2/5-pyrimidinyl and 2/3-pyridinyl aniline analogues 23, 24 and 25, 26 
respectively indicated that the position and number of the nitrogen heteroatoms had little 
effect on functional efficacy in stimulated glioblastoma cells (Table 5). But, aromatic rings 
containing heteroatoms resulted in improved activity over simple carbocyclic phenyl 27, 
benzyl 34, 4-methylphenyl 32 and 4 methylbenzyl 37 aniline analogues. Only benzyl aniline 
34 was equivalent to or more active than heteroaromatic analogues in the primary screening 
assay. The low efficacy of heterocyclic and carbocyclic analogues in glioblastoma cells 
meant that only 2-pyridinyl 25 and benzyl 34 aniline analogues were selected for further 
biological characterisation in microglia.  
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2-Pyridinyl aniline 25 was equipotent in secondary screening assay to IN1_G and lead 
aniline 1, decreasing IL-6 secretion by 48% at 1 µM. We postulated that 3-pyridinyl aniline 
26 may have similar activity in microglial cells, as it was equipotent with 2-pyridinyl aniline in 
the primary screening assay, but was not selected for subsequent analysis because of a 
larger standard deviation. Similarity in the docking pose of analogue 25 and 26 also 
suggested that they may be similarly efficacious if inhibitory efficacy was being achieved by 
binding to LRRK2.  
Favourable physicochemical properties were predicted for 2-pyridinyl aniline 25 when we 
designed our analogue library including: high oral absorption (100%), very few metabolically 
susceptible sites (only two), a moderate MW (398 g mol-1) and tPSA (52 Å2) and excellent 
BBB permeability. The combination of these predicted properties and in vitro efficacy 
suggests that 2-pyridinyl aniline 25 would be an excellent candidate to advance into further 
biological. 
4.3.2 Benzyl vs. Phenyl Aniline Analogues 
The relative inhibitory efficacy of benzyl and phenyl aniline analogues in the primary 
screening assay suggested that the methylene group incorporated in benzyl analogues did 
not significantly alter potency relative to the analogous phenyl analogues (Table 5). The only 
exception was the enhanced inhibitory efficacy of benzyl aniline 34 (63%) over phenyl aniline 
27 (47%) at 10 µM in U87 glioblastoma cells. 4-Nitrophenyl 31 (70%), 3-methoxyphenyl 30 
(71%) and 4-methylphenyl 32 (38%) aniline all decreased IL-6 secretion to a similar level as 
their counterparts: 4-nitrobenzyl 36 (72%), 3-methoxybenzyl 35 (69%) and 4-methyl benzyl 
37 (36%) aniline. 
Small differences in potency were exaggerated when the analogues were assessed in the 
secondary assay, particularly at low concentrations. Substituted phenyl analogues 31 (44%) 
and 30 (44%) were more potent than their corresponding benzyl analogues 36 (29%) and 35 
(25%) when administered at 1 µM. This might imply that there is an optimal distance 
between the aniline NH and polar aromatic residues for binding to the cellular target, and 
that increasing the distance between polar groups was disfavoured. Alternatively the 
increased flexibility of benzyl analogues might have reduced their ability to permeate the 
cellular membrane.  
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4.3.3 Effect of Aryl Substituents 
The nature and position of aromatic substituents had a large effect on the anti-inflammatory 
efficacy of truncated analogues. Substituent trends were similar in both phenyl and benzyl 
aniline analogue series.  
The relative potency of ortho-substituted phenyl aniline analogues 25, 28 and 29 in the 
primary screening assay indicated that nitro groups improved activity over methoxy groups 
or heteroatoms (Figure 24, Table 5). Similarly, comparison of para-substituted phenyl 
analogues 31, 32, and 33 in the primary assay indicated that nitro-groups 31 (70%) 
engendered greater activity, than either amide 33 (68%) or aliphatic 32 (38%) substituents. 
Para substituted benzyl analogues (NO2, ME) 36 and 37 mirrored this trend, inhibiting IL-6 
secretion by 72% and 36% respectively. Aliphatic substituents contribute to non-specific 
hydrophobic interactions in the enzyme active site and increase off-target protein binding. 
Hydrophobic substituents also decrease compound solubility and can negatively affect 
cellular absorption. These factors might explain the poor efficacy the methyl-substituted 
analogues 32 and 37, compared to analogues substituted with polar nitro 31, or 36 or amide 
33 substituents.187 
Para or meta substituted analogues were more efficacious that compared the corresponding 
ortho-substituent analogues. This was best illustrated by the activity trend of 2-nitrophenyl 
analogue 28 (69%, 66%, and 0% inhibition) and 4-nitrophenyl 31 (70%, 73%, and 44% 
inhibition) across all three assays, glioblastoma cells at 10 M, microglial at 10 M and 
microglial at 1 M respectively. Results from the analysis of 30 (71%) versus 28 (62%) 
analogue in the primary screening assay also supported this conclusion. Para and meta 
substituted phenyl aniline analogues mimic the relative position of the C5-lactam and C4-
amine substituents in the diazepinone motif of LRRK2IN1/IN1_G. Whilst not predicted to be 
important in binding to LRRK2 in our homology model, biological results suggest that the C5-
lactam and C4 amine might be important to the functional activity of LRRK2IN1/IN1_G.  
Electron withdrawing substituents were favoured in general. Electron deficient 4-nitro aniline 
31 exhibited greater anti-inflammatory efficacy across all three experiments (70%, 73%, and 
44% inhibition) than electron neutral N-phenylacetamide aniline 33 (68%, 54%, and 0% 
inhibition). This was surprising considering the greater structural similarity of the acetamide 
group to the lactam of LRRK2IN1/IN1_G. In the primary screening assay 2-nitro aniline 29 
(69% inhibition) was more potent than electron-rich 2-methoxy aniline 28 (62% inhibition).  
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4.3.4 Five‐membered Heteroaromatic Analogues 
Pyrrole analogues 21 and 22 moderately inhibited IL-6 secretion by 62% and 61% 
respectively when tested in the primary screening assay, but were inactive when tested in 
the secondary assay. Non-specific binding interactions or inhibition of enzymes other than 
LRRK2 in the primary screening assay might account for these observations. Alternatively, 
the weak inhibitory efficacy of analogue 21 and 22 in the primary screen might not have 
been detectable in less responsive secondary screening assay.  
4.3.5 Aliphatic vs. Aromatic Aniline Analogues 
Saturated cyclohexyl analogue 39 was more potent than aromatic phenyl 27 analogue in the 
primary screening assay, and also exhibited good inhibitory activity in the subsequent 
screening assays (60%, 83%, and 43% inhibition). The anti-inflammatory efficacy of 39 
closely mirrors lead aniline 1 (68%, 37%, and 58% inhibition). They also share very similar 
docking poses which suggests that they might be binding to the same target molecule.  
Simple aliphatic analogue 38 was similarly potent to 39 in the primary screening assay 
(55%), but was not assessed in subsequent assays because of insufficient quantities of 
primary human microglial cells, 
There was insufficient data to determine if aliphatic variants of the substituted phenyl and 
substituted benzyl aniline analogues would also be more potent. However, our results do 
indicate that additional polar or hydrogen bonding interactions are not necessary to achieve 
good anti-inflammatory efficacy, but it is possible that selectivity would be lost without polar 
contacts.  
4.3.6 Diazepinone Variants 
Reducing the diazepinone IN1_H amide of IN1_G to an amine caused a moderate decrease 
in the anti-inflammatory efficacy of analogue 40 (90%) compared to IN1_G (95-98%) when 
assessed in U87 cells (Figure 23, Figure 24, Table 5). This indicated that the C5-lactam 
group was important, but not imperative to functional efficacy. Similar to diazepinone IN1_H, 
synthetic intermediate diazepine 65 was inactive when assessed in microglia (0%) at 1 or 10 
µM. In contrast, 63 had strong anti-inflammatory efficacy (74% inhibition) when assessed in 
the primary screening assay, which was probably mediated through non-specific binding 
interactions. Unmethylated diazepine precursor 63 was found to be equipotent to LRRK2IN1 
and IN1_G when assessed in all three assays (87%, 96% and 57% inhibition). As potency 
was consistent across all three assess and decreased in a concentration dependent manner 
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it was likely that 63 is achieving anti-inflammatory efficacy by binding to a particular 
molecular target common to both signalling pathways. This may have been LRRK2, but 
further biological characterisation is required. The presence of hydrogen bond donor has 
been shown in the literature to be essentially for inhibiting LRRK2, which might explain the 
dramatic difference in anti-inflammatory efficacy of 63 compared to methylated counterpart 
65.97 We suggest that the corresponding unmethylated precursor to IN1_H (10, Scheme 1, 
Chapter 1.4.2) might also have potent anti-inflammatory activity. The structure of 
unmethylated diazepine and diazepinones is ubiquitous with other heterocyclic molecules 
that binding in the conserved kinase A-pocket, and they are widely represented in kinase 
inhibitor patent literature.188 Therefore we predict that diazepine 63 might inhibit numerous 
kinases, and despite being efficacious, 63 is unlikely to possess the selectivity that would be 
required for clinical applications. However, the aniline coupled analogue of 63, that is, the 
demethylated analogue of version of 40, might be both a highly potent anti-inflammatory 
mediator and be selective for LRRK2 because of additional binding interactions with the 
active site through the aniline moiety. This possibility will be pursued in future research. 
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Table 5. Anti-inflammatory efficacy of truncated LRRK2IN1/IN1_G analogues recorded as the percentage 
inhibition of cytokine secretion compared to cells that were no treated with analogues. Primary analysis 
was performed using IL-1β-stimulated U87 glioblastoma cells. Analogues were administered at 10 µM. IL-6 
secretion was measured and the calculated as a percentage relative to DMSO treated IL1β-stimulated control 
(100%). Values are reported as per cent inhibition. Secondary assays were performed using LPS-stimulated 
primary human microglial cells. Analogues were administered at 10 µM or 1 µM. Il-6 secretion was measured and 
the calculated as a percentage relative to DMSO treated LPS-stimulated control (100%). Values are reported as 
per cent inhibition.  
 
Code Structure Primary Assay 
Secondary 
Assay [10 µM] 
Secondary 
Assay [1 µM] 
1 1 68 37 58 
23 
 
53 - - 
24 
 
54 - - 
25 
 
58 35 48 
26 
 
58 - - 
27 
 
47 - - 
31 
 
70 73 44 
29 
 
69 66 0 
33 
 
68 54 0 
30 
 
71 79 44 
28 
 
62 - - 
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32 
 
38 - - 
34 
 
63 66 0 
36 
 
72 70 29 
35 
 
69 75 25 
37 
 
36 - - 
38 
 
55 - - 
39 
 
60 83 43 
21 
 
62 0 0 
22 
 
61 11 0 
40 
 
90 81 8 
63 
 
87 96 57 
65 
 
74 0 0 
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4.4 Reflection on Predictive Parameters for Analogue Design 
Preliminary biological analysis using cell-based models of neuro-inflammation was 
performed to assess the functional activity of our library of truncated LRRK2IN1/IN1_G 
analogues. A number of analogues potently inhibited cytokine secretion from both stimulated 
glioblastoma and microglial cells. Based on these promising results, further biological 
characterisation will be carried out to identify the mechanism of anti-inflammatory efficacy 
and experimentally determine physicochemical and pharmacokinetic properties. 
During our design of the truncated analogue series we used multiple in silico scoring 
functions and modelling programs to identify compounds that were likely to possess 
favourable in vivo pharmacokinetics and good binding affinity for LRRK2. At present, we are 
unable to determine whether these predictions correlate with experimental results.  
Functional assays do not necessarily reflect binding affinity to a target molecule because the 
mechanism by which drugs achieved a functional response is complicated by the presence 
of numerous other proteins. However, as mentioned in Chapter 4.2.1, they are extremely 
valuable for identifying compounds that are likely to have therapeutic benefits. In the same 
vein, many drugs may bind tightly to a protein target but be ineffective at inducing the 
desired biological response. It is thus imperative in pharmaceutical develop to perform both 
binding and functional assays to fully characterise drug action. We hope to justify our use of 
G-scores for synthetic prioritisation by assessing the binding affinity of analogues in 
biochemical assays in the near future. 
Cellular assays are good preliminary screens to identify compounds that are poorly soluble 
and unable to cross cellular membranes. Compounds that are efficacious in cellular assays 
are significantly less likely to fail during later development because of poor physicochemical 
properties. However, cellular assays performed using a single type of cell, such as CNS 
cells, cannot replicate the full complement of biological membranes, metabolic enzymes, 
efflux transporters and numerous other factors that will affect biological activity. We selected 
analogues for synthesis based on predictions and scoring functions that correlated with oral 
absorption, BBB permeability, metabolic stability and toxicity. These properties were not 
determined in our preliminary biological analysis. In the near future in vitro assays will be 
used to specifically assess these properties, which will provide greater insight into the 
validity of our design methodology.  
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Chapter 5 – Future Work 
5.1 Chemical Synthesis 
5.1.1 “Umpolung” of Synthetic Route 
We experienced considerable difficultly synthesising desirable LRRK2IN1/IN1_G analogues 
using reactions that relied on aniline 1 to act as a nucleophile. We propose that formal 
umpolung of reagents used in these reactions we may be able to synthesise interesting 
heterocyclic and functionalised aniline analogues, by exploiting the natural properties of the 
fragments (Scheme 17). By making the “aniline” synthon 99 an electrophile we will take 
advantage of the EWGs already substituted ortho and para to the reaction centre. Many 
desirable aryl amine nucleophilies, as typified by 100 or 101, are commercially available or 
are readily accessible through simple synthetic procedures such as the Chichibabin reaction, 
reduction of nitro precursors or from the corresponding diazo-species. By reversing the 
polarity of the coupling reaction we will introduce electron-rich substituents onto the scaffold 
of aniline 1 and expand our library of truncated LRRK2IN1/IN1_G analogues. 
 
Scheme 17. Retrosynthesis of truncated aniline analogues by umpolung of the key nucelophilic 
substitution reaction. 
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5.1.2 Synthesis of Diazepine and Oxazepine Analogues 
In the near future we hope to complete the synthesis of the proposed diazepine and 
oxazepine analogues 41, 42 and 43. Based on preliminary biological analysis we predict that 
unmethylated analogues 41 and 43 will show improve anti-
inflammatory efficacy over previously synthesised analogue 
40. We also propose that analogues 41 and 43 will be more 
selective for LRRK2 than potent synthetic intermediate 63, as 
the bipiperidine group is predicted to form binding interactions 
outside the highly conserved adenine-binding pocket (A-
pocket) (see Chapter 2.2 and 2.3) 
 The benzylic methylene-amine (-CH2-N) present in analogue 
40 introduced a site predicted to be susceptible to oxidative 
metabolism. In the near future, we hope to synthesise 
chlorinated analogues 102 which are predicted to be less 
susceptible to oxidative metabolism. The structures typified 
by 102 correspond to lactam analogues synthesised in 
previous work (Chapter 1.4) and would provide further 
opportunity to assess the functional importance of the 
lactam group. 
 
5.1.3 Reaction Optimisation  
Buchwald-Hartwig chemistry and all-water catalysis were imperative to the successful 
synthesis of a large proportion of our library of truncated analogues. Whilst a sufficient 
quantity of the desired analogues was obtained using these methods, yields were low and 
product purification was challenging. New synthetic procedures or optimised reaction 
conditions must be developed if the chemical diversity of our analogue library is to be 
increased.  
We propose to investigate the use of bi-dendate and ferrocene-based phosphine ligands in 
Buchwald-Hartwig chemistry. These ligands have been previously shown to be 
advantageous for coupling reactions involving five-membered heteroaromatic species. We 
also propose to investigate transition metal catalysed cross-coupling reactions for the 
synthesis of conjugated di-aryl aniline analogues 103. These analogues will incorporate 
Figure 26. Future diazepine and 
oxazepine aniline analogues 
predicted to have greater anti-
inflammatory efficacy (41, 43) 
than analogue 1, or improved 
metabolic stability (102). 
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heterocyclic groups with secondary amines that can act as hydrogen bond donors 104 
(Scheme 18). 
 
Scheme 18. Retrosynthesis of conjugated di-aryl analogues (103) that could be arrived at using standard 
transition-metal catalysed procedures. 
 
Aniline 1 was found to react under mild conditions with aldehyde 91 and ketone 92 
electrophilies (see Chapter 3.5 and 3.7). Consequently we propose that N-benzyl aniline 
analogues 34, 35, 36 and 37 might be synthesised in improved yield and purity by reductive 
amination of the appropriate benzaldehyde precursors (Scheme 19). 
 
Scheme 19. Modified retrosynthesis of N-benzyl aniline analogues. 
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5.2 Biological Characterisation 
5.2.1 Pharmacodynamic Characterisation 
Biochemical enzyme inhibition and binding assays will be performed in the near future to 
determine whether potent analogues achieve anti-inflammatory efficacy by inhibiting LRRK2, 
or an alternative mechanism. Biochemical assays will be performed as per the literature 
using artificial LRRK2 enzyme constructs, and the synthetic peptide substrate Nictide or 
LRRKtide in the presence of radiolabelled ATP. Multiple experiments at different inhibitor 
concentrations will be run to actually determine an IC50 value for each analogue. 
Biochemical assays are extracellular and run in the absence of other proteins. This will avoid 
functional responses mediated by off-target binding and help validate the mechanism of drug 
efficacy. Binding assays will provide crucial SAR data for further developing potent and 
selective LRRK2 inhibitors 
Kinome-wide screening assays will be performed to determine the relative binding affinity of 
analogues for LRRK2 over other human kinases. Compounds found to have high selectivity 
for LRRK2, and biochemical IC50 values that correlate with cellular efficacy will improve 
confidence that anti-inflammatory efficacy is being achieved by inhibiting LRRK2.  
Biochemical and binding analysis will be used to assess the validity of our design 
methodology and use of G-scores to prioritise analogues for synthesis. By reflecting on 
results, we will subsequently modify the model and constraints employed for future design 
projects.  
Compounds that exhibit favourable potency and selectivity across these assays will 
subsequently progress to in vivo analysis.  
5.2.2 Pharmacokinetic Characterisation 
The physicochemical and pharmacokinetics of truncated LRRK2IN1/IN1_G analogues will 
be assessed using a cohort of in vitro cell based assays. BBB and gastrointestinal 
permeability will be predicted using MDCK and Caco-2 monolayers respectively. Plasma 
protein binding, which reduces the concentration of free drug available to cross the BBB will 
be determined by incubating analogues in blood plasma or brain protein homogenate and 
detected per cent protein precipitation. 92 Metabolic stability will be determined by incubating 
analogues with human liver microsomes, which are rich in oxidative cytochrome P450 
enzymes, and subsequently analysing the homogenate using mass spectrometry.92  
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Compounds found to have favourable pharmacokinetic properties in vitro will subsequently 
be assessed in a mice using an efficient cassette dosing methodology to determine oral 
absorption (F%), brain exposure (AUCbrain/AUCblood), drug clearance (Cl, mL/min/kg), and 
safety parameters.189  
5.2.3 Further Functional Analysis  
LRRK2 has been shown to be involved in the signalling pathway of other Toll-like receptors 
(TLR2 and TLR9) that contribute to the production of the pro-inflammatory mediator nitric 
oxide.  
LRRK2 has been implicated in the signalling pathways TLR2 and TLR9, in addition the 
TLR4-p38 MAPK signalling pathway of microglia. TLR2 and TLR4 are involved in the 
production of pro-inflammatory mediator nitric oxide. 21 Further characterisation of the role 
LRRK2 in these biological pathways is crucial to understanding the pathogenesis of a 
growing number of diseases. We will employ a Multiplex screening assay to rapidly and 
efficiently determine whether truncated analogues inhibit the secretion of a panel of other 
pro-inflammatory cytokines including IL-2, IL-4, IL-8, IL-10, GM-CSF, and INFγ that are 
produced in response to the stimulation of various TLRs. Analogues are determined to be 
selective inhibitors for LRRK2 (see Chapter 5.2.1) will provide insight into the role of LRRK2 
in the cellular processes involved in producing the different pro-inflammatory cytokines. 
Together, this information will indicate the potential for our library of truncated analogues to 
be used as treatments for a range of diseases that are promoted by an inflammatory 
microenvironment. 
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Chapter 6 – Summary and Outlook 
6.1 Summary 
A library of truncated analogues was rationally designed to investigate whether the tricyclic 
diazepinone motif of known LRRK2 inhibitor LRRK2IN1 and close analogue IN1_G 
contributed to anti-inflammatory efficacy. In silico modelling and property predictions were 
used to guide the design of analogues. Small aromatic, heteroaromatic and aliphatic 
functional groups were added to the scaffold of aniline 1. Physicochemical and 
pharmacokinetic properties were calculated and scoring functions were used to select 
analogues that were predicted to have an improved biological and safety profile. Analogues 
were docked in a homology model of the LRRK2 kinase domain, and structures that 
conformed to the binding pose(s) of LRRK2IN1 and IN1_G were favoured. Analogues were 
prioritised for synthesis according to predicted binding affinity. 
Twenty truncated analogues were successfully synthesised, along with numerous synthetic 
intermediates. Standard organic synthetic protocols were employed but product yield was 
often modest due to the low nucleophilicity of the lead aniline 1. In depth study into the 
substrate scope of a specific catalytic system for Buchwald-Hartwig chemistry was made 
possible through the synthesis of a phenyl aniline series of analogues. A novel, 
environmentally-friendly approach to synthesising mono-N-alkylated anilines using all-water 
catalysis was explored. We demonstrated the utility of recently described methodology for 
the synthesis of pyrimidobenzo-diazepines and oxazepines.  
Preliminary biological analyses have been performed to assess the anti-inflammatory 
efficacy of truncated analogues. Screening efficiency was improved by the use of two 
separate cell-based assays which had relevance to both brain cancer and Parkinson’s 
disease. A number of compounds were identified with equivalent anti-inflammatory efficacy 
to LRRK2IN1 and IN1_G. Assessment of SARs indicated that the absence of a hydrogen 
bond donor group in the structure of diazepinone IN1_H most likely contributed to the poor 
anti-inflammatory efficacy of this fragment. 
Analogues 25, 30, 31, and 39 and synthetic intermediate 63 were identified as the most 
potent compounds when assessed in LPS stimulated microglia at concentrations of 1 µM. All 
5 compounds were all predicted to have a favourable pharmacokinetic profile including high 
oral absorption (F > 86%), moderate to high BBB permeability, fewer metabolites than 
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LRRK2IN1, and tPSA, cLogP and MW values that were all within an acceptable range for 
CNS active compounds. Complete in vitro biological characterisation of potent analogues will 
be performed in the near future.  
The synthesis a further library of analogues is underway in response to SAR observations 
and options to optimise challenging steps in the synthesis of our library of truncated 
analogues have been proposed. 
6.2 Outlook and Impact Potential 
The prevalence of Parkinson’s disease is predicted to rise rapidly as the average age and 
life expectancy of the global population increases. Symptomatic treatment requires a cocktail 
of various drugs that cause side-effects and have a limited period of use. There are no 
methods of directly addressing the cause of neurodegeneration or modifying the course of 
disease progression. LRRK2 has emerged as the most promising drug target for the 
development of neuro-protective therapeutics. Characterisation of LRRK2 and the 
development of LRRK2 inhibitors is a major area of research resulting in more 200 
publications in 2012. Whilst numerous potent compounds have been described they are 
typically plagued with either poor selectivity or poor physicochemical and pharmacokinetic 
properties.  
Our recent research into the development of metabolically stable LRRK2IN1 analogues 
yielded a potent inhibitor IN1_G of neuro-inflammation. LRRK2IN1 and IN1_G were 
subsequently used to identify a role for LRRK2 in the pathology of glioblastoma, a severe 
form of brain cancer. LRRK2 has not previously been linked to cancers of the CNS and this 
discovery added to the significance of our research and the potential for therapeutic LRRK2 
inhibitors. We have developed a series of truncated LRRK2IN1/IN1_G analogues that have 
potent functional activity in vitro, and more importantly are predicted to have an improved 
pharmacokinetic profile for application in vivo. Further characterisation of these analogues is 
necessary to confirm whether the anti-inflammatory efficacy observed was mediated through 
LRRK2. However, regardless of mechanism of action, the functional benefits of these 
analogues makes them viable candidates for further development as treatments for diseases 
promoted by an inflammatory microenvironment. Ongoing research into structurally similar 
analogues will likely yield novel, disease-modifying therapeutics for Parkinson’s disease in 
the near future. 
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Chapter 7 - Experimental Methods 
7.1 Molecular Modelling and Property Prediction 
Ligand Docking and GLIDE Scores 
The methods and rationale used to construct a homology domain of the LRRK2 kinase 
domain have been described previously.58 Analogues were prepared for docking using 
LigPrep, v.2.5 (Schrödinger, Inc.)103 to generate three dimensional energy minimised 
structures. Docking studies were carried out using Grid-based Ligand Docking with 
Energetics (GLIDE) XP. Docking was performed with one hydrogen bond constraint to either 
Glu-1948 (NH) or Ala-1950 (C=O) in the adenine pocket of the active site. Docking was 
repeated in the absence of constraints to identify novel ligand-protein binding interactions.  
Docking poses were evaluated by a combination of binding affinity (Glide score), internal 
molecular strain (E-model), and similarity to the binding mode of known LRRK2 inhibitors in 
the literature. Binding affinity of optimal pose(s) was calculated as a Glide score according to 
Equation 1.  
Eq 1.  GScore = 0.065*vdW + 0.130*Coul + Lipo + Hbond + Metal + BuryP + RotB + Site 
*vdW = van der Waals energy, Coul = coulomb energy, Lipo = favourable hydrophobic interactions, Hbond = 
weighted hydrogen bonding term, Metal = metal-anionic ligand interactions, BuryP = penalty for desolvating polar 
groups, RotB = penalty for freezing rotatable bonds, Site = reward for polar, non-hydrogen-bonding interactions 
Property Predictions 
The physicochemical and pharmacokinetic properties of LigPrep prepared analogue 
structures were predicted using QikProp v.3.5 (Schrödinger Inc.),104 Epik v.2.3 (Schrödinger 
Inc.)110 and Marvin v.6.0.2 (ChemAxon)111. Values were evaluated by reference to optimal 
value ranges published in the literature for CNS active drugs and lead compounds.109, 114  
Predicted molecular weight (MW), lipophilicity (cLogP and cLogD at pH7.4), acidity (pKa) and 
topological polar surface area (tPSA) were used when calculating the central nervous 
system multi-parameter optimisation (CNS MPO) score of each analogue. Values were 
transformed for calculations using desirability functions as reported in the literature.124 
The ligand efficiency (LE), lipophilic ligand efficiency (LLE) and lipophilic ligand efficiency 
(LELP) of initial compounds were calculated using physicochemical properties predicted by 
QikProp v.3.5,104 and experimentally determined functional efficacy determined in cell-based 
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assays. Evaluation of ligand efficiency scores was made with reference to the literature.118, 
119, 121, 122 
7.2 Biological Analysis 
7.2.1 Cell Culture Protocol 
Human U87 glioblastoma cells and primary human microglia were cultured in DMEM 
(Invitrogen) supplemented with 10% (v/v) FBS (foetal bovine serum), glutamine and 
antibiotic-antimycotic solution (Invitrogen). Primary human astrocytes were cultured using 
RPMI-1640 (Invitrogen) with supplements. Cells were incubated at 37 ˚C and 5% CO2. Cells 
were passaged every 3 to 4 days, or at 100% confluence. Primary astrocytes and microglia 
were obtained from 14 to 20 week old aborted foetuses, which were therapeutically 
terminated after obtaining informed consent (approved by the ethics committee of University 
of Sydney (HREC 2013/131) and University of New South Wales (HREC 08284), Australia).  
7.2.2 Primary Screening Assay in U87 Glioblastoma Cells 
Human U87 glioblastoma cells were seeded in 24-well plates at a density of 1x105 cells/mL 
for 24 hours. Cells were starved in serum-free media (supplemented with 0.5% bovine 
serum albumin) for 2 hours. Cells were then treated with newly synthesised LRRK2 
compounds at 10 µM for 1 hour, and stimulated with IL-1β at 10 ng/mL for 24 hours. 
Supernatant was harvested and stored at -20 ˚C. IL-6 concentration in the supernatants was 
analysed by ELISA with commercially available BD OptEIA Human IL-6 Kit (BD 
Biosciences). Absorbance was measured at 450 nm using the FLUOstar Omega plate 
reader.  
7.2.3 Secondary Screening Assay in Microglia 
Primary microglia were plated in 24-well plate at a density of 0.5x105 cells/mL for 24 hours. 
Primary microglia were treated with LRRK2IN1/IN1_G analogues at 10 µM or 1 µM for 1 
hour, and stimulated with LPS at 100 ng/mL for 24 hours. Supernatant was harvested and 
stored at -20 ˚C. IL-6 concentration in the supernatants was analysed by ELISA with 
commercially available BD OptEIA Human IL-6 Kits (BD Biosciences). Absorbance was 
measured at 450 nm using the FLUOstar Omega plate reader. 
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7.2.4 Data transformation 
Absorbance at 450 nm was transformed to pg/mL cytokine section with reference to a pre-
prepared standard curve. Cytokine secretion in pg/mL were normalised relative to the IL-1β 
or LPS-stimulated control (100% secretion). Replicated were averaged and plotted as a 
percentage of control cytokine secretion. Values were also reported as a percentage 
inhibition, defined by 100-(%cytokine secretion). 
7.3 Chemical Synthesis 
7.3.1 General Experimental Details 
Unless otherwise stated, reactions were conducted under positive pressure of a dry nitrogen 
or argon atmosphere. Temperatures of 0 oC, -10 and -78 oC were obtained by cooling the 
reaction vessel in a bath of ice, salt and ice, or acetone and dry ice (CO2(s)) respectively. All 
reagents were used as purchased from commercial sources unless otherwise specified. n-
butyl lithium was titrated prior to use against diphenylacetic acid in anhydrous 
tetrahydrofuran.190 Anhydrous dichloromethane was prepared by distillation over calcium 
hydride. N,N-dimethylacetamide was dried overnight over calcium hydride, then filtered and 
distilled under vacuum. N,N-dimethylformamide was distilled prior to use and stored over 4 Å 
molecular sieves. Phosphorus oxychloride was freshly distilled prior to use. N,N-
dimethylaniline was purified by reaction with 0.1 mol% acetic anhydride followed by 
fractional distillation. 1,4-dioxane was either freshly distilled over sodium wire, or stirred over 
calcium hydride (5% w/v) for 48 hours, then distilled and stored over 4 Å molecular sieves. 
Tetrahydrofuran was freshly distilled over sodium wire.191 1,2-dichloroethane, AR Grade 
acetone and all other solvents were purchased from commercial sources and used without 
further purification.  
Analytical thin layer chromatography (TLC) was performed using Merck aluminium backed 
silica gel 60 F254 (0.2mm) plates which were visualised using short wave (254nm) and/or 
long wave (365nm) ultra-violet fluorescence or potassium permanganate stain. Flash column 
chromatography was performed using Merck Kieselgel 60 (230–400 mesh) silica gel. 
Reverse phase chromatography was performed using C18-coated silca gel. Solvents for 
chromatography were used as purchased form commercial sources without further 
purification. Solvents are reported as volume/volume eluent mixture where applicable.  
Melting points were measured in open capillaries using a Stanford Research Systems 
Optimelt Automated melting point apparatus and are uncorrected. Infrared absorption 
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spectra were recorded on a Bruker ALPHA FT-IR spectrometer by attenuate total reflection 
(ATR) using a ZnSe crystal. Data are reported as vibrational frequency (cm-1) and intensity 
(strong, medium, weak or broad) for the assigned functional group. Nuclear magnetic 
resonance spectra were recorded at 300 K unless otherwise stated, using either a Bruker 
AVANCE DRX200 (200 MHz), DRX300 (300 MHz), DRX400 (400.1 MHz) or AVANCE III 
500 Ascend (500.1 MHz) spectrometer. Data is reported as chemical shift (δ ppm) relative to 
the residual protonated solvent resonance, relative integral, multiplicity (s = singlet, br = 
broad, d = doublet, dd = doublet of doublets, etc, t = triplet, tt = triplet of triplets, etc., q = 
quartet, m = multiplet), coupling constants (J Hz), and assignment. Assignment of signals 
was assisted by COSY, edited HSQC, and HMBC experiments where necessary. Low 
resolution mass spectra (LRMS) were determined by either electrospray ionization (ESI) or 
atmospheric pressure chemical ionisation (APCI) recorded on a Finnigan LCQ ion trap 
spectrometer, or electron impact recorded on a ThermoFinniganPolarisQ GC/MS 
spectrometer. High resolution mass spectra (HRMS) were recorded by ESI using a Bruker 
7T Fourier Transform Ion Cyclotron Resonance Mass Spectrometer (FTICR). The molecular 
ion, designated M+, and major fragment peaks are quoted as percentages relative to the 
base peak intensity. Where required, all structural assignments were made with reference to 
known spectral assignment manuals.192, 193 
7.3.2 Synthesis of Fragments/Coupling Partners 
Synthesis of 3-bromomaleimide [52] 
 
Bromine (128 µL, 2.5 mmol, 1 eq.) was added drop-wise to a solution of maleimide 50 
(242.7 mg, 2.5 mmol, 1 eq.) in chloroform (1.8 mL). The reaction was heated to reflux for 2.5 
hours and then allowed to cool to room temperature. The white succinimide precipitate was 
collected by filtration a washed with cold chloroform. The crude intermediate was redissolved 
in tetrahydrofuran (6 mL) and a solution of triethylamine (289 µL, 2.05 mmol, 1.05 eq.) in 
tetrahydrofuran (6 mL) was added slowly to the reaction mixture. The reaction was stirred at 
room temperature for 48 hours, at which point an orange precipitate had formed. The 
precipitate was collected by filtration and washed with tetrahydrofuran to afford a yellow 
powder 52 (307 mg, 1.75 mmol, 70%). 
IR (ZnSe, film) vmax: 3232, 3103 (m, N-H), 2676 (w, C-H), 1780, 1763, 1710 (m, s, C=O), 
1576 (m, C=C), 1329 (m, br, C=N), 1232, 1125 (m, C=C), 996 (m, C-H), 869 (s, N-H) cm-1; 
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1H NMR (300 MHz, MeOD): δ 7.02 (1H, s, 4-CH) ppm; 13C NMR (125 MHz, CDCl3): δ 171.2 
(2/5-C=O), 167.9 (2/5-C=O), 134.3 (4-CH), 132.6 ppm. 
 
Synthesis of 5-iodo-1-methyl-1H-pyrazole [45] 
N
NI
4 3
5
6
 
N,N,N’,N’-tetramethylethylenediamine (0.5 mL, 3.5 mmol, .1 eq.) and n-butyllithium (2.06 
mL, 1.7 mM in hexane, 1.1 eq.) were added to a solution of 1-methyl-1H-pyrazole 44 (0.250 
mL, 3 mmol, 1 eq.) in dry tertahydrofuran (7.5 mL) at -78 oC. The temperature was raised to 
-10 oC and the reaction was stirred for 35 minutes, before being cooled back to -78 oC. A 
solution of iodine (0.938 g, 3.4 mmol, 1.2 eq.) in dry tetrahydrofuran (5 mL) was added 
slowing to the cooled solution over 2 hours. The reaction was allowed to warm to -10 OC and 
stirred for a further hour. The reaction mixture was then concentrated and partition between 
dichloromethane and aqueous citric acid solution. The aqueous phase was extracted and 
the combined organic fractions were washed with sodium thiosulfate solution (10% w/v ) and 
brine. The organic layer was dried over anhydrous magnesium sulfate and the solvent 
evaporated to yield a brown crystalline solid 45 (433 mg, 2.08 mmol, 69%). 
IR (ZnSe, solid) vmax: 3420 (br, m, possibly demethylated NH), 2934, 2861 (w, C-H) 1704, 
1650 (s, C=N), 1394, 1365 (s, C-N, CH3), 1223, 1091, 978 (C=C-H) cm-1; 1H NMR (500 MHz, 
CDCl3): δ 7.46 (1H, s, 3/4-CH), 6.42 (1H, s, 3/4-CH), 3.93 (3H, s, 6-CH3) ppm; 13C NMR (125 
MHz, CDCl3): δ 141.2 (3/4-CH), 115.7 (3/4-CH), 81.2 (5-CI), 39.8 (6-CH3) ppm. 
 
Synthesis of N-(4-iodophenyl)acetamide [47] 
 
N,N-diisopropylethylamine (261 L, 1.5 mmol, 3 eq.) was added to a stirred solution of 4-
iodoaniline 46 (10 mg, 0.5 mmol, 1 eq.) in freshly distilled tetrahydrofuran (1.4 mL) at room 
temperature. Acetyl chloride (39 L, 0.55 mmol, 1.1 eq.) was added dropwise to the reaction 
over period of 15 minutes. The reaction was stirred at room temperature for 2.5 hours, or 
until all of the 4-iodoaniline had been consumed and a  yellow precipitate had formed. The 
solvent was evaporated under reduced pressure and the crude material was redissolved in 
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dichloromethane (6 mL). The organic layer was washed with sodium hydroxide solution (1M, 
3 mL), followed by dilute hydrochloric acid (1 M, 3 mL) and brine (3 mL). The organic layer 
was dried over anhydrous magnesium sulfate and the solvent was evaporated to yield a 
yellow-brown crystalline solid 47 (122 mg, 0.467 mmol, 93%) 
Rf 0.10 (1/3 v/v ethyl acetate/hexane); IR (ZnSe, solid) vmax: 3289, 3260, 3174 (w, N-H), 
3100, 3060 (w, C-H), 1699, 1665 (s, br, C=O), 1596, 1584 (m, C=C), 1525 (s, N-H), 1483 (s, 
CH3), 1389, 1366, 1307, 1290 (s, C=C-H), 1243 (s, C-N), 1007, 814 (s, C=C-H) cm-1; 1H 
NMR (500 MHz, d6-DMSO): δ 10.02 (1H, br, s, 1-NH), 7.61 (2H, d, 3J2-3 = 8.0 Hz, 2/3-CH), 
7.41 (2H, d, 3J2-3 = 7.5 Hz, 2/3-CH), 2.03 (3H, s, 6-CH3) ppm; 13C NMR (125 MHz, d6-
DMSO): δ 168.4 (5-C=O), 139.1 (1-C), 137.3 (3-CH), 121.4 (2-CH), 86.3 (4-CI), 24.0 (6-CH3) 
ppm. 
Synthesis of (5-bromothiophen-2-yl)(pyrrolidin-1-yl)methanone [18] 
 
1-hydroxybenzotriazole hydrate (408 mg, 3.02 mmol, 1.25 eq.) and 1-ethyl-3-(3-
dimethylaminopropyl)carbodimide hydrochloride (579 mg, 3.02 mmol, 1.25 eq.) were added 
to a stirred solution of 5-bromothiophene-2-carboxylic acid (500 mg, 2.42 mmol, 1 eq.) in 
anhydrous dichloromethane (12.5 mL). The reaction was cooled to 0 oC and a solution of N, 
N-diisopropylethylamine (1.642 mL, 9.42 mmol, 3.9 eq.) and pyrrolidine (202 µL, 2.42 mmol, 
1 eq.) in dry dichloromethane (12.5 mL) was added. The reaction was allowed to warm to 
room temperature and stirred for 3 hours or until the staring materials had been consumed. 
The reaction was brought to pH 8 with saturated sodium hydrogen carbonate, the organic 
layer was collected and the aqueous phase was extracted with dichloromethane (3 x 3 mL). 
The combined organic fractions were washed with water (3 mL) and then brine. The organic 
phase was dried with anhydrous magnesium sulfate and the solvent evaporated to yield a 
brown oil. The crude material was purified by silica gel chromatography (1/20 – 1/2 v/v ethyl 
acetate/hexane) to yield a pale yellow powder 21 (0.586 mg, 2.25 mmol, 84%). 
Rf 0.17 (1/10 v/v ethyl acetate/hexane); IR (ZnSe, solid) vmax: 3465 (w), 3088, 2970, 2874 
(m, C-H), 1592 (s, C=O), 1529 (m, C=C), 1434 (br, s, CH2), 1337, 1227 (m, C=C), 973, 876 
(s, C=C-H) cm-1; 1H NMR (300 MHz, CDCl3): δ 7.25 (1H, d, 3J = 3.3 Hz, 3/4-CH), 7.02 (1H, d, 
3J = 3.6 Hz, 3/4-CH), 3.71 (2H, br, 6/9-CH2), 3.63 (2H, br, 6/9-CH2), 2.05 (2H, br, 7/8-CH2), 
1.89 (2H, br, 7/8-CH2) ppm; 13C NMR (75 MHz, CDCl3): δ 160.6 (1-C=O), 141.3 (2-C), 130.3 
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(3/4-CH), 129.9 (3/4-CH), 117.9 (5-C), 48.7 and 47.6 (6-CH2), 26.9 and 24.1 (7-CH2) ppm; 
LRMS (+ ESI) m/z: 284, 282 ([M + Na]+, 100, 90%), 262, 260 ([M + H]+, 40, 40%). 
 
7.3.3 Synthesis of 7‐membered heterocyles 
Synthesis of 5-nitrobarbituric acid [6] 
 
Nitric acid solution (5.34 mL, 120 mmol, 70% solution) was added drop-wise to a 
concentrated sulfuric acid (19.7 mL, 360 mmol, 98% solution) during which time the 
temperature did not exceed 50°C. Pyrimidine-2,4(1H,3H)-dione 5 (7.204 g, 60 mmol) was 
added in several portions to the stirred solution ensuring the temperature did not exceed 50 
°C. The reaction was heated to 55 °C for 3 hours, and then cooled below room temperature 
and quenched with ice-water (38 mL). The  resulting white precipitate was collected by 
filtration, washed with a small amount of ice water and dried under reduced pressure at 55°C 
to yield a white solid 6 (8.658 g, 55.11 mmol, 92%).  
m.p. >288 oC decomposition; Rf 0.00 (1/10, ethyl acetate/hexane); IR (ZnSe cell , solid) vmax: 
3142-2811 (m, br, O-H/N-H/C-H), 1732 (s, C=O), 1677, 1624 (s, NO2), 1417 (m, C-H), 1356 
(m, NO2), 1318 (s, aromatic R2NH/R3N), 1234 (s, -OH), 975, 832 (w, aromatic ring bending); 
1H NMR (500 MHz, d6-DMSO): δ 8.84 (1H, s, 6-CH) ppm; 13C NMR (125 MHz, d6-DMSO): δ 
155.5 (4-C=O), 149.8 (6-CH), 147.9 (2-C=O), 125.1 (5-CNO2) ppm.  
 
Synthesis of 2,4-dichloro-5-nitropyrimidine [7] 
 
5-nitropyrimidine-2,4(1H,3H)-dione 6 (8.658 g, 55.11 mmol) was dissolved in freshly distilled 
phosphorus oxytrichloride (25.7 mL, 275.55 mmol) at room temperature. N,N-dimethylaniline 
(17.4 mL, 137.78 mmol) was added dropwise to the stirred solution and the reaction was 
refluxed for 3 hours, or until complete. The black solution was cooled and concentrated 
under reduced pressure to remove excess phosphorus oxytrichloride, then poured into ice-
water (82 mL). The aqueous solution was extracted with diethyl ether (3 x 110 mL), and the 
combined organic layers were washed with brine (160 mL), dried over anhydrous 
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magnesium sulfate and the solvent evaporated to yield a brown oil. The crude product was 
purified by silica gel chromatography using ethyl acetate/hexane (1/10 v/v) as an eluent. The 
product was obtained as a yellow oil 7 (4.359 g, 22.47 mmol, 41%) 
m.p. 29-30 oC; Rf 0.42 (1/10 v/v ethyl acetate/hexane); IR (ZnSe cell, solid) vmax: 1541 (s, 
NO2), 1342 (s, NO2/C-N=C), 1305 (s, NO2/C-N=C), 1203 (s, C-Cl), 1178 (s, C-Cl), 871 (s, 
C=C-H), 678 (s, C=C-H); 1H-NMR (500 MHz, CDCl3): δ 9.16 (1H, s) ppm; 13C-NMR (125 
MHz, CDCl3): δ 162.74 (4-CCl), 156.62 (6-CH), 155.69 (2-CCl), 141.67 (5-CNO2) ppm; 
LRMS (+ GC/MS, 3.14 min) m/z: 197, 195, 193 ([M]+, 7, 39, 59%), 160, 158 ([M - Cl]+, 25, 
70%), 137, 135 ([M - (CH2ClN)2. + H]+, 34, 53%), 124, 122, 120 ([M – (C2HClN)3.+ H]+, 11, 
65, 100%), 93 (63%), 65, 63 (32, 78%). 
 
Synthesis of 2-aminobenzaldehyde [59] 
 
2-nitrobenzaldehyde 58 (302 mg, 2.00 mmol) was dissolved in ethanol (5.7 mL) and the 
solution was stirred for approximately 1 minute. Iron powder (335 mg, 6.00 mmol) and dilute 
hydrochloric acid (2 mL of 0.15 M HCl, 0.31 mmol) were added to the stirred solution. The 
reaction was heated to reflux for 1 hour after which time all of the staring material had been 
reduced. The reaction was cooled to room temperature and stirred for 0.5 hours. The cooled 
solution was diluted with ethyl acetate (16.5 mL) and stirred for 5 minutes before being 
filtered through a short celite plug. The filtrate was concentrated to approximately 1.5 mL 
and then rapidly passed through a short silica plug, eluting with 1/5 v/v ethyl acetate/hexane. 
The solvent was evaporated under reduced pressure to yield a yellow solid 59 (238 mg, 1.96 
mmol, 98%).  
m.p. 190-192 oC; Rf 0.50 (1/5 v/v ethyl acetate/hexane); IR (ZnSe, solid) vmax: 3607-3321 (m, 
br, NH2), 2917, 2850 (w, C-H), 1703 (s, C=O), 1605 (m, N-H), 1479 (s, C=C), 1358 (s, C-N), 
1222, 1050 (s, C=C-H) cm-1; 1H NMR (300 MHz, CDCl3): δ 9.82 (1H, 7-COH), 7.43 (1H, dd, 
3J = 7.9 Hz, 4J = 1.4 Hz, 6-CH), 7.25 (1H, dd, 3J = 7.7 Hz, 4J = 1.7 Hz, 4-CH), 6.70 (1H, ddd, 
3J = 7.5 Hz, 4J = 0.9 Hz 5-CH), 6.60 (1H, d, 3J = 8.3 Hz, 3-CH), 6.07 (2H, br, s, 2-NH2) ppm; 
13C NMR (75 MHz, CDCl3): δ 194.2 (7-CHO), 150.0, 135.8, 135.3, 119.0, 116.5, 116.1 ppm; 
LRMS (+ APCI) m/z: 122 ([M+H]+, 59%), 106 ([M – NH2 + H ]+, 100%). 
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Synthesis of 2-((2-chloro-5-nitropyrimidin-4-yl)amino)benzaldehyde [61] 
 
2-aminobenzaldehyde 59 (42 mg, 0.34 mmol) was added to a stirred solution of 2,4-dichloro-
5-nitropyrimidine 7 (100 mg, 0.52 mmol) and N,N-diisopropylethyl amine (120 µL, 0.69 
mmol) in anhydrous 1,4-dioxane (1.8 mL). The solution was stirred at 50-55 °C for 2 hours or 
until all 2-aminobenzaldehyde had been consumed. The reaction was concentrated under 
reduced pressure and purified by silica gel chromatography (1/20-1/10 v/v, ethyl 
acetate/hexane) to yield a yellow-orange solid 61 (74 mg, 0.27 mmol, 78%).  
m.p. 107-110 oC; Rf 0.30 (1/5 v/v ethyl acetate/hexane); IR (ZnSe, solid) vmax: 3389 (m, br, 
NH2), 2932 (w, C-H), 1675 (s, C=O), 1577 (s, C=C), 1555 (s, NO2), 1451 (m, C=C/N), 1366 
(m, NO2), 1313 (m, C-NH2), 1253, 1221, 1195 (C=C/N) cm-1; 1H NMR (500 MHz, CDCl3): δ 
12.92 (1H, 8-NH), 10.04 (1H, s, 13-CHO), 9.25 (1H, s, 6-CH), 8.82 (1H, d, 3J = 8.3 Hz, 9-
CH), 7.82 (1H, d, 3J = 7.3 Hz, 12-CH), 7.42 (1H, dd, 3J = 7.5, 8.0 Hz, 10/11-CH), 7.43 (1H, 
dd, 3J = 7.0, 7.5 Hz, 10/11-CH) ppm; 13C NMR (125 MHz, CDCl3): δ 194.3 (13-CHO), 163.6, 
157.8 (6-C), 153.5, 137.9, 136.4 (9/12-CH), 135.6 (10/11-CH), 127.9, 125.6 (10/11-C), 
124.7, 122.7 (9/12-CH) ppm; LRMS (+ APCI) m/z: 281, 279 (M + H]+, 28, 35, 100%), 232, 
231 ([M – NO2]+, 11, 29%). 
 
Synthesis of 2-((2-chloro-5-nitropyrimidin-4-yl)oxy)benzaldehyde [62] 
 
2-hydroxybenzaldehyde 60 (36 µL, 0.34 mmol) was added drop-wise to a stirred solution of 
2,4-dichloro-5-nitropyrimidine 7 (100 mg, 0.52 mmol) and N,N-diisopropylethyl amine (120 
µL, 0.69 mmol) in anhydrous 1,4-dioxane (1.8 mL). The reaction was heated to 50 oC for 1.6 
hours and then at room temperature for 3 hours, or until no 2-hydroxybenzaldehyde 
remained. The reactions was concentrated under reduced pressure and purified by silica gel 
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chromatography, eluting 1/10 v/v ethyl acetate/hexane to yield a pale-yellow solid 62 (65 mg, 
0.23 mmol, 68%).  
m.p. 130-132 oC; Rf 0.20 (1/4 v/v ethyl acetate/hexane); IR (ZnSe, solid) vmax: 3078, 2880, 
2761 (w, aryl-C-H), 1695 (m, C=O), 1587 (s, C=C), 1555 (s, NO2), 1415 (s, C=C/N), 1331 (s, 
NO2), 1291, 1201 (s, C-O), 1100 (m, C-Cl), 962 (s, aryl-CH), 849 (C-NO2) cm-1; 1H NMR (300 
MHz, CDCl3): δ 10.02 (1H, s, 13-CHO), 9.22 (1H, s, 6-CH), 7.94 (1H, dd, 3J = 7.8 Hz, 4J = 1.7 
Hz, 12-CH), 7.75 (1H, ddd, 3J = 7.8 Hz, 4J = 1.7 Hz, 10-CH), 7.56 (1H, ddd, 3J = 7.6 Hz, 4J = 
0.7 Hz, 11-CH), 7.31 (1H, d, 3J = 8.3 Hz, 9-CH) ppm; 13C NMR (75 MHz, CDCl3): δ 188.7 
(13-CHO), 162.9, 162.2, 157.6 (6-CH), 150.7, 135.9, 133.6, 132.9, 131.49, 127.8, 123.3 
ppm; LRMS (+ APCI) m/z: 282, 280 ([M+H]+, 60, 67%). 
 
Synthesis of 2-chloro-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepine [63] 
 
Platinum(IV) dioxide (7 mg, 0.030 mmol, 0.03 eq.) was added to a stirred solution of 2-((2-
chloro-5-nitropyrimidin-4-yl)amino)benzaldehyde 61 (281 mg, 1 mmol) in methanol (9 mL). 
The reaction vessel, equipped with reflux condenser, was evacuated and re-opened to a 
positive pressure of hydrogen gas three times. The reaction was heated at reflux for 24 
hours at which point a second portion of platinum(IV) dioxide (7 mg, 0.030 mmol, 0.03 eq.) 
was added and the reaction vessel was re-evacuated with hydrogen gas. The reaction was 
refluxed for a further 24 hours or until all of the nitropyrimidine had been consumed. The 
reaction was cooled and passed through a short celite plug, eluting with 1/20 v/v 
methanol/ethyl acetate to yield a brown powder 63 (256 mg, 1.10 mmol, quant.) when the 
solvent was evaporated. The crude material could be purified by column chromatography, 
eluting with a solution of 1/4 v/v ethyl acetate/hexane which had been made basic with 2% 
aqueous ammonia in methanol, however the crude material was acceptably pure for 
subsequent reactions. 
m.p. decomp. 155-160 oC; Rf 0.46 (1/2 v/v ethyl acetate/hexane); IR (ZnSe, solid) vmax: 
3352, 3255 (w, N-H), 3045, 2925, 2856 (w, C-H), 1704, 1574, 1537, 1495 (s, C=C/N, N-H), 
1395 (s, CH2), 1279 (m, C-N, CH2), 1228, 1157 (m, C=C-H), 1121 (m, C-Cl), 1051 (alkyl-C-
N), 982 (s, C=C-H) cm-1; 1H NMR (300 MHz, MeOD): δ 7.68 (1H, s, 6-CH), 7.19 (1H, ddd, 3J 
= 8.3, 7.1, 1.5 Hz, 9-CH), 7.07 (2H, m, 11-CH, and 8-CH), 6.92 (1H, ddd, 3J = 7.4, 7.4, 1.1 
Hz, 10-CH), 4.17 (2H, s, 13-CH) ppm; 13C NMR (125 MHz, MeOD): δ 154.8 (2/4-C), 151.3 
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(5-C), 143.9 (6-CH), 141.1 (7-C), 132.6 (2/4-C), 129.8 (11-CH), 129.6 (12-C), 129.3 (9-CH), 
123.2 (10-CH), 120.4 (8-CH), 51.8 (13-CH2) ppm; LRMS (+ APCI) m/z: 235, 233 (M + H]+, 
27, 100%); HRMS (+ ESI) m/z: 257.0378 (Calcd. C11H937ClN4 = 234.0486) ([M + Na]+, 35%), 
255.0407 (Calcd. C11H935ClN4 = 232.0516) ([M + Na]+, 100%); Diff. 0.3 ppm. 
 
Synthesis of 2-chloro-5,11-dimethyl-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepine 
[65] 
 
Diazepine 63 (221 mg, 0.950 mmol, 1 eq.) was dissolved in dry N,N-dimethylacetamide 
(12.8 mL). The brown solution was cooled to -10 oC and sodium hydride (60% dispersion in 
mineral oil, 183 mg, 6.64 mmol, 7 eq.) was added in a single portion. The suspension was 
stirred at -10 oC for 10 minutes before the rapid, dropwise addition of iodomethane (141 µL, 
2.276 mmol, 2.4 eq.). The reaction was slowly warmed to 0 oC over 1-2 hours, at which point 
all of the starting material had been consumed. The reaction was poured into ice-water (10 
mL) and the resulting brown precipitate was collected by vacuum filtration, washed with ice 
water (1 mL) and dried at the pump to give a crude residue (131 mg) that was contaminated 
with N,N-dimethylacetamide. The aqueous filtrate was extracted with ethyl acetate (or 
dichloromethane) (3 x 5 mL). The organic fractions were combined, dried over anhydrous 
magnesium sulfate and the solvent evaporated to give a crude oil. The residue and oil were 
purified separately by silica gel chromatography (1/10 v/v ethyl acetate/hexane). The pure 
fractions were combined and the solvent evaporated to yield a crystalline green solid 65 (105 
mg, 0.403 mmol, 42%). 
m.p. 112-113 oC; Rf 0.27 (1/4 v/v ethyl acetate/hexane); IR (ZnSe, solid) vmax: 2970, 2923, 
2867 (w, C-H), 1557, 1526 (s, C=C/N), 1473, 1441, 1398 (s, CH2, CH3), 1343 (m, C-N), 1242 
(m, C-N), 1205 (C=C-H), 1139 (m, C-Cl), 1040 (alkyl-C-N), 938 (s, C=C-H) cm-1; 1H NMR 
(500 MHz, CDCl3): δ 7.62 (1H, s, 6-CH), 7.34 (1H, dd, 3J = 7.0 Hz, 9/10-CH), 7.14 (2H, m, 
11-CH, and 8-CH), 7.06 (1H, dd, 3J = 7.0 Hz, 9/10-CH), 4.22 (2H, s, 13-CH2), 3.51 (3H, s, 
14/15-CH3), 2.76 (3H, s, 14/15-CH3) ppm; 13C NMR (75 MHz, CDCl3) 155.8, 150.1, 146.5, 
145.4 (6-CH), 134.3, 132.2, 129.0, 129.3, 123.9, 122.1, 56.6 (13-CH2), 42.5 (14/15-CH3), 
40.4 (14/15-CH2) ppm; LRMS (+ APCI) m/z: 263, 261 (M + H]+, 32, 100%); HRMS (+ ESI) 
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m/z: 285.0691 (Calcd. C13H1337ClN4 + Na+ = 285.0691) ([M + Na]+, 33%), 283.0721 (Calcd. 
C13H1335ClN4 = 283.0721) ([M + Na]+, 100%); Diff. 0.1 ppm. 
 
Synthesis of 2-chloro-5,6-dihydrobenzo[f]pyrimido[4,5-b][1,4]oxazepine [64] 
 
Platinum(IV) dioxide (1.8 mg, 0.008 mmol, 0.03 eq.) was added to a stirred solution of 2-((2-
chloro-5-nitropyrimidin-4-yl)oxy)benzaldehydehyde 62 (74 mg, 0.265 mmol, 1 eq.) in 
methanol (2.3 mL). The reaction vessel, equipped with reflux condenser, was evacuated and 
re-opened to a positive pressure of hydrogen gas three times. The reaction was heated to 
reflux for 24 hours or until all of the starting material had been reduced. The reaction was 
cooled to room temperature and passed through a short celite plug, eluting with 1/20 v/v 
methanol/ethyl acetate. The crude material was purified by column chromatography 
(0.01:1:3 v:v methanol:ethyl acetate:hexane) to yield a white powder 64 (25 mg, 0.105 mmol, 
40%). 
m.p. 191-193 oC; Rf 0.24 (1/2 v/v ethyl acetate/hexane); IR (ZnSe, solid) vmax: 3365 (m, NH), 
2922 (w, C-H), 1579, 1547, 1483 (s, C=C/N), 1428 (s, CH2, C-N), 1358, 1340, 1208 (s, aryl-
C-O), 1170 (s, aryl-C-O), 1107 (m, C-Cl), 1040 (alkyl-C-N), 938 (s, C=C-H) cm-1; 1H NMR 
(500 MHz, MeOD): δ 7.97 (1H, s, 6-CH), 7.35 (1H, dd, 3J = 7.5 Hz, 9/10-CH), 7.28 (1H, d, 3J 
= 7.0 Hz, 8/11-CH), 7.24 (1H, d, 3J = 8.0 Hz, 8/11-CH), 7.18 (1H, dd, 3J = 7.0 Hz, 9/10-CH), 
4.44 (2H, s, 13-CH2) ppm; 13C NMR (125 MHz, MeOD): δ 157.2, 156.4, 148.6 (6-CH), 147.2, 
134.9, 132.3, 130.6, 129.7, 126.7, 121.8 (10 aromatic C(H)), 46.9 (13-CH2) ppm; HRMS (+ 
ESI) m/z: 236.0398 (Calcd. C11H837ClN3O =235.0326) ([M + H]+, 29%), 234.0429 (Calcd. 
C17H2435ClN3O = 233.0356) ([M + H]+, 100%), Diff. 0.1 ppm. 
 
Synthesis of 2-chloro-5-methyl-5,6-dihydrobenzo[f]pyrimido[4,5-b][1,4]oxazepine [66] 
 
Oxazepine 64 (23 mg, 0.098 mmol, 1 eq.) was dissolved in dry N,N-dimethylacetamide (1.3 
mL). The brown solution was cooled to -10 oC and sodium hydride (60% dispersion in 
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mineral oil, 14 mg, 0.343 mmol, 3.5 eq.) was added in a single portion. The suspension was 
stirred at -10 oC for 10 minutes before the rapid, drop-wise addition of iodomethane (7.2 µL, 
0.118 mmol, 1.2 eq.). The reaction was slowly warmed to 0 oC over 1.5 hours, at which point 
all of the starting material had been consumed. The reaction was poured into ice-water (3 
mL) and the resulting brown precipitate was collected by vacuum filtration, washed with ice 
water (1 mL) and dried at the pump to give a crude residue (5.9 mg) that did not contain the 
desired product. The aqueous filtrate was extracted with ethyl acetate (3 x 5 mL). The 
organic fractions were combined, dried over anhydrous magnesium sulfate and the solvent 
evaporated. Crude material was purified separately by silica gel chromatography (1/5 v/v 
ethyl acetate/hexane) to yield a pale-green resin 66 (8 mg, 0.032 mmol, 33%). 
Rf No UV activity or stain; IR (ZnSe, solid) vmax: 2923, 2852 (w, C-H), 1684, 1521, 1488 (w, 
s, C=C/N), 1423 (s, CH2), 1352 (m, aryl-C-N), 1235 (s, aryl-C-O), 1179 (s, aryl-C-O), 1113 
(m, C-Cl), 1026 (alkyl-C-N), 944 (s, C=C-H) cm-1; 1H NMR (500 MHz, CDCl3): δ 7.98 (1H, s, 
6-CH), 7.34 (1H, d, 3J = 7.0 Hz), 7.30 (1H, d, 3J = 8.5 Hz), 7.20 (1H, d, 3J = 7.0 Hz, 8/11-CH), 
7.16 (1H, dd, 3J = 7.0 Hz, 9/10-CH), 4.38 (2H, s, 13-CH2) 2.97 (3H, s, 14-CH3) ppm; 13C 
NMR (125 MHz, MeOD): δ 154.7, 149.3, 148.8 (6-CH), 138.0, 134.4, 130.0, 129.1, 128.7, 
125.4, 121.1, 56.0 (13-CH2), 42.1 (14-CH3) ppm; LRMS (+ APCI) m/z: 497,495 (2M + H]+, 
20, 35%), 250, 248 ([M + H]+, 28, 73%); HRMS (+ ESI) m/z: 250.0555 (Calcd. C12H1037ClN3O 
= 249.0483) ([M + H]+, 25%), 248.0585 (Calcd. C12H1035ClN3O = 247.0512) ([M + H]+, 100%); 
Diff. 0.3 ppm. 
 
7.2.4 Chemical Synthesis of Aniline Analogues 
Synthesis of tert-butyl [1,4'-bipiperidine]-1'-carboxylate [13] 
2
1
3
4
5
6
7 8
9
N
N
O O
 
Piperidine 12 (1.78 mL, 18 mmol) was added to a stirred solution of 1-tbutylcarbamate-4-
piperidone 11 (2.89g, 15 mmol) in 1,2-dichloroethane (50 mL). The reaction was stirred at 
room temperature for 0.5 hours and then cooled to 0 °C. Glacial acetic acid (1.72 mL, 30 
mmol) and sodium triacetoxyborahydride (6.358 g, 30 mmol) were added portion-wise to the 
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cooled solution. The reaction was allowed to warm to room temperature and stirred for 15 
hours, or until no 1-tbutylcarbamate-4-piperidone remained. The solution was brought to pH 
8 with saturated sodium carbonate solution and extracted with dichloromethane (4 x 50 mL). 
The organic layers were combined, washed with brine (60 mL), dried over anhydrous 
magnesium sulfate and the solvent evaporated to yield cloudy residue (3.720 g). The crude 
material was purified by silica gel chromatography (1/20 v/v (10% v/v aqueous ammonia in 
methanol)/dichloromethane) to give an orange oil 13 (0.986 g, 3.686 mmol, 25%).  
Rf 0.55 (1/10 v/v (10% v/v aqueous ammonia in methanol/dichloromethane); IR (ZnSe, oil) 
vmax: 2935 (m, C-H), 1690 (s, C=O), 1421 (m, C-H), 1243 (m, C-N), 1157 (s, C-O) cm-1; 1H 
NMR (300 MHz, CDCl3): δ 4.13 (2H, br, d, 3J1eq-2 = 11.1 Hz, 1-CH2eq), 2.65 (2H, br, t, 3J1ax-2. = 
12.5 Hz, 1-CH2ax), 2.48 (4H, br, t, 3J4-5 = 5.1 Hz, 4-CH2), 2.35 (1H, tt, 3J3-2eq = 3.6 Hz, 3J3-2ax = 
11.4 Hz, 3-CHax), 2.43 (2H, br, d, 3J2eq-1 ~ 3J2eq-3 = 12.6Hz, 2-CH2eq), 1.57 (4H, m, 5-CH2), 
1.43 (9H, s, 9-(CH3)3), 1.39 (4H, unresolved, 2-CH2, 6-CH2) ppm; 13C NMR (75 MHz, CDCl3): 
δ 154.9 (7-C=O), 79.5 (8-C), 62.9 (3-CH), 50.3 (4-CH2), 43.6 (br, 1-CH2), 28.6 (9-(CH3)3), 
28.0 (br, 2-CH2), 26.3 (5-CH2), 24.8 (6-CH2) ppm; LRMS (+ ESI) m/z: 573 ([2M + HCl + H]+, 
15%), 269 ([M + H]+, 100%), 213 ([M - (t-butyl radical (C4H8)) + H]+, 16%), 169 ([M - (C5H7O2 
+ H]+, 2%) 
 
Synthesis of 1,4'-bipiperidine hydrochloride [14] 
H
N
N .xHCl
1
2
3
4
5
6  
Hydrogen chloride solution (4 M in 1,4-dioxane, 12.5 mL) was added portion-wise at room 
temperature to tert-butyl [1,4'-bipiperidine]-1'-carboxylate 13 (0.986 g, 4.92 mmol). The white 
mixture was stirred for 1 hour until no starting material remained. The reaction mixture was 
diluted with methanol, and the solvent removed to yield an off-white, crystalline solid in 
quantitative yield 14 (1.186 g, 4.92 mmol, 100%). 
m.p. >250 oC decomposition; Rf 0.03 (1/10 v/v (10% v/v aqueous ammonia in 
methanol)/dichloromethane); IR (solid) vmax: 3417 (m, br, N-H), 2949 (m, C-H), 2721 (s, 
R2NH2+Cl-), 2462 (s, R3NH+Cl-), 1611 (w, R2NH2+Cl-), 1455 (m, C-H), 1081 (m, R2NH) cm-1; 
1H NMR (300 MHz, D2O): δ 3.70 (2H, br, d, 3J1-2 = 13.7 Hz, 1-CH2), 3.59 (2H, br, d, 3J4-5 = 
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12.7 Hz, 4-CH2), 3.57 (1H, unresolved, 3-CH), 3.14 (4H, br, m, 1-CH2, 4-CH2), 2.45 (2H, br, 
d, 3J2-1/3 = 13.3 Hz, 2-CH2), 2.04 (4H, br, m, 5-CH2), 1.81 (3H, br, m, 2H-(2-CH2), 1H-(6-
CH2)), 1.54 (1Hm, br, t, 3J6-5 = 12.7 Hz, 6-CH2) ppm; 13C NMR (75 MHz, D2O): δ 60.2 (3-CH), 
50.3 (4-CH2), 42.6 (1-CH2), 23.3 (2-CH2), 23.0 (5-CH2), 21.2 (6-CH2); LRMS (+ ESI) m/z: 
169 ([M + H]+, 93%), 102 ([C5H10N +H2O]+, 100%), 84 ([M - C5H10N]+. 
 
Synthesis of [1,4'-bipiperidin]-1'-yl(4-amino-3-chlorophenyl)methanone [1] 
 
4-Amino-3-chlorobenzoic acid 15 (1.202 g, 7.01 mmol, 1 eq.), 1- hydroxybenzotriazole 
hydrate (1.183 g, 8.76 mmol, 1.25 eq.) and 1-ethyl-3-(3-dimethylaminopropyl)carbodimide 
chloride (1.697, 8.76 mmol, 1.25 eq.) were dissolved in dry dichloromethane (30 mL). The 
solution was cooled on ice and solution of 1,4'-bipiperidine (free base or hydrochloride salt) 
14 (1.788 g, 7.01 mmol, 1 eq.) and N,N-diisopropylethylamine (4.759 mL, 27.30 mmol, 3.9 
eq.) in dry dichloromethane (21 mL) was added. The reaction was stirred at 0 oC for 1 hour, 
then allowed to warm to room temperature and stir for 24 hours. When complete, the 
reaction was quenched with ice-water and the aqueous phase was extracted with 
dichloromethane (4 x 30 mL). The combined organic layers were washed with brine (30 mL), 
dried over anhydrous magnesium sulfate and the solvent evaporated to yield a cloudy resin. 
The crude material was purified by silica gel chromatography eluting with 1/30-1/20 v/v (5% 
v/v aqueous ammonia in methanol)/dichloromethane to yield a pale pink solid 1 (2.099 g, 
6.52 mmol, 93%). 
m.p. 117-120 oC; Rf 0.38 (1/10 v/v (10% v/v aqueous ammonia in 
methanol)/dichloromethane); IR (ZnSe, film) vmax: 3326, 3209 (w, br, N-H), 2933 (m, aryl-C-
H), 2850, 2800 (w, alkyl-C-H), 1597 (s, C=O), 1436 (s, CH2), 1279, 1243 (m, aryl-C-N), 1115 
(w, aryl-C-Cl), 1018 (w, alkyl-C-N) cm-1; 1H NMR (500 MHz, CDCl3, 335 K): δ 7.34 (1H, d, 
4J2-6 = 1.9 Hz, 2-CH), 7.13 (1H, dd, 3J6-5 = 8.6 Hz, 4J6-2 = 1.9 Hz, 6-CH), 6.72 (1H, d, 3J5-6 = 
8.3 Hz, 5-CH), 4.24 (4H, br, s, 8-CH2), 3J8ax-7 = 11.8 Hz, 8-CH2), 2.51 (4H, br, t, 3J11-12 = 5.1 
Hz, 11-CH2), 2.47 (1H, tt, 3J10-9eq = 3.8 Hz, 3J10-9ax = 11.2 Hz, 10-CH), 1.84 (2H, br, d, 3J9eq-8/10 
= 11.3 Hz, 9-CH2), 1.58 (4H, br, m, 12-CH2), 1.50 (2H, dddd, 3J9ax-8/10 = 4.1Hz, 3J9-8/10 = 12.03 
Chapter 7 – Experimental Methods 
[104] 
 
Hz, 9-CH2), 1.44 (2H,br, m, 13-CH2) ppm; 13C NMR (125 MHz, CDCl3, 335 K): δ 169.5 (7-
C=O), 144.6 (4-C), 129.2 (2-CH), 127.4 (6-CH), 126.8 (3-C), 118.8 (1-C), 115.1 (5-CH), 62.8 
(10-CH), 50.5 (11-CH2), 45.2 (8-CH2), 28.7 (9-CH2), 26.5 (12-CH2), 24.8 (13-CH2), one 
carbon unresolved (8-CH2) ppm; LRMS (+ ESI) m/z: 667, 665 (2M + Na]+, 27, 40%), 324, 
322 ([M + H]+, 30, 100), 256 (24%), 211 ([M - C7H13N2. + H]+, 18%), 156, 154 [M - (26 - 2Cl - 
3H)]+, 11, 40%); HRMS (+ ESI) m/z: 324.1652 (Calcd. C17H2437ClN3O = 323.1578) ([M + H]+, 
33%), 322.1683 (Calcd. C17H2435ClN3O = 321.1608) ([M + H]+, 100%). 
 
Synthesis of [1,4'-bipiperidin]-1'-yl(3-chloro-4-(pyrimidin-2-ylamino)phenyl)methanone [23] 
 
o-Chloroaniline 1 (55 mg, 0.171 mmol, 2 eq.), and 2-chloropyrimidine (10 mg, 0.085 mmol, 1 
eq.) were dissolved in freshly distilled 1,4-dioxane (0.8 mL). Caesium carbonate (83 mg, 
0.255, 3 eq.) and 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl (X-Phos) (4 mg, 0.008 
mmol, 0.1 eq.) were added to the stirred solution, followed by tris-dibenzylideneacetone 
dipalladium (Pd2(dba)3) (4 mg, 0.004 mmol, 0.05 eq.). The reaction solution was degassed 
with argon over the course of reagent additions and for a further 3 minutes after the final 
addition of Pd2(dba)3. The reaction was heated at reflux for 2 hours, or until all the pyrimidine 
had been consumed. The reaction mixture was cooled to room temperature, diluted with 
dichloromethane (12 mL) and washed with water (5 mL). The aqueous phase was then 
extracted with dichloromethane (3 x 3 mL). The organic layers were combined, dried over 
magnesium sulfate and the solvent evaporated to yield a crude resin. The product was 
purified by silica gel chromatography (1/20 v/v 10% aqueous ammonia in 
methanol/dichloromethane) yielding a brown resin 23 (9 mg, 0.02 mmol, 27%). 
Rf 0.43 (1/10 v/v (10% v/v aqueous ammonia in methanol)/dichloromethane); IR (ZnSe, film) 
vmax: 3408 (w, N-H), 2927 (m, aryl-C-H), 2855 (w, alkyl-C-H), 1737 (w, C=O), 1607 (m, C=C), 
1578 (s, C=C), 1505 (s, NO2), 1525 (m, aryl-N-H), 1445 (br, s, CH2), 1402 (m, aryl-C-N), 
1260 (br, m, aryl-C=C/N), 1094 (s, aryl-C-Cl), 1018 (s, alkyl-C-N) cm-1; 1H NMR (500 MHz, 
CDCl3): δ 8.67 (1H, d, 3J = 8.4 Hz, 8-CH), 8.49 (2H, d, 3J = 4.2 Hz, 4,6-CH), 7.74 (1H, s, 
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NH), 7.50, (1H, d, 3J = 2.0 Hz, 11-CH), 6.84 (1H, dd, 3J = 4.5, 5.0 Hz 5-CH), 4.68 (1H, br, 14-
CH2), 3.95 ((1H, br, 14-CH2), 2.91 (2H, br, 14-CH2), 2.56 (5H, br, s, 15-CH2, 16-CH), 1.91 
(2H, br, s, 17-CH2), 1.67 (4H, br, s, 18-CH2), 1.55 (2H, m, 17-CH2), 1.46 (2H,br, s, 19-CH2) 
ppm; 13C NMR (125 MHz, CDCl3): δ 169.0 (C=O) 159.6, 158.2, 137.6, 128.5, 126.8, 122.0, 
119.2, 114.0 (aromatic C(H)), one resolved aromatic C, 62.8 (16-CH), 50.4 (15-CH2), four 
unresolved bipiperidine C signals, ppm; LRMS (+ ESI) m/z: 798 ([2M]+, 60%), 801 (2M + H]+, 
100%), 402, 400 ([M + H]+, 38%, 98%); HRMS (+ ESI) m/z: 402.1869 (Calcd. C21H2637ClN5O 
=401.1796) ([M + H]+, 29%), 400.1898 (Calcd. C21H2635ClN5O = 399.1826) ([M + H]+, 100%); 
Diff = 0.08 ppm. 
 
Synthesis of [1,4'-bipiperidin]-1'-yl(3-chloro-4-(pyrimidin-5-ylamino)phenyl)methanone [24] 
 
o-Chloroaniline 1 (55 mg, 0.171 mmol, 1.4 eq.), and 5-bromopyrimidine (19 mg, 0.120 mmol, 
1 eq.) were dissolved in freshly distilled 1,4-dioxane (0.8 mL). Caesium carbonate (83 mg, 
0.255, 2 eq.) and 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl (X-Phos)  (4 mg, 
0.008 mmol, 0.07 eq.) were added to the stirred solution, followed by tris-
dibenzylideneacetone dipalladium (Pd2(dba)3) (4 mg, 0.004 mmol, 0.04 eq.). The reaction 
solution was degassed with argon over the course of reagent additions and for a further 3 
minutes after the final addition of Pd2(dba)3. The reaction was heated at reflux for 2 hours, or 
until all the pyrimidine had been consumed. The reaction mixture was cooled to room 
temperature, diluted with dichloromethane (12 mL) and washed with water (5 mL). The 
aqueous phase was then extracted with dichloromethane (3 x 3 mL). The organic layers 
were combined, dried over magnesium sulfate and the solvent evaporated to yield a green 
oil. The product was purified by silica gel chromatography (1/20 v/v (5% v/v aqueous 
ammonia in methanol)/dichloromethane) yielding a pale coloured resin (8 mg, 0.02 mmol, 
12%). 
Rf 0.36 (1/10 v/v (10% v/v aqueous ammonia in methanol)/dichloromethane); IR (ZnSe, film) 
vmax: 3416-3238 (br, m, N-H), 2931 (m, aryl-C-H), 2851 (w, alkyl-C-H), 1604 (s, C=O), 1573 
(s, C=C), 1522 (m, aryl-N-H), 1428 (br, s, CH2), 1317, 1262 (m, aryl-C=C/N), 1114 (w, aryl-
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C-Cl), 1018 (w, alkyl-C-N) cm-1; 1H NMR (500 MHz, CDCl3): δ 8.93 (1H, s, 2-CH), 8.65 (2H, 
s, 4-CH), 7.51 (1H, s, 10-CH), 7.25 (1H, d, 3J = 9.0 Hz, 7/8-CH), 7.18 (1H, d, 3J = 8.4 Hz, 
7/8-CH), 6.24 (1H, s, 5-NH), 4.66 (1H, br, s, 13-CH2), 3.88 (1H, br, s, 13-CH2), 2.89 (2H, br, 
s, 13-CH2), 2.56 (5H, br, s, 14-CH2,, and 15-CH), 1.92 (2H, br, s, 16-CH2), 1.63 (4H, br, s, 
17-CH2), 1.54 (2H, br, s, 16-CH2), 1.46 (2H, br, s, 18-CH2) ppm; 13C NMR (125 MHz, CDCl3): 
δ 168.6 (12-C=O), 153.4, 148.5, 139.8, 136.3, 129.9, 129.7, 127.2, 122.4, 114.8, (9 aromatic 
C(H)), 62.7 (15-CH), 50.4 (-CH2), 29.8, 26.2, 24.7 (18-CH2), one unresolved bipiperidine CH2 
ppm; LRMS (+ ESI) m/z: 401, 399 ([M]+, 52, 48%), 402, 400 ([M+H]+, 42, 100%); HRMS (+ 
ESI) m/z: 402.1870 (Calcd. C21H2637ClN5O = 401.1796) ([M+H]+, 30%), 400.1900 (Calcd. 
C21H2635ClN5O = 399.1826) ([M+H]+, 100%); Diff. 0.08 ppm. 
 
Synthesis of [1,4'-bipiperidin]-1'-yl(3-chloro-4-(pyridin-2-ylamino)phenyl)methanone [25] 
 
o-Chloroaniline 1 (55 mg, 0.171 mmol, 1 eq.), and 2-bromopyridine (34 µL, 0.342 mmol, 2 
eq.) were dissolved in freshly distilled 1,4-dioxane (1 mL). Caesium carbonate (167 mg, 
0.513 mmol, 3 eq.) and 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl (X-Phos)  (8 
mg, 0.017 mmol, 0.1 eq.) were added to the stirred solution, followed by tris-
dibenzylideneacetone dipalladium (Pd2(dba)3) (9 mg, 0.009 mmol, 0.05 eq.). The reaction 
solution was degassed with argon over the course of reagent additions and for a further 3 
minutes after the final addition of Pd2(dba)3. The reaction was heated at reflux for 6 hours. 
The reaction mixture was cooled to room temperature, diluted with dichloromethane (12 mL) 
and washed with water (5 mL). The aqueous phase was then extracted with 
dichloromethane (3 x 3 mL). The organic layers were combined, dried over magnesium 
sulfate and the solvent evaporated to yield a crude resin. The product was purified by silica 
gel chromatography (1/20 v/v (5% v/v aqueous ammonia in methanol)/dichloromethane) 
yielding a white foam 25 (45 mg, 0.11 mmol, 66%). 
Rf 0.28 (1/10 v/v (10% v/v aqueous ammonia in methanol)/dichloromethane); IR (ZnSe, film) 
vmax: 3322 (w, N-H), 2931 (m, aryl-C-H), 2856, 2801 (w, alkyl-C-H), 1710 (w, C=O), 1601 (s, 
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C=C), 1519 (m, aryl-N-H), 1472, 1416 (s, C=C/N), 1430 (br, s, CH2), 1329 (m, aryl-C-N), 
1270, 1219 (m, aryl-C=C/N), 1116 (m, aryl-C-Cl), 1018 (m, alkyl-C-N) cm-1; 1H NMR (500 
MHz, CDCl3): δ 8.29 (2H, d, 3J = 7.6 Hz pyridine-CH), 7.58 (1H, dd, 3J= 7.6 Hz, pyridine-CH), 
7.49 (1H, s, 11-CH), 7.30 (1H, d, 3J = 8.5 Hz, 9-CH), 7.00 (1H, br, s, NH), 6.87 (2H, m, 8-CH 
and pyridine-CH), 4.65 (1H, br, s, 14-CH2), 3.95 (1H, br, s, 14-CH2), 2.79 (2H, br, s, 14-CH2), 
2.51 (5H, br, s, 15-CH2 and 16-CH), 1.86 (2H, br, s, 17-CH2), 1.71 (1H. br, s, 17-CH2), 1.59 
(4H, br, s, 18-CH2), 1.51 (1H, br, d, 3J = 7.0 Hz, 17-CH2), 1.25 (2H, m, 19-CH2) ppm; 13C 
NMR (125 MHz, CDCl3): δ 169.0 (13-C=O), 154.4, 148.3, 138.8, 138.0, 129.3, 128.8, 126.8, 
121.9, 118.0, 116.8, 111.3 (12 aromatic C(H)), 62.7 (16-CH), 50.4 (15-CH2), 26.5 (18-CH2), 
24.8 (19-CH2), two unresolved bipiperidine CH2, ppm; LRMS (+ ESI) m/z: 801, 799, 797 
([2M + H]+, 23, 90, 86%), 401, 399 ([M + H]+, 46, 100%); HRMS (+ ESI) m/z: 401.1917 
(C22H2737ClN4O = 400.1844) ([M + H]+, 28%), 399.1946 (Calcd. C22H2735ClN4O = 398.1873) 
([M + H]+, 100%), Diff. 0.05 ppm. 
 
Synthesis of [1,4'-bipiperidin]-1'-yl(3-chloro-4-(pyridin-3-ylamino)phenyl)methanone [26] 
 
o-Chloroaniline 1 (55 mg, 0.171 mmol, 1 eq.), and 3-bromopyridine (17 µL, 0.171 mmol, 1 
eq.) were dissolved in freshly distilled 1,4-dioxane (1 mL). Caesium carbonate (167 mg, 
0.513 mmol, 3 eq.) and 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl (X-Phos) (8 mg, 
0.017 mmol, 0.1 eq.) were added to the stirred solution, followed by tris-
dibenzylideneacetone dipalladium (Pd2(dba)3) (9 mg, 0.008 mmol, 0.05 eq.). The reaction 
solution was degassed with argon over the course of reagent additions and for a further 3 
minutes after the final addition of Pd2(dba)3. The reaction was heated at reflux for 2 hours, or 
until all the pyridine and aniline had been consumed. Additional equivalents of 3-
bromopyridine (0.171 mmol) were added with no change to the reaction solution. The 
reaction mixture was cooled to room temperature overnight. The completed reaction was 
diluted with dichloromethane (12 mL) and washed with water (5 mL). The aqueous phase 
was then extracted with dichloromethane (3 x 3 mL). The organic layers were combined, 
dried over magnesium sulfate and the solvent evaporated to yield a crude resin. The product 
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was purified by silica gel chromatography (1/30 v/v (5% v/v aqueous ammonia in 
methanol)/dichloromethane) to yield 26 (32 mg, 0.08 mmol, 47%). 
Rf 0.38 (1/10 v/v (10% v/v aqueous ammonia in methanol)/dichloromethane); IR (ZnSe, film) 
vmax: 3282 (br, w, N-H), 2929 (m, aryl-C-H), 2852, 2804 (w, alkyl-C-H), 1707 (w, C=O), 1605 
(s, C=C), 1522 (m, aryl-N-H), 1438 (br, s, CH2), 1319 (m, aryl-C-N), 1273, 1226 (m, aryl-
C=C/N), 1116 (m, aryl-C-Cl), 1018 (m, alkyl-C-N) cm-1; 1H NMR (500 MHz, CDCl3): δ 8.49 
(1H, s, pyridine-CH), 8.32 (1H, br, s, pyridine-CH), 7.52 (1H, d, 3J = 7.9 Hz, pyridine-CH), 
7.46 (1H, s, 11-CH), 7.26 (1H, br, s, pyridine-CH), 7.19 (1H, d, 3J = 8.2 Hz, 9-CH), 7.13 (1H, 
d, 3J = 8.2 Hz, 8-CH), 6.30 (1H, s, 7-NH), 4.62 (1H, br, s, 14-CH2), 3.89 (1H, br, s, 14-CH2), 
2.887 (2H, br, s, 14-CH2), 2.49 (5H, br, s, 15-CH2 and 16-CH2), 1.85 (2H, br, s, 17-CH2), 
1.57 (4H, br, s, 18-CH2), 1.49 (2H, br, d, 3J = 10.5 Hz, 17-CH2), 1.42 (2H, s, 19-CH2) ppm; 
13C NMR (125 MHz, CDCl3): δ 168.9 (13-C=O), 144.6, 143.3, 141.1, 137.4, 129.4, 128.6, 
127.7, 127.1, 124.0, 121.3, 114.2, 62.6 (16-CH), 50.4 (15-CH2), 29.8 (br, 17-CH2), 26.4 (18-
CH2), 24.8 (19-CH2), one unresolved bipiperidine CH2, ppm; LRMS (+ ESI) m/z: 797, 799, 
800 ([2M + H]+, 30, 36, 30%), 399, 400, 401 ([M + H]+, 97, 100, 66%); HRMS (+ ESI) m/z: 
401.1916 (C22H2737ClN4O = 400.1844) ([M + H]+, 33%), 399.1945 (Calcd. C22H2735ClN4O = 
398.1873) ([M + H]+, 100%), Diff. 0.2 ppm. 
 
Synthesis of [1,4'-bipiperidin]-1'-yl(3-chloro-4-(phenylamino)phenyl)methanone [27] 
 
o-Chloroaniline 1 (55 mg, 0.171 mmol, 1 eq.), and iodobenzene (19 µL, 0.171 mmol, 1 eq.) 
were dissolved in freshly distilled 1,4-dioxane (1 mL). Caesium carbonate (167 mg, 0.513 
mmol, 3. eq.) and 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl (X-Phos)  (8 mg, 
0.017 mmol, 0.1 eq.) were added to the stirred solution, followed by tris-
dibenzylideneacetone dipalladium (Pd2(dba)3) (9 mg, 0.009 mmol, 0.05 eq.). The reaction 
solution was degassed with argon over the course of reagent additions and for a further 3 
minutes after the final addition of Pd2(dba)3. The reaction was heated at reflux for 7 hours, or 
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until all the aryl-halide had been consumed. The reaction mixture was cooled to room 
temperature, diluted with dichloromethane (12 mL) and washed with water (5 mL). The 
aqueous phase was then extracted with dichloromethane (3 x 3 mL). The organic layers 
were combined, dried over magnesium sulfate and the solvent evaporated to yield a crude 
resin. The product was purified by silica gel chromatography (1/20 v/v 5% aqueous ammonia 
in methanol/dichloromethane) yielding a brown resin 27 (49 mg, 0.12 mmol, 71%). 
Rf 0.52 (1/10 v/v (10% v/v aqueous ammonia in methanol)/dichloromethane); IR (ZnSe, film) 
vmax: 3298 (w, N-H), 2932 (m, aryl-C-H), 2855, 2800 (w, alkyl-C-H), 1710 (w, C=O), 1590 (s, 
C=C), 1519 (m, aryl-N-H), 1439 (br, s, CH2), 1360 (w, aryl-C-N), 1317, 1270, 1218 (s, aryl-
C=C), 1115 (m, aryl-C-Cl), 1017 (m, alkyl-C-N) cm-1; 1H NMR (500 MHz, CDCl3): δ 7.44 (1H, 
s, 9-CH), 7.33 (2H, dd, 3J = 7.6 Hz), 7.17 (4H, m), 7.08 (1H, dd, 3J = 7.4 Hz), 6.27 (1H, s, 4-
NH), 4.02 (2H, br, 12-CH2), 2.86 (2H, br, s, 12-CH2), 2.50 (5H, br, s, 13-CH2 and 14-CH2), 
1.85 (2H, br, 15-CH2), 1.57 (4H, m, 16-CH2), 1.43 (2H, br, d, 3J = 11.1 Hz, 15-CH2), 1.39 (2H, 
m, 17-CH2) ppm; 13C NMR (125 MHz, CDCl3): δ 169.1 (11-C=O), 142.0, 140.5, 129.6, 129.2, 
127.2, 127.0, 123.7, 121.5, 120.4, 113.8 (10 aromatic C(H)), 62.6 (14-CH), 50.3 (-CH2), 28.5 
(-CH2), 26.4 (-CH2), 24.8 (17-CH2), one unresolved bipiperidine CH2, ppm; LRMS (+ ESI) 
m/z: 795, 797, 799, ([2M + H]+, 42, 100, 42%), 398, 400 ([M + H]+, 42, 20%); HRMS (+ ESI) 
m/z: 400.1963 (Calcd. C23H28ClN3O = 399.1891) ([M + H]+, 30%), 398.1993 (Calcd. 
C23H28ClN3O = 397.1921) ([M + H]+, 100%), Diff. 0.2 ppm. 
 
Synthesis of [1,4'-bipiperidin]-1'-y(3-chloro-4-((4-nitrophenyl)amino)phenyl)methanone [31] 
 
o-Chloroaniline 1 (55 mg, 2 eq.), and 1-iodo-2-nitrobenzene (1 eq.) were dissolved in freshly 
distilled 1,4-dioxane (0.8 mL). Caesium carbonate (83 mg) and 2-dicyclohexylphosphino-
2′,4′,6′-triisopropylbiphenyl (X-Phos)  (0.01 mmol) were added to the stirred solution, 
followed by tris-dibenzylidene dipalladium (0.005 mmol). The reaction solution was 
degassed with argon over the course of reagent additions and for a further 3 minutes after 
the final addition of Pd2(dba)3. The reaction was heated at reflux for 2 hours, or until all the 
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nitrobenzene had been consumed. The reaction mixture was cooled to room temperature, 
diluted with dichloromethane (13 mL) and washed with water (5 mL). The aqueous phase 
was then extracted with dichloromethane (3 x 3 mL). The organic layers were combined, 
dried over magnesium sulfate and the solvent evaporated to yield a crude resin. The product 
was purified by silica gel chromatography (1/30 v/v 10% aqueous ammonia in 
methanol/dichloromethane) yielding a bright yellow solid 31 (54 mg, 0.12 mmol, 98%) 
Rf 0.55 (1/10 v/v (10% v/v aqueous ammonia in methanol)/dichloromethane); IR (ZnSe, film) 
vmax: 3249 (w, N-H), 2932 (w, aryl-C-H), 2849, 2797 (w, alkyl-C-H), 1709 (w, C=O), 1585 (s, 
C=C), 1503 (m, NO2), 1442 (br, m, CH2), 1323 (m, aryl-C-N), 1306 (s, NO2), 1182 (m, aryl-
C=C), 1109 (s, aryl-C-Cl), 1018 (w, alkyl-C-N) cm-1; 1H NMR (300 MHz, CDCl3): δ 8.17 (2H, 
d, 3J = 9.5 Hz, 2-CH), 7.49 (1H, s, 9-CH), 7.39 (1H, d, 3J = 8.4 Hz, 6/7-CH), 7.27 (1H, m, 6/7-
CH), 7.11 (2H, d, 3J = 9.0 Hz, 3-CH), 6.90 (1H, s, NH), 4.66 (1H, br, s, 12-CH2), 3.92 (1H, br, 
s, 12-CH2), 2.92 (2H, br, s, 12-CH2), 2.52 (5H, br, s, 13-CH2 and 14-CH), 1.96 (4H, br, m, 15-
CH2), 1.59 (6-8H, m, 15-CH2, 16-CH2, 17-CH2) ppm; 13C NMR (75 MHz, CDCl3): δ 168.5 (11-
C=O), 148.0, 141.4, 138.5, 131.6, 129.4, 126.7, 126.1, 124.9, 119.4, 116.1 (10 aromatic 
C(H)), 62.5 (14-CH), 50.4 (13-CH2), 26.5 (16-CH2), 24.8 (17-CH2), two unresolved 
bipiperidine CH2 signals, ppm; HRMS (+ ESI) m/z: 445.1814 (Calcd. C23H2737ClN4O3 = 
444.1742) ([M + H]+, 28%), 443.1844 (Calcd. C23H2735ClN4O3 = 442.1772) ([M + H]+, 100%), 
Diff. 0.2 ppm. 
 
Synthesis of [1,4'-bipiperidin]-1'-yl(3-chloro-4-((2-nitrophenyl)amino)phenyl)methanone [29] 
 
o-Chloroaniline 1 (55 mg, 0.171 mmol, 2 eq.), and 1-iodo-2-nitrobenzene (21 mg, 0.085 
mmol, 1 eq.) were dissolved in freshly distilled 1,4-dioxane (0.8 mL). Caesium carbonate (83 
mg, 0.255 mmol, 3 eq.) and 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl (X-Phos) (4 
mg, 0.008 mmol, 0.1 eq.) were added to the stirred solution, followed by tris-
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dibenzylideneacetone dipalladium (Pd2(dba)3) (4 mg, 0.004 mmol, 0.05 eq.). The reaction 
solution was degassed with argon over the course of reagent additions and for a further 3 
minutes after the final addition of Pd2(dba)3. The reaction was heated at reflux for 2 hours, or 
until all the nitrobenzene had been consumed. The reaction mixture was cooled to room 
temperature, diluted with dichloromethane (13 mL) and washed with water (5 mL). The 
aqueous phase was then extracted with dichloromethane (3 x 3 mL). The organic layers 
were combined, dried over magnesium sulfate and the solvent evaporated to yield a crude 
resin. The product was purified by silica gel chromatography (1/30 v/v 10% aqueous 
ammonia in methanol/dichloromethane) yielding a bright yellow solid 29 (35 mg, 0.08 mmol, 
92%). 
Rf 0.62 (1/10 v/v (10% v/v aqueous ammonia in methanol)/dichloromethane); IR (ZnSe, film) 
vmax: 3339 (w, N-H), 2932 (m, aryl-C-H), 2851 (w, alkyl-C-H), 1710 (w, C=O), 1615 (s, C=C), 
1597 (s, C=C), 1505 (s, NO2), 1438 (br, s, CH2), 1345 (m, aryl-C-N), 1261 (s, NO2), 1221, 
1149 (m, aryl-C=C), 1116 (s, aryl-C-Cl), 1009 (w, alkyl-C-N), 837 (w, aryl-CH) cm-1; 1H NMR 
(300 MHz, CDCl3): δ 9.49 (1H, br, s, 7-NH), 8.22 (1H, d, 3J = 7.8 Hz, 8-CH), 7.55 (1H, d, 4J = 
1.5 Hz, 11-CH), 7.47 (2H, m, o-NO2 phenyl-CH), 7.30 (2H, m, o-NO2 phenyl-CH), 6.93 (1H, 
dd, 3J = 7.2 Hz, 9-CH), 4.66 (1H, br, s, 14-CH2), 3.89 (1H, br, s, 14-CH2), 2.88 (2H, br, s, 14-
CH2), 2.52 (5H, br, s, 15-CH2 and 16-CH2), 1.89 (2H, br, m, bipiperidine-CH2), 1.78 (2H, , br, 
m, bipiperidine-CH2), 1.60-1.44 (8H, br, m, bipiperidine-CH2) ppm; 13C NMR (75 MHz, 
CDCl3): δ 168.2 (C=O), 140.1, 137.8, 135.5, 135.3, 132.9, 129.4, 127.3, 126.8, 126.5, 122.0, 
119.5, 116.9 (12 aromatic C(H)), 62.5 (16-CH), 50.3 (15-CH2), 26.3, 24.7 (2 bipiperidine 
CH2), 2 unresolved bipiperidine C signals, ppm; LRMS (+ ESI) m/z: 908, 906 (2M + Na]+, 
40,50%), 885 ([2M + H]+), 70%), 884 ([2M]+, 100%), 445, 443 ([M + H]+, 34, 60%); HRMS (+ 
ESI) m/z: 445.1814 (Calcd. C23H2737ClN4O3 = 444.1742) ([M + H]+, 28%), 443.1844 (Calcd. 
C23H2735ClN4O3 = 442.1772) ([M + H]+, 100%), Diff. 0.2 ppm. 
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Synthesis of [1,4'-bipiperidin]-1'-yl(3-chloro-4-((2-methoxyphenyl)amino)phenyl)methanone 
[28] 
 
o-Chloroaniline 1 (56 mg, 0.174 mmol, 1 eq.), and 1-iodo-2-methoxybenzene (39 µL, 0.299 
mmol, 1.7 eq.) were dissolved in freshly distilled 1,4-dioxane (1.2 mL). Caesium carbonate 
(167 mg, 0.513 mmol, 3 eq.) and 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl (X-
Phos) (8 mg, 0.017 mmol, 0.1 eq.) were added to the stirred solution, followed by tris-
dibenzylideneacetone dipalladium (Pd2(dba)3) (9 mg, 0.01 mmol, 0.05 eq.). The reaction 
solution was degassed with argon over the course of reagent additions and for a further 3 
minutes after the final addition of Pd2(dba)3. The reaction was heated at reflux for 3 hours, 
then allowed to cool to room temperature and stir overnight. An additional equivalent of 1-
iodo-2-methoxybenzene (22 µL, 0.171 mmol), X-phos (8 mg, 0.017 mmol) and Pd2(dba)3 (9 
mg, 0.009 mmol) were added to the reaction at this point and the solution was heated at 
reflux for a further 5 hours, or until all of the o-chloroaniline had been consumed. The 
reaction mixture was cooled to room temperature, diluted with dichloromethane (15 mL) and 
washed with water (7 mL). The aqueous phase was then extracted with dichloromethane (3 
x 7 mL). The organic layers were combined, dried over magnesium sulfate and the solvent 
evaporated to yield a crude resin. The product was purified by silica gel chromatography 
(1/20 v/v (5% aqueous ammonia in methanol)/dichloromethane) to yield 28 as a resin (81 
mg, 0.17 mmol, quant.). 
Rf 0.48 (1/10 v/v (10% v/v aqueous ammonia in methanol)/dichloromethane); IR (ZnSe, film) 
vmax: 3405 (w, N-H), 2930 (m, aryl-C-H), 2852, 2802 (w, alkyl-C-H), 1711 (w, C=O), 1591 (s, 
C=C), 1523 (m, aryl-N-H), 1432 (br, s, CH2), 1350 (m, aryl-C-N), 1260, 1244, 1240 (s, aryl-
O-C, aryl-C=C), 1114 (s, aryl-C-Cl), 1047 (m, aryl-O-C), 1018 (s, alkyl-C-N) cm-1; 1H NMR 
(500 MHz, CDCl3): δ 7.44 (1H, s, 11-CH), 7.32 (1H, d, 3J = 7.5, 8/9-CH), 7.26 (1H, dd, 3J = 
8.5 Hz, 4/5-CH), 7.18 (1H, d,  3J = 8.1 Hz, 8/9-CH), 6.99 (1H, dd, 3J = 7.5 Hz, 4/5-CH), 6.91 
(2H, m, 3/6-CH), 6.55 (1H, s, 1-NH), 4.84 (1H, br, 14-CH2), 3.86 (3H, s, 20-CH3), 2.85 (2H, 
br, s, 14-CH2), 2.48 (5H, br, m, 15-CH2 and 16-CH), 1.83 (2H, br, s, 17-CH2), 1.56 (4H, br, s, 
18-CH2), 1.48 (2H, br, d, 3J = 11.8 Hz, 17-CH2), 1.23 (2H, br, ,s 19-CH2) ppm; 13C NMR (125 
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MHz, CDCl3): δ 169.2 (13-C=O), 150.3, 141.5, 130.1, 129.2, 127.3, 127.0, 123.0, 121.3, 
120.8, 118.9, 114.2, 111.2 (12 aromatic C(H)), 62.7 (16-CH), 55.8 (20-CH3), 50.3 (15-CH2), 
28.5 (17-CH2), 26.5 (18-CH2), 24.8 (19-CH2), one unresolved bipiperidine CH2 ppm; LRMS 
(+ ESI) m/z: 857, 855 (2M + H]+, 48, 100%), 430, 428 ([M + H]+, 22, 50%); HRMS (+ ESI) 
m/z: 430.2070 (Calcd. C24H3037ClN3O2 = 429.1997) ([M + H]+, 28%), 428.2100 (Calcd. 
C24H3035ClN3O2 = 427.2027) ([M + H]+, 100%); Diff. = 0.2 ppm 
 
Synthesis of [1,4'-bipiperidin]-1'-yl(3-chloro-4-((3-methoxyphenyl)amino)phenyl)methanone 
[30] 
 
o-Chloroaniline 1 (63 mg, 0.196 mmol, 1 eq.), and 1-iodo-3-methoxybenzene (26 µL, 0.196 
mmol, 1 eq.) were dissolved in freshly distilled 1,4-dioxane (1.2 mL). Caesium carbonate 
(192 mg, 0.588 mmol, 3 eq.) and 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl (X-
Phos)  (9 mg, 0.02 mmol, 0.1 eq.) were added to the stirred solution, followed by tris-
dibenzylideneacetone dipalladium (Pd2(dba)3) (10 mg, 0.01 mmol, 0.05 eq.). The reaction 
solution was degassed with argon over the course of reagent additions and for a further 3 
minutes after the final addition of Pd2(dba)3. The reaction was then heated at reflux for 2 
hours. An additional equivalent of 1-iodo-3-methoxybenzene (26 µL, 0.196 mmol) and 
Pd2(dba)3 (10 mg, 0.01 mmol) were added to the reaction at this point and the solution was 
stirred overnight at room temperature. After refluxing the reaction for a further 1 hour all the 
o-chloroaniline had been consumed. The reaction mixture was cooled to room temperature, 
diluted with dichloromethane (15 mL) and washed with water (7 mL). The aqueous phase 
was then extracted with dichloromethane (3 x 5 mL). The organic layers were combined, 
dried over magnesium sulfate and the solvent evaporated to yield a crude resin. The product 
was purified by silica gel chromatography (1/20 v/v (5% aqueous ammonia in 
methanol)/dichloromethane) to yield 30 as a resin (79 mg, 0.19 mmol, 94%). 
Rf 0.40 (1/10 v/v (10% v/v aqueous ammonia in methanol)/dichloromethane); IR (ZnSe, film) 
vmax: 3300 (w, N-H), 2931 (m, aryl-C-H), 2852 (w, alkyl-C-H), 1710 (w, C=O), 1596 (s, C=C), 
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1523 (m, aryl-N-H), 1437 (br, s, CH2), 1326 (m, aryl-C-N), 1274 (m, aryl-O-C, aryl-C=C), 
1157 (m, aryl-C=C), 1116 (s, aryl-C-Cl), 1037 (w, aryl-O-C), 1018 (s, alkyl-C-N) cm-1; 1H 
NMR (500 MHz, CDCl3): δ 7.48 (1H, s, 11-CH), 7.26 (2H, m), 7.21 (1H, d, 3J = 8.3 Hz), 6.79 
(1H, d,  3J = 8.0 Hz), 6.76 (1H, s, 2-CH), 6.66 (1H, d, 3J = 8.4 Hz), 6.30 (1H, s, 1-NH), 4.70-
4.10 (1H, br, 14-CH2), 3.82 (3H, s, 20-CH3), 2.90 (2H, br, s, 14-CH2), 2.53 (5H, br, m, 15-
CH2 and 16-CH), 1.88 (2H, br, s, 17-CH2), 1.61 (4H, br, s, 18-CH2), 1.53 (2H, br, d, 3J = 11.1 
Hz, 17-CH2), 1.28 (2H, br, s, 19-CH2) ppm; 13C NMR (125 MHz, CDCl3): δ 169.1 (13-C=O), 
160.8 (3-COCH3), 141.9, 141.7, 130.3, 129.2, 127.5, 127.0, 120.6, 114.4, 113.5, 109.0, 
107.0  (12 aromatic C(H)), 62.8 (16-CH), 55.4 (20-CH3), 50.3 (15-CH2), 28.4 (17-CH2), 26.4 
(18-CH2), 24.8 (19-CH2), one unresolved bipiperidine CH2 ppm; LRMS (+ ESI) m/z: 858, 
856, 855 (2M + H]+, 30, 62, 100%), 430, 428 ([M + H]+, 28, 54%); HRMS (+ ESI) m/z: 
430.2070 (Calcd. C24H3037ClN3O2 = 429.1997) ([M + H]+, 33%), 428.2099 ((Calcd. 
C24H3035ClN3O2 = 427.2027) ([M + H]+, 100%); Diff. 0.01 ppm. 
 
Synthesis of [1,4'-bipiperidin]-1'-yl(3-chloro-4-(p-tolylamino)phenyl)methanone [32] 
 
o-Chloroaniline 1 (56 mg, 0.174 mmol, 1 eq.), and 4-iodotoluene (41 mg, 0.188 mmol, 1.1 
eq.) were dissolved in freshly distilled 1,4-dioxane (1.2 mL). Caesium carbonate (167 mg, 
0.513 mmol, 3 eq.) and 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl (X-Phos) (8 mg, 
0.017 mmol, 0.1 eq.) were added to the stirred solution, followed by tris-
dibenzylideneacetone dipalladium (Pd2(dba)3) (9 mg, 0.009 mmol, 0.05 eq.). The reaction 
solution was degassed with argon over the course of reagent additions and for a further 3 
minutes after the final addition of Pd2(dba)3. The reaction was heated at reflux for 4 hours, or 
until all the 4-iodotoluene had been consumed. The reaction mixture was cooled to room 
temperature, diluted with dichloromethane (12 mL) and washed with water (5 mL). The 
aqueous phase was then extracted with dichloromethane (3 x 2 mL). The organic layers 
were combined, dried over magnesium sulfate and the solvent evaporated to yield a crude 
resin. The product was purified by silica gel chromatography (1/20 v/v (5% aqueous 
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ammonia in methanol)/dichloromethane) yielding a golden foam 32 (77 mg, 0.19 mmol, 
quant). 
Rf 0.53 (1/10 v/v (10% v/v aqueous ammonia in methanol)/dichloromethane); IR (ZnSe, film) 
vmax: 3314 (w, N-H), 2931 (m, aryl-C-H), 2856, 2804 (w, alkyl-C-H), 1711 (w, C=O), 1598 (s, 
C=C), 1514 (s, aryl-N-H), 1430 (s, CH2), 1325 (m, aryl-C-N), 1271 (m, aryl-C=C), 1116 (w, 
aryl-C-Cl), 1018 (w, alkyl-C-N) cm-1; 1H NMR (500 MHz, CDCl3): δ 7.43 (1H, s, 10-CH), 7.15 
(3H, m, 2-CH, 8-CH), 7.08 (3H, m, 3-CH, 7-CH), 6.19 (1H, s, 4-NH), 4.70-3.70 (2H, br, s, 13-
CH2), 2.86 (2H, br, s, 13-CH2), 2.50 (5H, br, m, 14-CH2, 15-CH), 2.34 (3H, s, 5-CH3), 1.85 
(2H, br, d, , xJx-x = 9.5 Hz, 16-CH2), 1.58 (4H, br, m, 17-CH2), 1.51 (2H, br, m, 16-CH2), 1.43 
(2H, br, s, 18-CH2) ppm; 13C NMR (125 MHz, CDCl3): δ 169.3 (132-C=O), 142.8 (6-C), 
137.7, 133.9, 130.2 (2-CH), 129.2 (8/10-CH), 127.1 (8/10-CH), 126.7, 122.5 (3-CH), 119.8 
(11-C), 113.2 (7-CH), 62.7 (15-CH), 50.4 (14-CH2), 28.4 (16-CH2), 26.5 (17-CH2), 24.8 (18-
CH2), 21.0 (5-CH3), unresolved 13-CH2 ppm; LRMS (+ ESI) m/z: 825, 823 ([2M + H]+, 52, 
60%), 414, 412 ([M+H]+, 10%, 30%); HRMS (+ ESI) m/z: 414.2121 (Calcd. C24H3037ClN3O = 
413.2048) ([M+H]+, 28%), 412.2151 (Calcd. C24H3037ClN3O = 411.2077) ([M+H]+, 100%); Diff. 
= 0.1 ppm. 
 
Synthesis of N-(4-((4-([1,4'-bipiperidine]-1'-carbonyl)-2-
chlorophenyl)amino)phenyl)acetamide [33] 
 
o-Chloroaniline 1 (56 mg, 0.174 mmol, 1 eq.), and N-(4-iodophenyl)acetamide (49 mg, 0.188 
mmol, 1.1 eq.)were dissolved in dry 1,4-dioxane (1.2 mL). Caesium carbonate (167 mg, 
0.513 mmol, 3 eq.) and 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl (X-Phos) (8 mg, 
0.017 mmol, 0.1 eq.) were added to the stirred solution, followed by tris-
dibenzylideneacetone dipalladium (Pd2(dba)3) (9 mg, 0.009 mmol, 0.05 eq.). The reaction 
solution was degassed with argon over the course of reagent additions and for a further 3 
minutes after the addition of Pd2(dba)3. The reaction was heated at reflux for6 hours, or until 
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all the N-(4-iodophenyl)acetamide and o-chloroaniline had been consumed. The reaction 
mixture was cooled to room temperature, diluted with dichloromethane (12 mL) and washed 
with water (5 mL). The aqueous phase was then extracted with dichloromethane (3 x 2 mL). 
The organic layers were combined, dried over anhydrous magnesium sulfate and the solvent 
evaporated to yield a crude resin. The product was purified by silica gel chromatography 
(1/30 v/v (5% aqueous ammonia in methanol)/dichloromethane) to yield 33 (35 mg, 0.078 
mmol, 45%). 
Rf 0.21 (1/10 v/v (10% v/v aqueous ammonia in methanol)/dichloromethane); IR (ZnSe, film) 
vmax: 3300 (br, w, aryl-N-H), 2931 (m, aryl-C-H), 2857 (w, alkyl-C-H), 1710 (w, aryl-C=O), 
1671 (w, acetamide-C=O), 1599 (s, C=C), 1513 (s, N-H), 1439 (s, CH2), 1309 (m, aryl-C-N), 
1272, 1221 (m, aryl-C=C), 1116 (w, aryl-C-Cl), 1018 (w, alkyl-C-N) cm-1; 1H NMR (500 MHz, 
CDCl3): δ 7.80 (1H, br, s, 1-NH), 7.44 (3H, m, 2x acetamide-CH, 1x 11-CH), 7.11 (3H, m, 2x 
acetamide-CH, 1x 9-CH), 7.03 (1H, d, 3J5-6 = 8.0 Hz, 8-CH), 6.19 (1H, s, 7-NH), 4.60-4.04 
(2H, br, 14-CH2), 2.88 (1H, br, s, 14-CH2), 2.50 (5H, br, s, 15-CH2 and 16-CH2), 2.17 (3H, s, 
6-CH3), 1.85 (2H, br, s, 17-CH2), 1.58 (4H, br, s, 18-CH2), 1.50 (2H, m, 17-CH2), 1.43 (2H, 
br, s, 19-CH2) ppm; 13C NMR (125 MHz, CDCl3): δ 169.3 (5/13-C=O), 168.6 (5/13-C=O), 
142.6, 136.4, 134.5, 129.2, 127.1 (9-CH), 126.8, 123.0, 121.5, 120.0, 113.3 (8-CH) (10 
aromatic C(H)), 62.7 (16-CH), 50.4 (15-CH2), 28.6 (17-CH2), 26.5 (18-CH2), 24.8 (19-CH2), 
24.5 (6-CH3), one unresolved bipiperidine CH2 ppm; LRMS (+ ESI) m/z: 911, 909 (2M + H]+, 
16/20%), 457, 455 ([M + H]+, 34, 100%); HRMS (+ ESI) m/z: 457.2180 (Calcd. 
C25H3137ClN4O2 = 456.2106) ([M + H]+, 33%), 455.2209 (Calcd. C25H3135ClN4O2 = 454.2136) 
([M + H]+, 100%); Diff. 0.2 ppm. 
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Synthesis of [1,4'-bipiperidin]-1'-yl(4-(benzylamino)-3-chlorophenyl)methanone [34] 
 
Benzyl bromide (21 µL, 0.180 mmol, 1.2 eq.) was added to a stirred suspension of o-
chloroaniline 1 (48 mg, 0.150 mmol, 1 eq.) in tap water (0.3 mL). The suspension was 
heated at reflux for 3.5 hours at which point all of the benzyl bromide and aniline had been 
consumed. The reaction was cooled to room temperature and diluted with dichloromethane 
(5 mL). The organic fraction was brought to pH 8 with saturated sodium hydrogen carbonate. 
The organic fraction was separated and the aqueous layer was extracted with 
dichloromethane (3 x 2 mL). The organic fractions were combined, dried over anhydrous 
magnesium sulfate and the solvent evaporated. The crude material was purified by silica gel 
chromatography (1/30 v/v (5% aqueous ammonia in methanol)/dichloromethane) to yield a 
colourless oily resin 34 (37 mg, 0.09 mmol, 60%). 
Rf 0.35 (1/10 v/v (10% v/v aqueous ammonia in methanol)/dichloromethane); IR (ZnSe, film) 
vmax: 3340 (w, N-H), 2931 (m, aryl-C-H), 2851, 2804 (w, alkyl-C-H), 1711 (w, C=O), 1600 (s, 
C=C), 1524 (s, aryl-N-H), 1426 (br, s, CH2), 1327 (m, aryl-C-N), 1275, 1219 (m, aryl-C=C), 
1115 (w, aryl-C-Cl), 1018 (w, alkyl-C-N) cm-1; 1H NMR (500 MHz, CDCl3): δ 7.40 (1H, d, 4J10-
8 = 1.7 Hz 10-CH), 7.35 (4H, m, benzyl-CH), 7.29 (1H, m, 4-CH), 7.18 (1H, dd,  3J7-8 = 8.4 
Hz, 4J = 1.6 Hz, 8-CH), 6.58 (1H, d,  3J = 8.4 Hz, 7-CH), 4.96 (1H, br, t, 3J = 5.4 Hz, 6-NH), 
4.43 (2H, d, 3J = 5.6 Hz, 5-CH2), 2.85 (2H, br, m, 13-CH2), 2.50 (5H, br, m, 14-CH2, 15-CH), 
1.84 (3H, br, d, 3J = 11.6 Hz, 13/16-CH2), 1.58 (4H, br, m, 17-CH2), 1.49 (2H, qd, 3J = 12.1 
Hz, 3J = 1.5 Hz, 16-CH2), 1.44 (2H, br, m, 18-CH2) missing 1H or 13-CH2 ppm; 13C NMR 
(125 MHz, CDCl3): δ 169.6 (12-C=O), 145.1, 138.3, 129.0, 128.9, 127.7, 127.6, 127.33, 
124.8, 118.7, 110.6 (10 aromatic C(H)), 62.8 (15-CH), 50.4 (14-CH2), 47.8 (5-CH2), 28.6 (16-
CH2), 26.5 (17-CH2), 24.9 (18-CH2) ppm; LRMS (+ ESI) m/z: 823 ([2M]+), 414, 412 (M + H]+, 
52, 100%); HRMS (+ ESI) m/z: 823.4228 (Calcd. C24H3035ClN3O = 411.2077) ([2M + H]+, 1%); 
412.2149 (Calcd. C24H3035ClN3O = 411.2077) ([M + H]+, 100%); Diff. 0.30 ppm. 
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Synthesis of [1,4'-bipiperidin]-1'-yl(3-chloro-4-((3-methoxybenzyl)amino)phenyl)methanone 
[35] 
 
3-Methoxybenzyl bromide 86 (24 µL, 0.168 mmol, 1 eq.) was added to a stirred suspension 
of o-chloroaniline (65 mg, 0.202 mmol, 1.2 eq.) in tap water (0.4 mL). The suspension was 
heated at reflux for 2 hours at which point an additional 0.2 equivalents of 3-methoxybenzyl 
bromide (5 µL, 0.003 mmol) was added to the mixture. The reaction was heated for a further 
0.5 hours at which point all 3-methoxybenzyl bromide had been consumed. The reaction 
was cooled to room temperature overnight before being diluted with dichloromethane (6 mL). 
The organic fraction was brought to pH 8 with saturated sodium hydrogen carbonate. The 
organic fraction was separated and the aqueous layer was extracted with dichloromethane 
(3 x 3 mL). The organic fractions were combined, dried over anhydrous magnesium sulfate 
and the solvent evaporated. The crude material was purified by silica gel chromatography 
(1/30 v/v (5% aqueous ammonia in methanol)/dichloromethane). Co-eluted fractions were 
recombined and repurified with those retained from previous experiments to give a 
pearlescent foam 35 (Overall yield = 44 mg, 0.0995 mmol, of which 0.085 mmol, or 42% was 
calculated for the described reaction). 
Rf 0.30 (1/10 v/v (10% v/v aqueous ammonia in methanol)/dichloromethane); IR (ZnSe, film) 
vmax: 3353 (w, N-H), 2930 (m, aryl-C-H), 2855, 2806 (w, alkyl-C-H), 1711 (w, C=O), 1600 (s, 
C=C), 1525 (s, aryl-N-H), 1428 (br, s, CH2), 1326 (m, aryl-C-N), 1260, 1234 (s, aryl-O-C, 
aryl-C=C), 1116 (w, aryl-C-Cl), 1042 (m, aryl-O-C), 1018 (w, alkyl-C-N) cm-1; 1H NMR (500 
MHz, CDCl3): δ 7.39 (1H, s, 13-CH), 7.26 (1H, dd, 3J = 7.5 Hz, aryl-CH), 7.16 (1H, d, 3J = 7.9 
Hz, aryl-CH), 6.92 (1H, d,  3J = 7.5 Hz, 6-CH), 6.88 (1H, s, 2-CH), 6.82 (1H, d,  3J = 7.9 Hz, 
aryl-CH), 6.57 (1H, d, 3J = 8.3 Hz, aryl-CH), 4.97 (1H, br, s, 9-NH), 4.39 (2H, d, 3J8-NH = 4.3 
Hz, 8-CH2), 4.28 (1H, br, s, 16-CH2), 3.79 (3H, s, 7-CH3), 2.84 (2H, br, s, 16-CH2), 2.49 (5H, 
br, m, 17-CH2, 18-CH), 2.08 (1H, s, 16-CH2), 1.83 (2H, br, d, 3J = 10.1 Hz, 19-CH2), 1.57 
(4H, br, s, 20-CH2), 1.48 (2H, m, 19-CH2), 1.43 (2H, br, s, 21-CH2) ppm; 13C NMR (125 MHz, 
CDCl3): δ 169.6 (15-C=O), 160.1, 145.1, 139.9, 129.9, 128.8 (13-CH), 127.6 (d-CH), 124.7, 
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119.5 (6-CH), 118.6, 112.9 (2-CH), 112.8, 110.6 (10-CH), 62.7 (18-CH), 55.3 (7-CH3), 50.3 
(17-CH2), 47.7 (8-CH2), 28.4 (19-CH2), 26.5 (20-CH2), 24.8 (21-CH2) ppm; LRMS (+ ESI) 
m/z: 823, 825 ([2M + H]+, 66, 62%), 412, 414 ([M + H]+, 100, 53%); HRMS (+ ESI) m/z: 
444.2225 (Calcd. C24H3037ClN3O = 443.2184) ([M + H]+, 31%), 442.2255 (Calcd. 
C24H3035ClN3O = 441.2183) ([M + H]+, 100%); Diff. 0.2 ppm. 
 
Synthesis of [1,4'-bipiperidin]-1'-yl(3-chloro-4-((4-nitrobenzyl)amino)phenyl)methanone [36] 
 
4-nitrobenzyl bromide 84 (36 mg, 0.165 mmol, 1.1 eq.) was added to a stirred suspension of 
o-chloroaniline (48 mg, 0.150 mmol, 1 eq.) in tap water (0.3 mL). The suspension was 
heated at reflux for 3 hours at which point an additional 1 equivalents of 4-nitrobenzyl 
bromide (32 mg, 0.150 mmol) was added to the mixture. The reaction was heated for a 
further 2 hours or until all of the aniline had been consumed. The reaction was cooled to 
room temperature and diluted with dichloromethane (6 mL). The organic fraction was 
brought to pH 8 with saturated sodium hydrogen carbonate. The organic fraction was 
separated and the aqueous layer was extracted with dichloromethane (3 x 3 mL). The 
organic fractions were combined, dried over anhydrous magnesium sulfate and the solvent 
evaporated to yield an oily, yellow solid. The crude material was purified by silica gel 
chromatography (1/40-1/30 v/v (5% aqueous ammonia in methanol)/dichloromethane) to 
yield a yellow foam 36 (11 mg, 0.023 mmol, 15%). 
Rf 0.40 (1/5 v/v (10% v/v aqueous ammonia in methanol)/dichloromethane); IR (ZnSe, film) 
vmax: 3351 (w, N-H), 2932 (m, aryl-C-H), 2854, 2805 (w, alkyl-C-H), 1711 (w, C=O), 1600 (s, 
C=C), 1518 (s, NO2), 1432 (br, s, CH2), 1344 (s, NO2), 1329 (m, aryl-C-N), 1277, 1152 (m, 
aryl-C=C), 1115 (w, aryl-C-Cl), 1043 (w, alkyl-C-N) cm-1; 1H NMR (500 MHz, CDCl3): δ 8.21 
(2H, d, 3J = 8.6 Hz, 2/3-CH), 7.50 (2H, d, 3J = 8.6 Hz, 2/3-CH), 7.42 (1H, d, 4J = 1.7 Hz, 10-
CH), 7.14 (1H, dd, 3J = 8.4 Hz, 4J = 1.7 Hz, 8-CH), 6.43 (1H, d, 3J = 8.5 Hz, 7-CH), 5.13 (1H, 
br, t, 3J = 5.9 Hz, 6-NH), 4.58 (2H, d, 3J = 6.1 Hz, 5-CH2), 2.89 (2H, br, s, 13-CH2), 2.49 (5H, 
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br, m, 14-CH2, and 15-CH), 1.85 (2H, br, d, 3J = 9.5 Hz), 1.71 (2H, br, s), 1.58 (4H, br, m, 17-
CH2), 1.48 (2H, m, 16-CH2), 1.44 (2H, m, 18-CH2) ppm; 13C NMR (125 MHz, CDCl3): δ 169.3 
(12-C=O), 147.6, 146.1, 144.4, 129.1 (10-CH), 127.7 (2/3-CH), 127.6 (8-CH), 125.7, 124.2 
(2/3-CH), 119.0, 110.7 (7-CH), 62.7 (15-CH), 50.4 (14-CH2), 47.1 (5-CH2), 26.5 (17-CH2), 
24.8 (18-CH2), two unresolved bipiperidine C(H) signals ppm; LRMS (+ ESI) m/z: 915, 913 
(2M + H]+, 25, 30%), 459, 457 ([M + H]+, 32, 100%); HRMS (+ ESI) m/z: 459.1972 (Calcd. 
C24H2937ClN4O3 = 458.1899) ([M + H]+, 33%), 457.2001 (Calcd. C24H2935ClN4O3 = 456.1928) 
([M + H]+, 100%); Diff. 0.1 ppm. 
 
Synthesis of [1,4'-bipiperidin]-1'-yl(3-chloro-4-((4-methylbenzyl)amino)phenyl)methanone 
[37] 
 
4-Methylbenzyl bromide (88 mg, 0.540 mmol, 1.2 eq.) was added to a stirred suspension of 
o-chloroaniline 1 (144 mg, 0.450 mmol, 1 eq.) in tap water (0.9 mL). The suspension was 
heated at reflux for 3 hours at which point all of the 4-methylbenzyl bromide had been 
consumed. The reaction was cooled to room temperature and diluted with dichloromethane 
(10 mL). The organic fraction was brought to pH 8 with saturated sodium hydrogen 
carbonate. The organic fraction was separated and the aqueous layer was extracted with 
dichloromethane (3 x 8 mL). The organic fractions were combined, dried over anhydrous 
magnesium sulfate and the solvent evaporated to yield an opaque, yellow oil. The crude 
material was purified by silica gel chromatography (1/30 v/v (5% aqueous ammonia in 
methanol)/dichloromethane) to yield a white foam 37 (40 mg, 0.095 mmol, 21%). 
Rf 0.54 (1/10 v/v (10% v/v aqueous ammonia in methanol)/dichloromethane); IR (ZnSe, film) 
vmax: 3342 (w, N-H), 2931 (m, aryl-C-H), 2856, 2806 (w, alkyl-C-H), 1711 (w, C=O), 1601 (s, 
C=C), 1525 (m, aryl-N-H), 1427 (br, s, CH2, CH3), 1329 (m, aryl-C-N), 1276, 1231m 1152 (m, 
aryl-C=C), 1116 (s, aryl-C-Cl), 1018 (s, alkyl-C-N) cm-1; 1H NMR (500 MHz, CDCl3): δ 7.39 
(1H, s), 7.23 (2H, d, 3J = 7.0 Hz), 7.17 (3H, m, )6.59 (1H, d, 3J = 8.0 Hz, 8-CH), 4.91 (1H, br, 
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s, NH), 4.38 (2H, d, 3J = 5.0 Hz, 6-CH2), 2.85 (2H, br, s, 14-CH2), 2.50 (5H, br, m, 15-CH2 
and 16-CH), 2.35 (3H, s, 5-CH3), 1.84 (2H, br, d, J = 10.0 Hz, 17-CH2), 1.7 (2H, br, s, 14-
CH2), 1.58 (4H, br, m, 18-CH2), 1.49 (2H, m, 17-CH2), 1.44 (2H, m, 19-CH2) ppm; 13C NMR 
(125 MHz, CDCl3): δ 169.7 (13-C=O), 145.2, 137.4, 135.2, 129.6, 129.1, 127.7, 127.4, 
124.6, 118.6, 110.6 (10 aromatic C(H)), 62.8 (16-CH), 50.4 (15-CH2), 47.6 (6-CH2), 31.0 (17-
CH2), 28.5 (18-CH2), 24.9 (19-CH2), 21.2 (5-CH3) ppm; LRMS (+ ESI) m/z: 853, 852 (2M + 
H]+, 20/25%), 428, 426 ([M + H]+, 32, 100%; HRMS (+ ESI) m/z: 428.2276 (Calcd. 
C25H3237ClN3O = 427.2204) ([M + H]+, 33%), 426.2307 (Calcd. C25H3235ClN3O = 425.2234) 
([M + H]+, 100%); Diff. 0.05 ppm. 
 
Synthesis of [1,4'-bipiperidin]-1'-yl(3-chloro-4-(propylamino)phenyl)methanone [38] 
 
Propanal 91 (25 µL, 0.342 mmol, 2 eq.) was added to a solution of o-chloroaniline 1 (56 mg, 
0.174 mmol, 1 eq.) in 1,2-dichloroethane (1 mL). The reaction was stirred at room 
temperature for 0.5 hours and then cooled to 0 °C. Glacial acetic acid (59 µL, 1.026 mmol, 6 
eq.) and sodium triacetoxyborohydride (101 mg, 0.479 mmol, 2.8 eq.) were added portion-
wise to the cooled solution. The reaction was allowed to warm to room temperature and 
stirred overnight. The solution was diluted with dichloromethane (3 mL) and brought to pH 8-
9 with saturated sodium hydrogen carbonate. The aqueous phase was separated and 
extracted with dichloromethane (3 x 2 mL). The organic layers were combined, dried over 
magnesium sulfate and the solvent evaporated to yield cloudy residue. The crude material 
was purified by silica gel chromatography (1/30 v/v (5% v/v aqueous ammonia in 
methanol)/dichloromethane) to give a colourless oil 38 (17 mg, 0.047 mmol, 28%). 
Rf 0.48 (1/10 v/v (10% v/v aqueous ammonia in methanol)/dichloromethane); IR (ZnSe, film) 
vmax: 3423-3335 (br, w, N-H), 2931 (w, aryl-C-H), 2856, 2802 (w, alkyl-C-H), 1711 (w, C=O), 
1601 (s, C=C), 1524 (m, aryl-N-H), 1425 (br, s, CH2), 1328 (m, aryl-C-N), 1272-1220, 1152 
(m, aryl-C=C), 1115 (m, aryl-C-Cl), 1018 (m, alkyl-C-N) cm-1; 1H NMR (500 MHz, CDCl3): δ 
7.36 (1H, d, 4J = 1.5 Hz, 8-CH), 7.21 (1H, d, 3J = 8.5 Hz, 6-CH), 6.59 (1H, d, 3J = 8.5 Hz, 5-
CH), 4.49 (1H, t, 3J = 5.5 Hz, NH), 3.16 (2H, q, 3J = 6.4 Hz, 3-CH2), 2.89 (2H, br, 11-CH2), 
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2.50 (5H, br, s, 12-CH2 and 13-CH2), 1.85 (2H, br, s, 11-CH2), 1.69 (2H, m, 2-CH2), 1.63, 
(2H, br, 14-CH2), 1.58 (4H, br, m, 15-CH2), 1.50 (2H, q, 3J = 11.2 Hz, 14-CH2), 1.44 (2H, br, 
m, 16-CH2), 1.01 (3H, t, 3J = 7.1 Hz, 1-CH) ppm; 13C NMR (125 MHz, CDCl3): δ 169.38 (10-
C=O), 145.5, 128.9, 127.8, 124.0, 118.4, 110.1 (6 aromatic C(H)), 62.8 (13-CH), 50.4 (12-
CH2), 45.4 (3-CH2), 26.5 (15-CH2), 24.8 (16-CH2), 22.5 (2-CH2), 11.7 (1-CH3) ppm; LRMS (+ 
ESI) m/z: 751, 749 (2M + Na]+, 19, 30%), 366, 364 ([M + H]+, 34, 100%); HRMS (+ ESI) m/z: 
366.2120 (Calcd. C20H3037ClN3O = 365.2048) ([M + H]+, 36%), 364.2150 (Calcd. 
C20H3035ClN3O = 363.2077) ([M + H]+, 100%), Diff. 0.1 ppm. 
 
Synthesis of [1,4'-bipiperidin]-1'-yl(3-chloro-4-(cyclohexylamino)phenyl)methanone [39] 
 
Anhydrous magnesium sulfate (180 mg, 1.50 mmol, 10 eq.) was added to a solution of o-
chloroaniline 1 (48 mg, 0.150 mmol, 1 eq.) dissolved in glacial acetic acid (850 µL, 14.86 
mmol, 100 eq.). Cyclohexanone (93 µL, 0.900 mmol, 6 eq.) was added in a dropwise 
manner to stirred suspension and allowed to react at room temperature for 2.5 hours. At this 
point sodium triacetoxyborohydride (143 mg, 0.675 mmol, 4.5 eq.) was added in several 
portions and the reaction was allowed to stir at room temperature overnight, or until very little 
of the aniline remained. The reaction solution was quenched with water (1 mL) and brought 
to pH 8 with sodium hydrogen carbonate. The aqueous phase was extracted with 
dichloromethane (5 x 3 mL), the organic fractions were combined, dried over anhydrous 
magnesium sulfate and the solvent evaporated. The crude material was purified by silica gel 
chromatography (1/30-1/20 v/v (5% v/v aqueous ammonia in methanol)/dichloromethane) to 
yield a colourless resin 39 (14 mg, 0.035 mmol, 23%).  
Rf 0.35 (1/10 v/v (10% v/v aqueous ammonia in methanol)/dichloromethane); IR (ZnSe, film) 
vmax: 3414 (w, N-H), 2928 (m, aryl-C-H), 2852, 2799 (w, alkyl-C-H), 1712 (w, C=O), 1600 (s, 
C=C), 1521 (m, aryl-N-H), 1465, 1424, 1403 (br, s, CH2), 1328 (m, aryl-C-N), 1274, 1259, 
1244 (m, aryl-C=C), 1115 (m, aryl-C-Cl), 1018 (m, alkyl-C-N) cm-1; 1H NMR (500 MHz, 
CDCl3): δ 7.36 (1H, d, 4J = 1.9 Hz, 9-CH), 7.20 (1H, dd, 3J = 8.5 Hz, 4J = 1.9 Hz, 7-CH), 6.62 
(1H, s, 3J = 8.5 Hz, 6-CH), 4.43 (1H, d, 3J = 8.0 Hz, NH), 4.33 (1H, br, s, 12-CH2), 2.50 (4H, 
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m, 13-CH2), 2.47 (1H, tt, J = 11.4 Hz, 3.4 Hz, 14-CH), 2.04 (2H, br, d, J = 13.1 Hz), 1.85 (2H, 
br, d, J = 12.5 Hz), 1.65 (1H, m), 1.58 (4H, m), 1.50 (2H, qd, J = 11.9, 4. Hz), 1.45-1.35 (5H, 
m), 1.26 (4H, m) ppm; 13C NMR (125 MHz, CDCl3): δ 169.9 (C=O), 144.5, 129.1, 127.7, 
123.6, 118.3, 110.5 (6 aromatic C(H)), 62.8 (14-CH), 51.5, 50.4, 33.1, 28.5, 26.5, 25.9, 
24.89, 24.86 (8 alkyl CH2 ppm; LRMS (+ ESI) m/z: 811, 810, 808 (2M + H]+, 42, 73, 100%), 
406, 404 ([M + H]+, 16, 32%); HRMS (+ ESI) m/z: 406.2438 (Calcd. C23H3437ClN3O = 
405.2361) ([M + H]+, 72%), 404.2461 (Calcd. C23H3435ClN3O = 403.2390) ([M + H]+, 100%); 
Diff. 0.4 ppm. 
 
Synthesis of [1,4'-bipiperidin]-1'-yl(3-chloro-4-(((1-methyl-1H-pyrrol-2-
yl)methyl)amino)phenyl)methanone [22] 
 
1-methyl-1H-pyrrole-2-carbaldehyde (25 µL, 0.342 mmol, 2 eq.) was added to a solution of 
o-chloroaniline 1 (56 mg, 0.174 mmol, 1 eq.) in 1,2-dichloroethane (0.8 mL). The reaction 
was stirred at room temperature for 3 hours and then cooled to 0 °C. Glacial acetic acid (59 
µL, 1.026 mmol, 6 eq.) and sodium triacetoxyborohydride (101 mg, 0.479 mmol, 2.8 eq.) 
were added portion-wise to the cooled solution. The reaction was allowed to warm to room 
temperature and stirred for 24-48 hours. When very little of the 1-methyl-1H-pyrrole-2-
carbaldehyde remained the solution was diluted with dichloromethane (10 mL) and brought 
to pH 8-9 with saturated sodium hydrogen carbonate. The aqueous phase was separated 
and extracted with dichloromethane (3 x 3 mL). The organic layers were combined, dried 
over magnesium sulfate and the solvent evaporated to yield and pink-black oil. The crude 
material was purified by silica gel chromatography (1/30 v/v (5% v/v aqueous ammonia in 
methanol)/dichloromethane) to give a brown, pearlescent foam 22 (26 mg, 0.064 mmol, 
37%). 
Rf 0.43 (1/10 v/v (10% v/v aqueous ammonia in methanol)/dichloromethane); IR (ZnSe, film) 
vmax: 3408 (br, w, N-H), 2934 (w, aryl-C-H), 2851, 2806 (w, alkyl-C-H), 1709 (w, C=O), 1601 
(s, C=C), 1522 (m, aryl-N-H), 1429 (br, s, CH2), 1324 (m, aryl-C-N), 1271, 1236, 1217 (m, 
aryl-C=C/N), 1115 (m, aryl-C-Cl), 1018 (m, alkyl-C-N) cm-1; 1H NMR (500 MHz, CDCl3): δ 
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7.39 (1H, s, 11-CH), 7.25 (1H, d, 3J = 7.7 Hz, 9-CH), 6.75 (1H, d, 3J = 8.3 Hz, 8-CH), 6.65 
(1H, s, 2-CH), 6.15 (1H, s, 3-CH), 6.09 (1H, s, 1-CH), 4.54 (1H, s, NH), 4.30 (2H, s, 5-CH2), 
3.62 (3H, s, 6-CH3), 2.86 (2H, br, 14-CH2), 2.51 (4H, br, m, 15-CH2 and 16-CH), 1.85 (2H, br, 
s, 17-CH2), 1.58 (4H, br, s, 18-CH2), 1.50 (2H, d, 3J = 11.7 Hz, 17-CH2), 1.44 (2H, br, s, 19-
CH2) ppm; 13C NMR (125 MHz, CDCl3): δ 169.5 (13-C=O), 144.9, 128.9, 128.3, 127.7, 
124.9, 123.3, 118.8, 110.4, 109.2, 107.1 (10 aromatic C(H)), 62.6 (16-CH), 50.4 (15-CH2), 
40.1 (5-CH2), 33.9 (6-CH3), 28.5 (17-CH2), 26.4 (18-CH2), 24.8 (19-CH2) ppm; LRMS (+ ESI) 
m/z: 831, 829 (2M + H]+, 15, 20%), 417, 415 ([M + H]+, 33, 100%); HRMS (+ ESI) m/z: 
417.2230 (Calcd. C23H3137ClN4O = 416.2157) ([M + H]+, 33%), 415.2260 (Calcd. 
C23H3135ClN4O = 414.2186) ([M + H]+, 100%); Diff. 0.1 ppm. 
 
Synthesis of N-(4-([1,4'-bipiperidine]-1'-carbonyl)-2-chlorophenyl)-1H-pyrrole-2-carboxamide 
[21] 
 
1H-pyrrole-2-carboxylic acid 98 (23 mg, 0.205 mmol), 1.2 eq.) dissolved in oxalyl chloride 
(100 µL, 1.17 mmol, 5.7 eq.) and the white solution was heated to 50 oC for 1 hour. The 
residual oxalyl chloride was evaporated to yield 1H-pyrrole-2-carbonyl chloride as a pink 
solid. The crude material was redissolved in dry dichloromethane (300 µL) and cooled to 0 
oC. Triethylamine (28 µL, 0.205 mmol, 1.2 eq.) and o-chloroaniline 1 (56 mg, 0.174 mmol, 1 
eq.) were then added and the solution rapidly turned orange. The reaction was allowed to 
warm to room temperature and stir overnight. As no reaction was observed to have occurred 
at this point, a catalytic quantity of N,N-dimethylaminopyridine was added to the reaction 
mixture and the solution was allowed to ontinue to stir at room temperature. After 4 hours 
product formation was detected, and while o-chloroaniline remained, the reaction was 
quenched with water (10 mL). The aqueous phase was separated and extracted with 
dichloromethane (3 x 3 mL). The organic fractions were combined, dried over anhydrous 
magnesium sulfate, and the solvent evaporated to yield a colourless, cloudy resin. The crude 
material was purified by reverse phase chromatography ( 1:3 v:v (10% aqueous ammonia in 
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methanol):water) - 2:3:1 v:v (10% aqueous ammonia in methanol:water:methanol) to yield a 
colourless resin 21 (10 mg, 0.024 mmol, 14%).  
Rf 0.46 (1/10 v/v (10% v/v aqueous ammonia in methanol)/dichloromethane); Rf (reverse 
phase silica) 0.24 (3/5 v/v (10% v/v aqueous ammonia in methanol)/water); IR (ZnSe, film) 
vmax: 3529 (br, w, pyrrole-N-H)194, 3252 (w, br, amide-N-H), 2928 (m, aryl-C-H), 2856, 2809 
(w, alkyl-C-H), 1709 (m, amide-C=O), 1614 (s, pyrrole-C=O, amide-N-H), 1600 (m, C=C) 
1514 (s, N-H), 1442 (s, CH2), 1317 (s, aryl-C-N), 1280, 1252 (m, aryl-C=C), 1116 (w, aryl-C-
Cl), 1017 (w, alkyl-C-N) cm-1; 1H NMR (500 MHz, CDCl3): δ 9.66 (1H, s, pyrrole-NH), 8.50 
(1H, d, 3J = 8.5 Hz, 7-CH), 8.26 (1H, s, 1-3-CH), 7.49 (1H, d, 4J = 1.7 Hz, 10-CH), 7.32 (1H, 
dd, 3J = 14 Hz,  4J = 2.5 Hz, 8-CH2), 7.03 (1H, s, pyrrole-CH), 6.80 (1H, s, pyrrole-CH), 6.32 
(1H, q, 6-NH), 4.70 (1H, s, 13-CH2), 3.86 (1H, s, 13-CH2), 2.86 (2H, s, 13-CH2), 2.51 (5H, m, 
14-CH2 and 15-CH), 1.92 (4H, br, 16-CH2), 1.58 (4H, br, m, 17-CH2), 1.44 (2H, m, 18-CH2) 
ppm; 13C NMR (125 MHz, CDCl3): δ 168.6 (12-C=O), 158.9 (5-C=O), 136.0, 131.9, 128.3, 
126.7, 125.7, 123.3, 122.7, 120.7, 110.7, 110.6 (10 aromatic C(H)), 62.6 (15-CH), 50.4 (14-
CH2), 47.7 (13-CH2), 42.4 (13-CH2), 28.9 (16-CH2), 28.0 (16- CH2), 26.5 (17-CH2), 24.8 (18-
CH2) ppm; LRMS (+ ESI) m/z: 417, 415 ([M + H]+, 38, 100%); HRMS (+ ESI) m/z: 417.1865 
(Calcd. C22H2737ClN4O2 = 416.1793) ([M + H]+, 33%), 415.1895 (Calcd. C22H2735ClN4O2 = 
414.1823) ([M + H]+, 100%); Diff. 0.1 ppm. 
 
Synthesis of [1,4'-bipiperidin]-1'-yl(3-chloro-4-((5,11-dimethyl-6,11-dihydro-5H-
benzo[e]pyrimido[5,4-b][1,4]diazepin-2-yl)amino)phenyl)methanone [40] 
 
o-Chloroaniline 1 (40 mg, 0.124 mmol, 1 eq.), and diazepine 65 (34 mg, 0.130 mmol, 1.05 
eq.) were dissolved in dry 1,4-dioxane (0.8 mL). Caesium carbonate (121 mg, 0.372 mmol, 3 
eq.) and 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl (X-Phos) (6 mg, 0.012 mmol, 
0.1 eq.) were added to the stirred solution, followed by tris-dibenzylideneacetone dipalladium 
(Pd2(dba)3) (6 mg, 0.006 mmol, 0.05 eq.). The reaction solution was degassed with argon 
over the course of reagent additions and for a further 3 minutes after the addition of 
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Pd2(dba)3. The reaction was heated at reflux for6 hours, at which point product formation 
was detected, but both starting material remained. The reaction mixture was cooled to room 
temperature, diluted with dichloromethane (12 mL) and washed with water (5 mL). The 
aqueous phase was then extracted with dichloromethane (3 x 2 mL). The organic layers 
were combined, dried over anhydrous magnesium sulfate and the solvent evaporated to 
yield a crude resin.  
In a separate reaction flask, o-chloroaniline 1 (40 mg, 0.124 mmol, 1 eq.), and diazepine 65 
(34 mg, 0.130 mmol, 1.05 eq.) were combined with potassium tert-butoxide (15 mg, 0.136 
mmol, 1.1 eq.), 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl (X-Phos) (10 mg, 0.02 
mmol, 0.16 eq.) and tris-dibenzylideneacetone dipalladium (Pd2(dba)3) (10 mg, 0.01 mmol, 
0.08 eq.) in a solution of tert-butanol (124 µL) and dry 1,4-dioxane (400 µL). The reaction 
solution was degassed with argon over the course of reagent additions. The reaction was 
heated at 65 oC overnight. At this point product formation was detected, although both 
starting materials remained. At this point the reaction mixture was cooled to room 
temperature, diluted with dichloromethane (12 mL) and washed with water (5 mL). The 
aqueous phase was then extracted with dichloromethane (3 x 2 mL). The organic layers 
were combined, dried over anhydrous magnesium sulfate and the solvent evaporated to 
yield a crude resin.  
The crude material from the two reactions were purified progressively by silica gel 
chromatography in various eluent systems and combined to yield a yellow-green resin 40 (4 
mg, 0.007 mmol, 3%, or 10% b.r.s.m.). The majority of the product remain in co-eluted 
column fractions. The product was analysed by NMR spectroscopy in deuterated chloroform, 
and the solvent was rapidly removed to prevent degradation. 
Rf 0.37 (1/10 v/v (10% v/v aqueous ammonia in methanol)/dichloromethane); IR (ZnSe, 
solid) vmax: 3324, 3186 (w, br, NH2), 2921, 2798 (w, C-H), 1646 (m, -NH2), 1594 (s, amide 
C=O), 1433 (m, C-H), 1239 (m, R3N amine) cm-1; 1H NMR (500 MHz, CDCl3): δ 8.65 (1H, d, 
3J17-18 = 7.7 Hz, 17-CH), 7.83 (1H, s, 6-CH), 7.47 (1H, s, 20-CH), 7.42 (1H, s, 16-NH), 7.32 
(2H, m, 9-CH, 18-CH), 7.19 (1H, d, 3J8-9 = 7.6 Hz, 8-CH), 7.14 (1H, d, 3J11-10 = 7.0 Hz, 11-
CH), 7.05 (1H, dd, 3J10-11/9 = 6.3 Hz, 10-CH), 4.15 (2H, s, 13-CH2), 3.59 (3H, s, 15-CH3), 2.90 
(2H, br, 23-CH2), 2.60 (3H, s, 14-CH3), 2.56 (5H, br, s, 24-CH2 and 25-CH), 1.92 (2H, br, 26-
CH2), 1.63-1.56 (6H, br, m, 26-CH2 and 27-CH2), 1.47 (2H,br, 28-CH2) ppm; 13C NMR (125 
MHz, CDCl3): δ 169.3 (22-C=O), 156.4 (7-C), 153.3 (2-C), 150.6 (6-CH), 147.1 (7-C), 138.7 
(16-C), 132.3 (12-C), 129.2 (11-CH), 129.1 (20-CH), 128.6 (18/9-CH), 128.5 (18/9-CH), 
126.7, 121.9 (10-CH), 121.1 (8-CH), 121.1, 118.1 (one unresolved aromatic C), 62.6 (25-
CH), 56.6 (13-CH2), 50.4 (24-CH2), 44.1 (14-CH3), 40.5 (15-CH3) 26.5 (28-CH2), bipiperidine 
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CH2 unresolved ppm; LRMS (+ ESI) m/z: 548, 546 (M + H]+, 15, 39%); HRMS (+ ESI) m/z: 
546.2743 (Calcd. C22H2737ClN4O2 = 547.2640) ([M + H]+, 35%), 548.2713 (Calcd. 
C22H2735ClN4O2 = 545.2620) ([M + H]+, 100%); Diff. 0.1 ppm. 
Isolated by-product [1,4'-bipiperidin]-1'-yl(4-((5-([1,4'-bipiperidine]-1'-carbonyl)-2-
aminophenyl)amino)-3-chlorophenyl)methanone [84] 
 
Rf 0.16 (1/20 v/v (10% v/v aqueous ammonia in methanol)/dichloromethane); 1H NMR (500 
MHz, CDCl3): δ 7.44 (1H, s, 5’-CH), 7.22 (1H, s, 5-CH), 7.19 (1H, d, 3J = 9.0 Hz), 7.12 (1H, 
d, 3J = 8.0 Hz), 6.80 (1H, d, 3J = 8.0 Hz), 6.55 (1H, d, 3J = 9.0 Hz), 5.86 (1H, s, 6-NH), 4.03 
(2H, s, 1-NH2), 2.86 (4H, br), 2.53 (10H, br, s, 9/9’-CH2 and 10/10’-CH), 1.89-1.79 (10H, br), 
1.61 (10H, br, s), 1.50-1.44 (8H, m, 12/12’-CH2 and 13/12’-CH2) ppm; 13C NMR (125 MHz, 
CDCl3): δ 170.0, 169.3 (7/7’-C=O), 144.9, 143.0, 129.1, 127.33, 127.26, 127.0, 126.9, 126.3, 
125.0, 119.5, 115.5, 113.4 (12 aromatic C(H)), 62.83, 62.76, 50.4, 29.8, 26.31, 26.26, 24.74, 
24.70 ppm; LRMS (+ ESI) m/z: 1237 ([2M + Na]+, 30%), 1215, 1213 ([2M + H]+, 40, 39%), 
609, 607 ([M + H]+, 30, 100%); HRMS (+ ESI) m/z: 609.3490 (Calcd. C34H4737ClN6O2 = 
608.3420) ([M + H]+, 35%), 607.3520 (Calcd. C34H4735ClN6O2 = 606.3449) ([M + H]+, 100%); 
Diff. 0.3 ppm. 
 
Isolated by-product (5,10-dihydrophenazine-2,7-diyl)bis([1,4'-bipiperidin]-1'-ylmethanone) 
[83] 
 
Rf 0.24 (1/20 v/v (10% v/v aqueous ammonia in methanol)/dichloromethane); IR (ZnSe, film) 
vmax: 3416 (w, N-H), 2959, 2915, 2872, 2848 (s, aryl-C-H, alkyl-C-H), 1720 (m, C=O), 1639 
(m, C=C), 1460 (m, CH2), 1377 (m, aryl-C-N), 1260 (m, aryl-C=C), 969 (w, alkyl-C-N) cm-1; 
1H NMR (500 MHz, CDCl3): δ 8.30 (1H, d, 3J = 8.5 Hz, 2/3-CH), 8.24 (1H, s, 5-CH), 7.88 
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(1H, d, 3J = 8.5 Hz, 2/3-CH), 4.86 (1H, br, s, 8-CH2), 3.92 (1H, br, s, 8-CH2), 3.13 (1H, br, s, 
8-CH2), 2.88 (1H, br, s, 8-CH2), 2.58 (5H, br, s, 9-CH2 and 10-CH), 2.04-1.64 (8H, br, m), 
1.50 (2H, s, 13-CH2) ppm; 13C NMR (125 MHz, CDCl3): δ 168.6 (7-C=O), 144.0, 143.3, 
138.4, 130.7, 129.9, 127.8 (6 aromatic C(H) signals), 62.6 (10-CH), 50.4 (9-CH2), 31.06, 
29.8, 26.3, 24.7 (6 aliphatic CH2 signals) ppm; LRMS (+ ESI) m/z: 569.27 ([M - H]+, 100%). 
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